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The innate immune system is the first line of defense against invading pathogens. In 
order to establish a productive infection, microorganisms must effectively evade host defenses.  
The intracellular bacterium Francisella tularensis possesses multiple strategies to actively and 
passively avoid recognition and clearance by the host.   Moreover, F. tularensis elicits a delayed 
innate immune  response compared to other respiratory pathogens such as Klebsiella pneumoniae. 
Whether this immune  response plays a beneficial or detrimental role in tularemia pathogenesis is 
not known.  In this thesis, the contribution of innate hos t de fenses against F. tularensis was 
evaluated in two different settings: acute infection of naïve animals with a type A strain and after 
vaccination with the live vaccine strain (LVS).  First, a comprehens ive comparison of the early 
host response to the virulent type A F. tularensis strain Schu S4 and the attenuated type B strain 
LVS revealed several unique features of type A F. tularensis infection.   The most significant 
immunological difference between these strains was a reduction in the number of viable lung 
cells, particularly NK cells and T cells, in Schu S4-infected mice. Since the decline in NK cells 
correlated with morbidity and mortality, the role of these cells in host defense against Schu S4 
infection was evaluated.  Modulation of NK cells did not have a demonstrable effect on Schu S4 
infection in vivo suggesting these cells do not contribute to immunity against type A F. 
tularensis. In the final part of this thesis, LVS was genetically modified in order to better 
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stimulate antigen-presenting cells and improve vaccine efficacy.  Although LVS FTL_0883 
mutants elicited increased proinflammatory cytokine production and costimulatory molecule 
expression by macrophages and DCs, they failed to provide better protection against Schu S4 
challenge than wild-type LVS.  The data presented in this thesis expands our current knowledge 
of the innate immune response to F. tularensis and provides insight into tularemia vaccine 
development and immunotherapy. 
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1.0  INTRODUCTION 
1.1 FRANCISELLA TULARENSIS 
Originally named “Bacterium tularense”, Francisella tularensis was first isolated from ground 
squirrels exhibiting a “plaguelike disease” in Tulare County, CA in 1911 (Francis, 1925). The 
first cases of human F. tularensis infection were reported in Ohio in 1914 (Wherry, 1914) and b y 
1928; more than 600 cases had been documented (Francis, 1928).  Currently, F. tularensis has 
been isolated from over 250 animal species including fish, birds, rodents, lagomorphs, and 
arthropods (Oyston et al., 2004). F. tularensis is also capable of infecting protozoans such as 
amoeba, which may serve as natural reservoirs (Abd et al., 2003; Oyston et al., 2004). 
Infection with F. tularensis results in the potentially fatal illness, tularemia.  Less than 10 
organisms can cause disease and up to 60% of individuals with F. tularensis pneumonia die in 
the absence of antibiotic therapy (Dennis et al., 2001; McLendon et al., 2006). Transmission of 
tularemia can occur through an arthropod vector, handling of infected animals, or inhalation of 
infectious particles (Oyston, 2008). In the United States, approximately 100-200 cases of 
tularemia are diagnosed each year (Barry et al., 2009; Feldman et al., 2001).  Worldwide, there 
also is a low incidence of disease although tularemia outbreaks are common, particularly in 
Eastern Europe (Ryden et al., 2012). Large outbreaks involving up to 900 people have been 
regularly reported in Sweden and Finland since 2000 (Ryden et al., 2012).  Due to its 
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aerosolization potential and high infectivity and mortality, the Centers for Disease Control and 
Prevention designated F. tularensis a Category A bioterror ism agent (Barry et al., 2009). 
Following the events of September 2001 and the subsequent anthrax attacks  in the United States, 
increased biodefense funding resulted in a renewed interest in this bacterium (Oyston, 2008).   
1.1.1 F. tularensis subspecies 
F. tularensis consists of four subspecies: tularensis, holarctica, novicida, and mediasiatica. 
Subspecies classification is based on degree of virulence and geographic location (Table 1).  F. 
tularensis subspecies mediasiatica is the only subspecies that has not been associated with 
human disease (Oyston et al., 2004).  This subspecies has been isolated in Central Asia and some 
parts of the former Soviet Union. F. tularensis subspecies novicida (F. novicida) rarely causes 
human disease, though it can infect immunocompromised individuals (Oyston et al., 2004).  
Isolates of this subspecies have been found in North America and Australia (Oyston et al., 2004).  
A moderately virulent F. tularensis subspecies prevalent in Europe, Asia, and Nor th America, F. 
tularensis subspecies holarctica (Type B Francisella), causes a mild, protracted disease typically 
involving infection through the skin (Oyston et al., 2004). F. tularensis subspecies tularensis 
(Type A Francisella) is the most virulent subspecies with an estimated LD50 of less than 10 
colony forming units (CFU) in humans when inha led (Pechous et al., 2009).  This subspecies is 
responsible for approximately 90% of all tularemia cases documented in North America (Choi, 
2002).  Type A Francisella can be further divided into two distinct clades: A.I and A.II (Keim et 
al., 2007).  These two clades differ in their geographic distribution in the United States, disease 
outcome, and transmission route (Keim et al., 2007).  Clade A.II, found in the Rocky Mountain 
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region, is less virulent than clade A.I, found in the eastern United States and California (Keim et 
al., 2007; Staples et al., 2006).  
 
Table 1:  F. tularensis subspecies 
F. tularensis subspecies  Virulence in humans Global Distribution 
tularensis clade A.I +++++ North America (Eastern United States) 
 clade A.II ++++ North America (Western United States) 
holarctica  +++ Europe, Asia, North America 
mediasiatica  NDa Central Asia and some pa rts of the former Soviet Union 
novicida  + North America and Australia 
aND, not determined 
bmodified from Oyston et al. 2004 with permission from Nature Publishing Group 
 
1.1.2 Tularemia 
Tularemia can present in various forms depending on the route of F. tularensis infection (Table 
2).  Ulceroglandular tularemia is the most common and involves infection through the skin 
(Oyston et al., 2004). Typically, an individual acquires this disease by the bite of infected 
arthropod vector or direct contact with an infected animal (Oyston et al., 2004). Three to five 
days later, the patient develops flu- like symptoms including fever, chills, malaise, headache, and 
sore throat (Oyston, 2008).  An ulcer also forms at the site of infection (Titball and Oyston, 
2003).  The draining lymph nodes may become enlarged and suppuration occurs in 30% of cases 
if left untreated (Oyston, 2008).  The mortality rate for this specific form of tularemia is less than 
5% (Pechous et al., 2009).  Typhoidal tularemia is diagnosed in cases where an individual 
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presents with the flu- like symptoms but the route of infection remains unknown (Dennis et al., 
2001).  In rare instances, F. tularensis can infect the eye resulting in oculoglandular tularemia 
(Oyston et al., 2004). The eye becomes inflamed and a purulent secretion surrounds the area 
(Oyston, 2008).  If antibiotic therapy is not administered, the infection can spread to the local 
lymph nodes (Oyston, 2008).  Ingestion of food or water contaminated with F. tularensis is 
known as oropharyngeal or gastrointestinal tularemia (Oyston, 2008).  Oropharyngeal tularemia 
is diagnosed when symptoms are localized to the upper gastrointestinal tract including ulcers, 
pharyngitis, swollen cervical lymph nodes and the development of a yellow-white 
pseudomembrane over the pharynx (Oyston, 2008).  Depending on the infectious dose, 
gastrointestinal tularemia can present as mild to moderate diarrhea or extensive bowel ulceration 
(Oyston, 2008).  The most severe form of tularemia involves inha lation of F. tularensis known as 
pneumonic tularemia. Farmers and landscapers are most at-risk due to occupational exposure 
through hay-making, lawn-mowing, and brush cutting (Oyston, 2008).  Presentation of this 
disease varies depending on the infecting F. tularensis strain.  Type B Francisella causes mild 
pneumonia, while infection with Type A Francisella results in severe illness with high fever, 
malaise, chills, cough, delirium, and pulse-temperature dissociation (Oyston, 2008).  Without 
administration of antibiotics, pneumonic tularemia has a case fatality rate of 30-60% (Dennis et 
al., 2001).  Outbreaks of pneumonic tularemia are rare although one occurred recently in 
Martha’s Vineyard in 2000 (Feldman et al., 2001; Oyston, 2008). Fifteen cases of tularemia were 
reported with one fatality (Feldman et al., 2001).  The largest recorded outbreak of pneumonic 
tularemia occurred in Sweden from 1966-1967 and involved more than 600 individuals (Oyston 
et al., 2004; Pechous et al., 2009).  Today, cases of tularemia are often underreported due to the 
non-specific symptoms associated with disease (Pechous et al., 2009). 
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Table 2:  Clinical  forms of tularemia 
Form Route of Acquisition Mortality Rateb 
Ulceroglandular Bite of infected arthropod vector or direct contact with an infected animal 
< 5% 
Oculoglandular Touching the eye with a contaminated finger ND
c 
Oropharyngeal or 
Gastrointestinal  Ingestion of contaminated food o r water 
NDc 
Pneumonic Inhalation of aerosolized F. tularensis 30-60% 
Typhoida l Unknown  30-60% 
aInformation presented in this table obtained from (Oyston, 2008; Oyston and Quarry, 2005; 
Oyston et al., 2004) 
bWithout antibiotic treatment  
cND = Not Determined 
1.1.3 F. tularensis as a bioterrorism agent 
Based on historical records, F. tularensis has been used for thousands of years as a biowarfare 
agent.  In 1300 B.C., infected Neshite soldiers deliberately spread the disease to their Arzawan 
enemies during the Anatolian war (Trevisanato, 2007). F. tularensis was investigated by the 
Japanese as part of their biological weapons development program from 1932-1945 (Barry et al., 
2009).  During World War II, a tularemia outbreak among thousands of Soviet and German 
soldiers was attributed to an intentional release of this pathogen (Dennis et al., 2001). The United 
States and Soviet Union worked to develop a weapon that could disseminate F. tularensis 
aerosols during the Cold War (Nigrovic and Wingerter, 2008).  By the late 196 0s, F. tularensis 
was one of several biological weapons stockpiled by the United States military (Christopher et 
al., 1997).  While the United States terminated its biological weapons program in 1970, the 
Soviet Union continued its program until the early 1990s (Dennis et al., 2001).  Ken Alibek, a 
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former Soviet Union scientist, claimed that antibiotic- and vaccine-resistant F. tularensis strains 
were generated during this time (Sjostedt, 2007).  The World Health Organization predicted that 
aerosolization of F. tularensis within a metropo litan area containing five million people would 
result in 19,000 deaths and leave another 250,000 individuals incapacitated (McLendon et al., 
2006).  Currently, F. tularensis is one of six agents characterized as the most likely biological 
threats to the United States (Sjostedt, 2007).   
1.1.4 Bacteriology of F. tularensis 
F. tularensis is a non-motile Gram-negative coccobacillus capable of infecting numerous cell 
types including macrophages, dendritic cells, neutrophils, hepatocytes, fibroblasts, epithelial 
cells, and endothelial cells (Cowley and Elkins, 2011; Oyston, 2008).  It is a nutritionally 
fastidious or ganism  and requires the amino acid cysteine for growth (Sandstrom, 1994).  Based 
on 16S ribosomal RNA sequencing, F. tularensis is assigned to the class Gammaproteobacteria 
with its closest relatives being endosymbionts like Wolbacchia persica (Oyston, 2008).  This 
bacterium is also distantly related to the human pathogens Coxiella burnetti and Legione lla 
pneumophila (Oyston, 2008).  Given its success at causing severe disease and invading a wide 
repertoire of host cells, F. tularensis must possess numerous virulence factors. 
1.1.5 F. tularensis virulence factors 
1.1.5.1 Francisella Pathogenicity Island (FPI) 
First identified in 2004, the FPI is a 30kb region of the F. tularensis genome that is essential for  
intracellular growth and virulence in mice (Nano et al., 2004).  Type A and Type B Francisella 
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contain two copies of the FPI, while F. novicida contains only one (Oyston, 2008).  For this 
reason, most investigations on the function of different FPI genes have been conducted with F. 
novicida (Oyston, 2008).  The FPI contains approximately 19 genes including the intracellular 
growth locus (iglA-J, iglF is also known as clpV), the pathogenicity determinant protein family 
(pdpA-E, pdpB and pdpE are also known as icmF and hcp respectively), vsrG (valine glycine 
repeat), dotU (defect in organelle trafficking), and anmK (anhydro-N-acetylmuramic acid kinase)  
(Fig. 1).  The best characterized FPI protein is IglC.  It is highly expressed in macrophages and is 
required to inhibit phagosome maturation and for escape into the cytosol (Golovliov et al., 1997; 
Lindgren et al., 2004a; Santic et al., 2005b).  It also plays a role in the downregulation of NF-κB 
signaling and induction of apoptosis in macrophages (Lai et al., 2004; Telepnev et al., 2003). 
Similar to iglC mutants, pdpA mutants colocalize with lysosomal markers suggesting this gene 
also plays a role in phagosomal escape (Schmerk et al., 2009).  The genes pdpB, vgrG, iglF/clpV, 
pdpE/hcp, and dotU are homologous to members of the type VI secretion system found in P. 
aeruginosa and V. cholera (Barker et al., 2009).  Conventionally, IcmF, ClpV, and DotU mediate 
secretion of Hcp and VgrG (Oyston, 2008).  In F. tularensis, VgrG and IglI are secreted into 
macrophages and are required for phagosomal escape and replication in the cytosol (Barker et 
al., 2009).  IglA and IglB have also been implicated in type VI secretion (de Bruin et al., 2007).  
PdpD localizes to the outer membrane and interacts with members of the type VI secretion 
system, IglA, IglB, and IglC (Ludu et al., 2008).  AnmK is only fully expressed in F. novicida 
and it is not essential for intracellular growth in vitro or in vivo (Ludu et al., 2008).  Other FPI 
genes, iglE, iglG, iglH, and iglJ, have no known function and have not been confirmed to play a 
role in F. tularensis intracellular growth (Barker et al., 2009; Broms et al., 2010).  
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Figure 1.  Schematic representation of the Francisella pathogenicity island.  
The ORFs of the FPI are essentially the same in all subspecies, with the exception of the anmK-pdpD region.  
Compared to F. novicida, the pdpD gene in Schu S4 is slightly smaller and the anmK gene is separated into two 
distinct ORFs.  LVS lacks anmK and most of the pdpD gene due to a large deletion within this region. The open 
reading frames represented by black arrows indicate gene products with no significant homology to other proteins; 
while white arrows represent products with homologs in other bacterial systems.  Adapted from (Broms et al., 2010) 
with permission. 
 
 FPI gene expression is regulated by a variety of transcription factors.  MglA 
(macrophage growth locus A) is a globa l transcription factor in F. tularensis, regulating the 
expression of more than 100 genes (Brotcke et al., 2006; Lauriano et al., 2004).  This protein 
forms a complex with SspA (stringent starvation protein A) to associate with the RNA 
polymerase and regulate transcription (Charity et al., 2007).  PmrA was identified as an orphan 
two-component response regulator in F. tularensis that regulates the expression of genes within 
and outside the FPI (Mohapatra et al., 2007).  Very few genes are regulated by bo th PmrA and 
MglA (Brotcke and Monack, 2008).  In addition, PmrA does not regulate MglA and vice versa 
suggesting these two transcription factors function independently of each other (Mohapatra et al., 
2007).  FevR (Francisella effector of virulence regulation) is regulated by the MglA/SspA 
complex and functions in parallel to MglA to positively regulate FPI genes (Brotcke and 
Monack, 2008).  Another transcription element, MigR (macrophage intracellular growth 
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regulator), regulates FevR as well as the iglABCD operon (Buchan et al., 2009).  The only 
negative regulator of the FPI is Hfq which functions to downregulate the pdp operon (Meibo m et 
al., 2009). 
1.1.5.2 Capsule 
The existence of an F. tularensis capsule is controversial.  Several researchers have 
successfully visualized the capsule using electron microscopy (Golovliov et al., 2003; Hood, 
1977; Sandstrom et al., 1988).  Others question its presence due to an inability to detect or isolate 
this electron dense material (Clay et al., 2008; Clemens et al., 2005; Raynaud et al., 2007).  F. 
tularensis possesses orthologs of the Bacillus anthracis capBCA operon which encodes the po ly-
D-glutamic acid capsule biosynthesis machinery (Larsson et al., 2005).  While poly-D-glutamic 
acid could not be detected in F. tularensis extracts or on the surface of the bacteria (Michell et 
al., 2010; Raynaud et al., 2007), deletion of capB or the entire operon attenuates F. tularensis in 
vivo (Jia et al., 2010; Michell et al., 2010; Su et al., 2007).  This suggests that while capBCA may 
not encode components necessary for capsule assembly, this loc us contributes to virulence.  
Apicella and colleagues isolated capsular material from F. tularensis and determined that it was 
comprised of repeating O-antigen subunits (Apicella et al., 2010).  A subsequent study by 
Lindemann et al. identified the gene loci in the type A F. tularensis strain Schu S4 (FTT1236, 
FTT1237, and FTT1238) responsible for the synthesis of this O-antigen capsule (Lindemann et 
al., 2011).  Mutations in any of the three genes resulted in increased sensitivity and reduced 
intracellular growth (Lindemann et al., 2011).  Furthermore, macrophages infected with these 
mutants undergo rapid cell death suggesting these genes play a role in intramacrophage surviva l 
(Lindemann et al., 2011).  More recently, a second capsular material has been described that is 
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distinct from the O-antigen capsule (Bandara et al., 2011).  This capsule- like complex (CLC) is 
believed to consist of an unidentified glycoprotein (Bandara et al., 2011). 
1.1.5.3 Lipopolysaccharide (LPS) 
Compared to other Gram-negative bacteria, the LPS of F. tularensis has a unique structure (Fig. 
2) and poorly activates proinflammatory responses due to lack of recognition by TLR2 and 
TLR4 (Gunn and Ernst, 2007).  The lipid A component is missing free phosphate moieties and is 
hypoacylated compared to other LPS species (Phillips et al., 2004; Vinogradov et al., 2002; 
Wang et al., 2006).  Removal of the 4’-phosphate is mediated by the lipid A phosphatase LpxF 
(Wang et al., 2007).  The lpxF mutant is attenuated in a mouse model of infection suggesting the 
altered lipid A structure of F. tularensis contributes to its virulence (Wang et al., 2007). The LPS 
O-antigen is also important for F. tularensis pathogenesis.  O-antigen mutants are more 
susceptible to complement-mediated killing by serum and are attenuated for growth in vitro 
(Raynaud et al., 2007; Thomas et al., 2007). Furthermore, two F. tularensis phase variants, blue 
and grey, which differ in their O-antigen structure, engender different immune responses 
(Cowley et al., 1996).  Unlike the blue variant, the grey variant stimulated increased NO 
production resulting in limited growth in macrophages (Cowley et al., 1996). 
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Figure 2.  Lipid A structures for E. coli and F. tularensis. 
The lipid A component of F. tularensis LPS is missing free phosphate moieties and is hypoacylated compared to E. 
coli LPS.  Adapted from (Wang et al., 2004) with permission. 
1.1.5.4  Type IV Pili 
Pili are filamentous bacterial surface structures invo lved in many physiological processes 
including adhesion, biofilm formation, and protein secretion (Pechous et al., 2009). The type IV 
pilus is composed of one major pilin subunit, PilA, and several additional minor pilins, PilB, 
PilC, PilD, PilQ, and PilT (Forslund et al., 2010) (Fig. 3).  Within the F. tularensis genome, 
homologs of all the pilin genes are present (Forsberg and Guina, 2007).  Pili have also been 
observed on the surface of F. tularensis by electron microscopy (Gil et al., 2004). Deletion of 
any of the pilin genes in F. tularensis results in reduced virulence in mice (Chakraborty et al.,  
2008; Forslund et al., 2006; Forslund et al., 2010).  Furthermore, the attenuation of the F. 
tularensis live vaccine strain, LVS, was attributed to loss of pilA (Salomonsson et al., 2009).  
The pilin genes, pilB, pilC, pilQ, and pilD are homologous to components of the type II secretion 
Lacks 4’ 
phosphate 
group 
Missing 
acyl groups  
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system and are required for protein secretion in F. novicida (Hager et al., 2006; Salomonsson et 
al., 2011). 
 
 
Figure 3. Schematic overview of the type IV pilin system. 
PilA is synthesized in a prepilin form that requires cleavage by PilD for proper p ilus assembly and function.  
Following translocation across the inner membrane, multiple PilA subunits assemble to form the pilus fiber within 
the periplasmic space.  Th is mult imeric structure is then secreted across the outer membrane by PilQ.  The extension 
and retraction of the pilus is mediated by the ATPases PilB and PilT.  PilC is an inner membrane protein of 
unknown function associated with the type IV complex.  Adapted from (Salomonsson et al., 2011) with permission. 
1.1.5.5 Additional Virulence Factors 
In addition to the type II and type  VI secretion systems, F. tularensis possesses orthologs 
of the type I secretion system (Gil et al., 2006). Both tolC and ftlC mutants were susceptible to 
different antibiotics and detergents in vitro, but only the tolC mutant was attenuated in vivo (Gil 
et al., 2006).  F. tularensis also expresses the acid phosphatases, AcpA, AcpB, AcpC, and Hap, 
which catalyze the hydrolysis of phosphomonoesters at an acidic pH (Mohapatra et al., 2008).  
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While these enzymes contribute to the intracellular survival of F. novicida by dephosphorylating 
components of the NADPH oxidase complex thereby inhibiting the respiratory burst (Mohapatra 
et al., 2008; Reilly et al., 1996), de letion of the acp genes had no effect on intracellular growth or 
virulence in a mouse model of type A Francisella infection (Child et al., 2010).  Genes typically 
associated with metabolism such as deoB, pyrF, purMCD, and ctu have also been shown to 
contribute to Francisella pathogenesis (Horzempa et al., 2008a; Horzempa et al., 2010; Mahawar 
et al., 2009; Pechous et al., 2006; Pechous et al., 2008).  Deletion or disruption of any of these 
genes results in invasion, growth, and/or virulence defects (Horzempa et al., 2008a; Horzempa et 
al., 2010; Mahawar et al., 2009; Pechous et al., 2006; Pechous et al., 2008).  To identify novel 
virulence factors, the genomes of attenuated and virulent F. tularensis strains have been 
sequenced and compared (Broekhuijsen et al., 2003; Svensson et al., 2005).  Several regions of 
difference (RD) have been identified with two genetic loci of particular interest (Salomonsson et 
al., 2009).   A portion of RD18 (FTT0918) and RD19 (pilA) are deleted from the genome of the 
attenuated type B stain LVS. Complementation of LVS with these two genes restored full 
virulence (Salomonsson et al., 2009).  Identification and characterization of additional F. 
tularensis virulence genes is ongoing, as most encode hypothetical proteins (Oyston, 2008). 
1.1.6 Regulation of F. tularensis virulence 
For F. tularensis to be a successful intracellular pathogen, it must adapt to the host environment 
by altering virulence gene expression (Dai et al., 2010).  F. tularensis senses its environment 
through various signals including temperature, iron, oxidative stress, and the polyamine spermine 
(Dai et al., 2010).  To identify those genes regulated by mammalian body temperature, the gene 
expression profiles of F. tularensis cultured at 26ºC (environmental temperature) and 37ºC 
 29 
(mammalian body temperature) were compared (Horzempa et al., 2008a). Forty percent of the 
LVS genes upregulated at 37ºC were previously identified or predicted to be important for 
intracellular growth and/or virulence (Horzempa et al., 2008a).  Two genes of unknown function, 
FTL_1581 and FTL_1664, were further characterized and confirmed to play a role in F. 
tularensis pa thogenesis (Horzempa et al., 2008a).  Another transcriptomic study evaluated gene 
expression changes in response to iron limitation (Deng et al., 2006).  Approximately 80 genes 
were differentially expressed in iron-restricted growth conditions, including many of the FPI and 
fig (Francisella iron-regulated gene) genes (Deng et al., 2006).  Similar results were observed in 
a F. tularensis proteomics study (Lenco et al., 2007).  A different proteomics study identified 
proteins regulated by oxidative stress (Ericsson et al., 1994).   Following exposure to hydrogen 
peroxide, the most highly expressed proteins were the chaperones DnaK, GroEL, and GroES 
(Ericsson et al., 1994).  Lenco and colleagues confirmed the upregulation of these proteins and 
identified 18 additional proteins that are synthesized at an increased level in response to 
oxidative stress (Lenco et al., 2005).  Following invasion of eukaryotic cells, F. tularensis senses 
and responds to the hos t-specific polyamine, spermine, to change its global gene expression 
profile (Carlson et al., 2009).  These modifications reduce the capacity of F. tularensis to 
stimulate cytokine production from macrophages (Carlson et al., 2009).  A subsequent study 
identified FTL_0883/FTT_0615c as a gene necessary for F. tularensis spermine responsiveness 
(Russo et al., 2011).  Mutation of this gene resulted in higher cytokine production from 
macrophages and attenuation of this mutant in vitro and in vivo (Russo et al., 2011). 
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1.1.7 F. tularensis intracellular life cycle 
The intracellular life cycle of F. tularensis has primarily been studied in macrophages (Fig. 4).  
This bacterium is also capable of infecting other cell types including dendritic cells, neutrophils, 
hepatocytes, and lung epithelial cells (Pechous et al., 2009).  To invade these cells, F. tularensis 
utilizes a novel phagocytosis strategy involving the engulfment of bacteria by pseudopod loops 
(Clemens et al., 2005).  This process is dependent on complement factor C3 and complement 
receptor CR3 (Clemens et al., 2005). Additional host receptors can contribute to F. tularensis 
uptake including: complement receptor CR4, FcγR, mannose receptor, SP-A, class A scavenger 
receptors, and cell surface expressed nucleolin (Balagopal et al., 2006; Barel et al., 2008; Ben 
Nasr et al., 2006; Pierini, 2006; Schulert and Allen, 2006).  Once inside the cell, F. tularensis 
resides in a membrane bound vacuole known as the Francisella-containing phagosome (FCP) 
(Checroun et al., 2006; Chong et al., 2008; Clemens et al., 2004; Santic et al., 2005b).  
Acidification of the FCP is transient, as phagosome maturation is arrested at the late endosomal 
stage (Chong et al., 2008; Clemens et al., 2009; Santic et al., 2008).  Within 30-60 minutes, the 
phagosomal membrane degrades and F. tularensis enters the cytoplasm where it replicates 
exponentially (Checroun et al., 2006; Chong et al., 2008; Clemens et al., 2004; Golovliov et al., 
2003; Santic et al., 2005b; Wehrly et al., 2009). Later in infection, bacteria have been found in 
vesicles that are structurally similar to autophagolysosomes (Checroun et al., 2006; Wehrly et al., 
2009).  These Francisella-containing vacuoles (FCV) have only been described in murine 
macrophages (Checroun et al., 2006; Wehrly et al., 2009).  Bacterial egress likely occurs through 
apoptosis or pyroptosis, although the final stages of the F. tularensis life cycle are not well 
understood (Lai et al., 2001; Lai and Sjostedt, 2003; Mariathasan et al., 2005; Santic et al., 
2009). 
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Figure 4.  Model of the Francisella intracellular life cycle in macrophages. 
F. tularensis invades macrophages through a process known as looping phagocytosis.  Upon cell entry, bacteria 
reside in an early phagosome (FCP) that interacts with early (EE) and late (LE) endocytic compartments but not 
lysosomes (Lys). Bacteria rap idly degrade the FCP membrane and reach the cytosol where they undergo extensive 
replicat ion, a process followed by cell death and bacterial release or reentry of cytosolic bacteria within Francisella-
containing vacuoles (FCV) via autophagy.  Adapted from (Chong and Celli, 2010) with permission. 
 
Several genes have been identified to participate in specific stages of the Francisella life 
cycle.  Mutation of deoB, pilF, or pilT results in reduced invasion of phagocytic and/or non-
phagocytic cells (Chakraborty et al., 2008; Horzempa et al., 2008a).  The mechanism by which 
these genes contribute to host cell entry is still being investigated.  Escape of F. tularensis from 
the phagosome is mediated by FPI members (iglABCD), transcription regulators (mglA, fevR, 
and migR), and acid phosphatases (acpABCH) (Bosio et al., 2007; Broms et al., 2009; Buchan et 
 32 
al., 2009; Mohapatra et al., 2008). While multiple genes are known to mediate replication of F. 
tularensis in the cytosol, only one has been characterized in detail.  Expression of ggt, which 
encodes a putative γ-glutamyl transpeptidase, allows F. tularensis to utilize glutathione and γ-
glutamyl-cysteine dipeptide as a source of cysteine, which is required for growth (Alkhuder et 
al., 2009).  The genes FTT0584 and FTT0782 are known to play a role in regulating the 
induction of pyroptosis in infected cells and therefore, may facilitate the exit of F. tularensis 
(Weiss et al., 2007). 
1.2 IMMUNE RESPONSE TO FRANCISELLA 
For the past thirty years, most studies on Francisella immunology have involved the attenuated 
type B strain LVS (Conlan et al., 2003). While LVS is avirulent in humans, mice are very 
susceptible to LVS infection through various administration routes (Rick Lyons and Wu, 2007).  
Moreover, infection of mice with this strain mimics the course of infection observed in humans 
(Rick Lyons and Wu, 2007).   Therefore, most of the discussion on the function of different 
immune cells, cytokines, and chemokines in F. tularensis infection will focus on this model 
system (Fig. 5). Differences in the immune response elicited to type A Francisella compared to 
LVS will be discussed at the end of this section. 
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Figure 5.  Components of murine innate and adaptive immune res ponses to Francisella.  
(1) The initial interaction of Francisella with host cells, such as macrophages, dendritic cells, and epithelial cells, 
stimulates production of pro-inflammatory cytokines and chemokines (2a) in a manner that is dependent upon 
MyD88 and TLR2. Simultaneously, important innate immune cells recru ited to the area of in fection produce effector 
cytokines such as IL-12p40, TNF-α, IFN-γ, and IL-17A (2b) that influence T cell development (3), and induce host 
cell production of antimicrobial molecules (4). In addition to the classic Th1-type cytokines, other mediators include 
mast cell production of IL-4, which can directly inhibit Francisella intramacrophage growth, and B-1a B cell 
production of anti-LPS antibodies that limit intraperitoneal in fection. Neutrophils or polymorphonuclear cells 
(PMNs) are essential for survival o f Francisella infections initiated via some routes, but fail to eradicate intracellular 
organisms in vitro, so their contribution to infection remains unclear. After several days, activation and expansion of 
Francisella-specific T cells and B cells occurs (3). αβ T cells are essential for clearance of primary infection, and 
produce effector cytokines such as IL-17A, IFN-γ, and TNF-α. These factors activate infected host cells to produce 
reactive oxygen and nitrogen species, as well as other unidentified antimicrobials, and limit intracellular F. 
epithelial cells* 
(Neutrophils) 
 34 
tularensis growth (4). Asterisks (*) indicate host cells that have been shown to harbor intracellular Francisella. The 
blue box indicates cell types that are neither fully innate nor adaptive, based on classical definit ions.  Adapted from 
(Cowley and Elkins, 2011) with permission. 
1.2.1 Role of innate immune cells in F. tularensis immunity 
1.2.1.1 Macrophages 
Macrophages have historically been considered the primary replicative niche of F. tularensis in 
the host (Elkins et al., 2007).   In the absence of immune stimulation, bacterial replication 
proceeds exponentially, often resulting in death of the cell (Elkins et al., 2007). Cell death is 
believed to be caspase-3 dependent although this has only been shown at high multiplicities of 
LVS infection (Lai et al., 2001; Lai and Sjostedt, 2003).  Treatment with IFN-γ is the most 
common way to activate macrophages and inhibit growth of F. tularensis (Anthony et al., 1992; 
Fortier et al., 1992; Lindgren et al., 2004a).  IFN-γ induces the expression of iNOS and assembly 
of the NADPH oxidase complex resulting in robust production of reactive oxygen species (ROS) 
and reactive nitrogen species (RNS) (Lindgren et al., 2005).  Mice deficient in p47phox or iNOS 
were more susceptible to intradermal challenge with LVS supporting a role for RNS and ROS in 
vivo (Lindgren et al., 2004b).  Peroxynitrite, a compound generated by the interaction of nitric 
oxide with superoxide, is believed to be the major mediator of IFN-γ induced killing (Lindgren et 
al., 2005). IFN-γ also controls F. tularensis growth by promoting phagolysosome fusion 
(Lindgren et al., 2004a; Santic et al., 2005a).   
F. tularensis evades host bactericida l mechanisms by suppressing the activation of 
macrophages (Bosio and Dow, 2005; Carlson et al., 2007; Loegering et al., 2006; Parsa et al., 
2008; Telepnev et al., 2003; Telepnev et al., 2005).  Macrophages produce little to no 
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proinflammatory cytokines in vitro in response to LVS and type  A F. tularensis infection (Bos io 
and Dow, 2005; Carlson et al., 2007; Loegering et al., 2006; Russo et al., 2011; Telepnev et al., 
2003; Telepnev et al., 2005), although they do express high levels of the immunosuppressive 
molecule prostaglandin E2 (PGE2) (Woolard et al., 2007).   PGE2 inhibits IL-2 production and 
promotes Th2 responses (Woolard et al., 2007). F. tularensis- infected macrophages also do not 
increase expression of the costimulatory molecule CD86 or MHCII (Bosio and Dow, 2005).  
Stimulation with TLR ligands such as E. coli LPS fails to restore cytokine secretion by these 
cells suggesting F. tularensis actively suppresses TLR signa ling (Bosio and Dow, 2005; Carlson 
et al., 2007; Loegering et al., 2006; Telepnev et al., 2003).  This suppression is due to the 
downregulation of critical inflammatory signaling pathways involved in MAPK and NF-κB 
activation (Telepnev et al., 2005).  Furthermore, F. tularensis can inhibit IFN-γ signaling through 
the upregulation of SOCS3 which blocks the phosphorylation and activation of STAT1 (Parsa et 
al., 2008).  While macrophages are the predominant cell infected by F. tularensis, replication 
within them is not essential for virulence (Horzempa et al., 2010).  A F. tularensis pyrF mutant 
that was attenuated for growth in macrophages retained full virulence in a mouse model of 
pneumonic tularemia (Horzempa et al., 2010). 
1.2.1.2 Dendritic Cells  
Similar to macrophages, dendritic cells are preferentially targeted by F. tularensis (Bosio and 
Dow, 2005).  F. tularensis-infected DCs are poor producers of proinflammatory cytokines, fail to 
upregulate costimulatory molecules, and are unresponsive to stimulation with TLR ligands 
(Bosio et al., 2007; Bosio and Dow, 2005; Chase et al., 2009; Schmitt et al., 2012). Suppression 
of these cells by F. tularensis was partially attributed to production of the immunosuppressive 
cytokine TGF-β (Bosio et al., 2007; Bosio and Dow, 2005).  Elevated levels of TGF-β were 
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detected in the lungs of mice following pulmonary F. tularensis infection (Bosio et al., 2007).  
Neutralization of this cytokine had a minimal effect on reducing bacterial burdens in the lung of 
infected mice compared to isotype  controls (Bosio et al., 2007). In an intranasal LVS mouse 
mod el, F. tularensis- infected DCs were found to migrate from the lung to the mediastinal lymph 
node suggesting DCs play a role in F. tularensis dissemination (Bar-Haim et al., 2008). 
1.2.1.3 NK Cells 
In bacterial infections, NK cells have two primary functions: secrete IFN-γ and lyse infected 
cells through the release of perforin and granzymes (Warren and Smyth, 1999) .  Following 
pulmonary LVS infection, NK cells are the primary early producers of IFN-γ (Bokhari et al.,  
2008; Lopez et al., 2004; Wickstrum et al., 2007). In vitro, NK cells control F. tularensis 
intramacrophage growth in an IFN-γ-dependent manner (Elkins et al., 2009; Sanapala et al., 
2012; Skyberg et al., 2012).  Depletion of NK cells using anti-asialo GM1 or anti-NK1.1 
antibody shortened mouse survival following lethal LVS infection (Lopez et al., 2004; Metzger 
et al., 2007).  A few studies have investigated the role of NK cell lytic activity in F. tularensis 
immunity. Beige mice, which are defective in NK cell cytotoxicity, are not more susceptible than 
wild-type to lethal LVS infection (Duckett et al., 2005).  There was also no difference in survival 
between wild-type and perforin knockout mice infected with LVS (Sanapala et al., 2012). 
A number of therapies that prolong survival in a mouse model of pneumonic tularemia 
are dependent on NK cells.  In the absence of NK cells, recombinant IL-12 does not extend the 
survival time of mice infected with either F. novicida or LVS (Duckett et al., 2005; Pammit et 
al., 2004).  The protective effect of both CpG DNA and acai polysaccharides against LVS and 
Schu S4 infection, respectively, was dependent on control of intramacrophage growth by NK 
cells (Elkins et al., 2009; Elkins et al., 1999b; Skyberg et al., 2012).  Prolonged survival from 
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Schu S4 infection through treatment with cationic liposome-DNA complexes (CLDC) was 
abolished when NK cells were depleted (Troyer et al., 2009).  These studies suggest that NK 
cells play a beneficial role in the host response to F. tularensis. 
1.2.1.4 Mast Cells 
While mast cells are classically known to mediate allergic responses, they also play a critical role 
in host defense against bacterial infections (Chan et al., 2012).  Mast cell-deficient mice are more 
susceptible to pulmonary infection with LVS (Ketavarapu et al., 2008).  In vitro, mast cells 
control the growth of F. tularensis in macrophages through the production of IL-4 (Ketavarapu 
et al., 2008).  Inhibition of F. tularensis replication was associated with increased ATP levels 
and colocalization of bacteria with acidified organelles (Rodriguez et al., 2011).  In the absence 
of IL-4 signaling, lung macrophages expressed elevated levels of caspase-3 suggesting mast cell-
produced IL-4 regulates host cell death during F. tularensis infection (Rodriguez et al., 2011). 
1.2.1.5 Neutrophils 
Neutrophils are the first innate immune  cells recruited to the site of infection.  These cells ingest 
and kill invading microbes through the production of cationic peptides, proteases, ROS, and RNS 
(Appelberg, 2007). Following phagocytosis of F. tularensis, neutrophils fail to undergo a 
respiratory burst (McCaffrey and Allen, 2006).  F. tularensis inhibits assembly of the NADPH 
oxidase complex, thereby allowing for phagosomal escape and replication in the cytosol 
(McCaffrey and Allen, 2006).  Furthermore, F. tularensis prolongs the lifespan of the neutrophil 
by blocking caspase activation (Schwartz et al., 2012).  In a mouse model of pneumonic 
tularemia, the recruitment of neutrophils is delayed and dependent on the production of IL-17 
(Cowley et al.,  2010; Hall et al., 2008; Lin et al., 2009; Mares et al., 2008).  Limiting neutrophil 
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recruitment ameliorates disease as demonstrated by the enhanced resistance of MMP-9-/- mice to 
respiratory F. tularensis infection (Malik et al., 2007).  MMP-9 is a metalloproteinase that 
cleaves extracellular matrix proteins to generate neutrophil chemoattractants (Malik et al., 2007). 
Complete depletion of neutrophils, however, has no effect on the susceptibility of mice to 
pulmonary LVS infection (Conlan et al., 2002).  In contrast, neutropenic mice succumb to 
intrade rmal or intravenous LVS infection earlier than wild-type (Conlan et al., 2002; Elkins et 
al., 1996; Sjostedt et al., 1994), suggesting the role of neutrophils in host defense is dependent on 
the route of infection.   
1.2.2 Role of cytokines and chemokines in F. tularensis infection 
The production of proinflammatory cytokines essential for control of F. tularensis infection is 
dependent on MyD88 and TLR2 (Abplanalp et al., 2009; Collazo et al., 2006; Malik et al.,  
2006).  Following intradermal or intraperitoneal F. tularensis infection, the Th1 cytokines IFN-γ, 
TNF-α, and IL-12 can be detected within 24-48 hours (Stenmark et al., 1999; Wickstrum et al., 
2007).  In comparison, these cytokines are not produced until three to four days post infection 
upon inhalation of F. tularensis (Abplanalp et al., 2009; Bokhari et al., 2008; Duckett et al., 
2005).  In F. novicida- infected mice, many of these cytokines and chemokines are produced at 
excessive levels, 10-500 fold greater than uninfected controls (Mares et al., 2008). This 
“cytokine storm” is believed to contribute to the pathology and mortality associated with 
respiratory F. novicida infection (Mares et al., 2008). 
Surviva l from F. tularensis infection is dependent upon the production of TNF-α and 
IFN-γ (Cowley and Elkins, 2011).  Neutralization of either cytokine renders mice more 
susceptible to LVS infection (Elkins et al., 1996; Leiby et al., 1992).  Similar results were 
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observed with TNF-α and IFN-γ knockout mice (Chen et al., 2004; Collazo et al., 2009; Duckett 
et al., 2005).  TNF-α mediates resistance to LVS infection through the induction of reactive 
nitrogen species (Cowley et al., 2008).  One function of IFN-γ is to induce the expression of 
monocyte and T cell chemoattractants, such as MCP-1 and MIG (Park et al., 2002; Pietras et al., 
2011).  Mice deficient in CCR-2, the receptor for MCP-1, had higher bacterial burdens, 
correlating with reduced recruitment of monocytes and production of TNF-α and nitric oxide  
(Pietras et al., 2011). On the other hand, no difference in morbidity and mortality was observed 
in F. tularensis-infected Mig-/- mice (Park et al., 2002).   
The role of IL-12 in the host response to F. tularensis is complex and appears dependent 
on the route of infection.  IL-12 is a heterodimeric cytokine comprised of two subunits, p35 and 
p40.  The p40 subunit can also interact with another protein, p19, to form the cytokine IL-23.  
Therefore, IL-12p40-/- mice are deficient in both IL-23 and IL-12, while IL-12p35-/- mice only 
lack IL-12. Both subunits contribute to host resistance against respiratory LVS infection 
(Duckett et al., 2005; Lin et al., 2009), although p35 and p40 have divergent roles in intradermal 
LVS infection (Elkins et al., 2002).  IL-12p35-/- mice completely resolve the infection following 
intradermal inoculation, while IL-12p40-/- mice do not (Elkins et al., 2002).  These data suggest 
IL-23, not IL-12, facilitates resistance to intradermal LVS infection. IL-23 also plays a role in 
pulmonary LVS infection as IL-23p19-/- mice are more susceptible than wild type to intranasal 
challenge (Lin et al., 2009).   A recent study by Slight  et al. demonstrated a novel role for  IL-
12p40 in the migration of DCs from the lung to the draining lymph node following intranasal 
LVS infection (Slight et al., 2011). 
Several other cytokines and chemokines play an important role in F. tularensis immunity.  
IL-17 was detected in the lungs within three days of LVS infection (Lin et al., 2009).  In the 
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absence of IL-17, mice are more susceptible to pulmonary, but not intradermal, LVS infection 
(Cowley et al., 2010; Lin et al., 2009).   In a mouse model of pneumonic tularemia, IL-17 
induces the secretion of IL-12 and IFN-γ from LVS-infected macrophages and DCs, promoting 
bacterial clearance and Th1 cell differentiation (Lin et al., 2009).  IL-17 has also been shown to 
act synergistically with IFN-γ to control LVS growth in murine macrophages and ATII epithelial 
cells (Cowley et al., 2010).  TGF-β is produced by airway cells following F. tularensis infection 
(Bosio et al., 2007; Bosio and Dow, 2005).   Treatment of F. tularensis- infected mice with an 
anti-TGF-β neutralizing antibody had a minimal effect on reducing bacterial burden in the lung 
and spleen compared to isotype controls (Bosio et al., 2007).  Type I IFNs negatively regulate 
the generation of IL-17-producing γδ T cells (Henry et al., 2010). IFNAR-/- mice possess an 
increased frequency of IL-17+ γδ T cells and are resistant to F. novicida infection (Henry et al., 
2010).  Deletion of CX3CR1, a receptor for the T cell and monocyte chemoattractant CX3CL1, 
did not alter disease progression in a mouse model of pneumonic tularemia (Hall et al., 2009). 
1.2.3 Adaptive  immune responses of lymphocytes to F. tularensis infection 
1.2.3.1 B Cells and Antibodies 
In humans naturally infected with F. tularensis, production of IgM, IgA, and IgG antibodies 
begins around two weeks post infection and peaks at four to seven weeks (Koskela and 
Salminen, 1985).  Antibod ies are still present in individuals anywhere from six months to eleven 
years after expos ure (Koskela and Salminen, 1985).  Similar kinetics of antibody production 
were observed in LVS vaccinees (Koskela and Herva, 1982). In mice, antibodies can be detected 
as early as five days post LVS infection (Rhinehart-Jones et al., 1994).  Antibody levels peak 
two weeks after infection and slowly decline thereafter, but can still be detected for up to four 
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months (Rhinehart-Jones et al., 1994).  The role of F. tularensis-specific antibod ies in F. 
tularensis immunity has been primarily been studied through the transfer of immune serum.  
Mice administered immune human or murine sera were protected against lethal challenge with 
LVS or a virulent type B strain (Drabick et al., 1994; Fortier et al., 1991; Kirimanjeswara et al., 
2007; Stenmark et al., 2003).  Serum from mice immunized with LVS LPS or heat-killed LVS 
was also protective (Fulop et al., 2001; Lavine et al., 2007). In a mouse model of pneumonic 
tularemia, the protective effect of immune serum was dependent upon FcγR as well as the 
presence of macrophages and neutrophils (Kirimanjeswara et al., 2007).  These data suggest 
antibody opsonization of LVS is a critical mechanism for uptake and killing of bacteria by 
phagocytes (Kirimanjeswara et al., 2007) . 
Besides their role in antibody production, it is not well understood how B cells contribute 
to F. tularensis immunity.  F. tularensis can infect and replicate in B cells resulting in apoptosis 
(Krocova et al., 2008). Compared to wild-type mice, B cell-deficient mice are equally 
susceptible to intradermal and pulmonary LVS infection, although higher bacterial burdens were 
measured in all organs (Chen et al., 2004; Elkins et al., 1999a).  A unique innate population of B 
cells, known as B-1 cells, mediates protection elicited by immunization with F. tularensis LPS 
(Cole et al., 2009).  B-1 cells are primarily located in the spleen, peritoneal cavity, and intestinal 
mucosa (Cowley and Elkins, 2011).  They produce natural antibod ies against T- independent 
antigens and are divided into two distinct populations: B-1a (CD5+) and B-1b (CD5-) (Cole et al.,  
2009).  Immunization with LVS LPS stimulates the proliferation and differentiation of B-1a cells 
into plasma cells that secrete LPS-specific antibodies (Cole et al., 2009).  Depletion of these cells 
renders LPS-immunized mice suscept ible to lethal LVS infection (Cole et al., 2009). 
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1.2.3.2  T Cells 
T cells are indispensable for resolution of F. tularensis infection. Athymic and TCR-β-
deficient mice are able to control LVS growth for the first two weeks following infection (Elkins 
et al., 1993; Yee et al., 1996).  LVS is never completely eradicated in the absence of T cells, 
however, and high bacterial burdens persist in all organs (Elkins et al., 1993; Yee et al., 1996).   
Eventually, these mice succumb to infection within 4-6 weeks (Elkins et al., 1993; Yee et al.,  
1996).  Using knockout mice and antibody depletion, Yee et al. demonstrated that either CD4+ or 
CD8+ T cells are sufficient for clearance of F. tularensis (Yee et al., 1996).  Interestingly, mice 
depleted of both T cell populations survive lethal LVS challenge but develop a chronic infection 
(Conlan et al., 1994; Cowley et al., 2005; Cowley et al., 2010; Yee et al., 1996).  These data 
suggest a CD4-CD8- T cell population contributes to control of F. tularensis.  Subsequent studies 
demonstrated that these “double negative” T cells inhibit in vitro LVS intramacrophage growth 
in a TNF-α and IFN-γ dependent manner (Cowley and Elkins, 2003; Cowley et al., 2005).  
Control of LVS replication by CD4+ and CD8+ T cells is also dependent on the production of 
these cytokines (Cowley and Elkins, 2003; Cowley et al., 2007).  Preliminarily, T cell 
cytotoxicity does not appear to contribute to inhibition of LVS growth in macrophages (Cowley 
and Elkins, 2011).  The role of γδ T cells in F.tularensis immunity has also been investigated and 
determined to be insignificant (Markel et al., 2010; Yee et al., 1996). 
To better characterize the T cell response to F. tularensis, researchers are also working to 
identify T cell epitopes. In one study, recombinant F. tularensis culture filtrate proteins were 
incubated with immune splenocytes to determine which proteins are capable of eliciting robust T 
cell proliferation and IFN-γ production (Lee et al., 2006).  Three proteins, GroEL, KatG, and 
bacterioferritin, were identified to be immunostimulatory, although the specific epitopes within 
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these proteins has not been identified (Lee et al., 2006). A recent study discovered an 
immunodo minant CD4+ T cell epitope within the outer membrane protein Tul4 (amino acids 86-
99) (Valentino et al., 2009).  In F. tularensis-infected C57BL/6 mice, up to 20% of the 
responding CD4+ T cell population is specific for Tul4 (Valentino et al., 2009). 
Human T cell responses to F. tularensis have also been investigated using PBMCs from 
tularemia patients and LVS vaccinees.  In ex vivo re-stimulation assays, PBMCs from infected 
and vaccinated individuals proliferate and produce IFN-γ, TNF-α, and IL-2 (Karttunen et al.,  
1991; Surcel et al., 1991).  Peak responses were observed two to three weeks following 
immunization or the onset of symptoms (Karttunen et al., 1991; Surcel et al., 1991).  PBMCs 
from LVS vaccinees also produce canonical Th17 cytokines, IL-17 and IL-22 (Paranavitana et 
al., 2010).  Another study identified the rapid expans ion of a unique population of γδ T cells in 
the blood o f tularemia patients following infection (Poquet et al., 1998).   For the first two weeks 
post infection, approximately 30% of the CD3+ population in the blood was comprised of γδ T 
cells expressing the Vγ9/Vδ2 receptor which recognizes phosphorylated non-peptidic ligands on 
bacteria (Poquet et al., 1998).  A homologous population of γδ T cells cannot be found in mice so 
the role of this specific T cell population in F. tularensis immunity has not been further 
investigated (Cowley and Elkins, 2011). 
1.2.4 Immune Response to Type A Francisella 
Compared to LVS, Schu S4 infection results in rapid morbidity and mortality in mice (Bosio, 
2011).  The enhanced virulence of this strain is attributed to its ability to evade and suppress the 
immune response (Bosio, 2011).  Schu S4 avoids phagocytosis by binding plasmin to block 
antibody opsonization (Chase et al., 2009).  Plasmin-bound Schu S4 also poorly elicits the 
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production of proinflammatory cytokines from macrophages (Chase et al., 2009).  Schu S4 is 
resistant to the bactericidal effects of ROS and RNS, allowing for uncontrolled replication 
(Lindgren et al., 2007).  In vivo, Schu S4-infected mice exhibit severe thymic atrophy and 
depletion of CD4+CD8+ thymocytes (Chen et al., 2005).  All immunode ficient mice tested thus 
far, including those lacking IFN-γ and TNF-α, show no increased sensitivity to type A F. 
tularensis compared to immunocompetent mice (Chen et al., 2004; Zhang et al., 2008).  This 
demonstrates that type A F. tularensis fails to elicit an effective host immune response. 
1.3 VACCINES AND THERAPIES AGAINST F. TULARENSIS 
If implemented early in infection, antibiotics are an effective treatment for tularemia (Barry et 
al., 2009).  Antibiotic therapy has been shown to reduce the case fatality rate from 30-60% to 2% 
(Dennis et al., 2001).   Aminoglycosides, specifically streptomycin or gentamicin, are the drugs 
of choice, although ciprofloxacin has also been prescribed in uncomplicated cases of tularemia 
(Nigrovic and Wingerter, 2008; Oyston, 2009).   Since the symptoms of tularemia are non-
specific, misdiagnoses are common resulting in delayed treatment and reduced survival (Barry et 
al., 2009).  There is also a potential for the introduction of antibiotic-resistant strains (Oyston, 
2009).  Due to these concerns, there is a large interest in developing alternative anti-F. tularensis 
therapies. Another area of active research is development of an effective tularemia vaccine. The 
only tularemia vaccine known to elicit protection from virulent F. tularensis, LVS, is not 
currently licensed for use in the United States (Oyston, 2009). 
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1.3.1   Killed Vaccines 
The earliest tularemia vaccine, referred to as the Foshay vaccine, consisted of F. tularensis that 
was killed through acid extraction and preservation in phenol  (Pechous et al., 2009).  Several 
thousand volunteers in Ohio were immunized with this vaccine between 1933 and 1941 (Foshay 
et al., 1942).  While the Foshay vaccine reduced the incidence of laboratory-acquired tularemia 
cases by 70% in the 1950s, the majority of vaccinees still developed severe disease (Kadull et al.,  
1950).  Fifty-seven percent of Foshay vaccinees displayed symptoms of tularemia following 
challenge with virulent F. tularensis compared to 17% of individuals vaccinated with a live 
attenuated F. tularensis strain (Saslaw et al., 1961).  Failure of the Foshay vaccine to elicit 
protective immunity was attributed to poor stimulation of cell-mediated immune responses. 
After those initial studies, little work has focused on the development of killed F. 
tularensis vaccines.  Recently, several researchers have tried to improve the efficacy of the 
Foshay vaccine by testing d ifferent preparations and including adjuvants.  Administration of heat 
killed LVS protected mice from homologous challenge (Lavine et al., 2007). Similarly, 
immunization of mice with UV-irradiated LVS in combination with recombinant IL-12 elicited 
protection against LVS (Baron et al., 2007). Neither vaccine, however, was tested in a mouse 
model of virulent F. tularensis infection (Baron et al., 2007; Lavine et al., 2007).   UV-irradiated 
LVS mixed with immune-stimulating complexes (ISCOMS) and CpG was completely protective 
against challenge with virulent type B F. tularensis, but only minimally protective against type A 
(Eyles et al., 2008). Protection from LVS challenge mediated by chemically killed LVS could be  
enhanced by the addition of mouse anti-F. tularensis LPS monoclonal antibodies or cholera toxin 
B (Bitsaktsis et al., 2009; Rawool et al., 2008).  Neither of these vaccine combinations afforded 
complete protection against Schu S4 challenge (Bitsaktsis et al., 2009; Rawool et al., 2008). 
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1.3.2 Subunit Vaccines 
A number of F. tularensis antigens have been tested as subunit vaccines. LPS was a logical first 
choice as a subunit vaccine candidate because it is the primary target of the antibody response in 
LVS vaccinees (Oyston, 2009).  LPS-immunized mice were protected against LVS challenge, 
but not Schu S4 (Fulop et al., 1995).  Conjugation of the LPS O-antigen to BSA protected mice 
against intradermal, but not aerosol, challenge with virulent type B F. tularensis (Conlan et al., 
2002).  Little to no protection was elicited by O-antigen-BSA complexes against Schu S4 
challenge (Conlan et al., 2002).  Coupling LPS immunization with N. meningitidis PorB, a robust 
stimulator of TLR2, or an LVS boost improved vaccine efficacy but still did not afford complete 
protection against Type A Francisella challenge (Chiavolini et al., 2008; Fulop et al., 2001).  
The highly immunogenic protein Tul4 was also tested as a vaccine candidate and provided only 
modest protection against intravenous LVS challenge when administered with ISCOMS 
(Golovliov et al., 1995).  Researchers tried to improve the immune  response elicited to subunit 
vaccines by generating recombinant bacteria species that expressed F. tularensis proteins. IglC-
expressing Listeria monocytogenes and FopA-expressing Salmonella typhimurium were 
comparable to LVS in the protection provided against Schu S4 challenge (Fulop et al., 1995; Jia 
et al., 2009).  The best subunit vaccine candidate tested so far is a mixture of LVS outer 
membrane proteins (OMP). Tissue burdens were significantly reduced by OMP immunization 
and 50% of mice survived Schu S4 challenge (Huntley et al., 2008). 
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1.3.3 Live Attenuated Vaccines 
The limited effectiveness of Foshay vaccines and subunit vaccines suggests an ideal tularemia 
vaccine would consist of multiple antigenic components capable of stimulating both humoral and 
cell-mediated immune responses (Pechous et al., 2009). A live attenuated F. tularensis vaccine 
possesses these characteristics.  Thousands of people in the Soviet Union have been successfully 
immunized with live attenuated type B Francisella strains during and after World War II (De 
Pascalis et al., 2012).  The United States received a few of these vaccine strains in the 1950s as 
part of a formal scientific exchange program (Wayne Conlan and Oyston, 2007).  Repeated 
passage of one of these strains on peptone cysteine agar yielded two distinct colony variants, 
blue and grey (Wayne Conlan and Oyston, 2007).  Immunization of mice and guinea pigs with 
the blue variant protected them against Schu S4 infection (Eigelsbach and Downs, 1961).  
Subsequently, the blue variant was lyophilized and serially passaged through mice before being 
designated LVS (Eigelsbach and Downs, 1961).  In a vaccine trial conducted by Saslaw et al., 
83% of LVS-vaccinated individuals were completely protected from aerosol challenge with type  
A Francisella (Saslaw et al., 1961).  A similar rate of protection was observed against low dose, 
but not medium to high dose, aerosol challenge in another study of LVS-vaccinated individuals 
(McCrumb, 1961).  In the 1960s, LVS reduced the incidence of tularemia from 5.7 cases to 0.27 
cases per 1000 researchers and was subsequently given investigational new drug status by the 
Food and Drug Administration (FDA) (Burke, 1977). 
While early vaccine studies demonstrated a protection rate for LVS of greater than 80%, 
additional human vaccine trials by Hornick and Eige lsbach have shown that protection afforded 
by this vaccine is incomplete and short- lived against aerosol challenge (Hornick and Eigelsbach, 
1966).  When LVS was administered by scarification, all individuals were protected from aerosol 
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challenge for up to two months following vaccination (Hornick and Eigelsbach, 1966), similar to 
previous studies (McCrumb, 1961; Saslaw et al., 1961).  However, when subjects were 
challenged with aerosolized virulent Francisella 1-3 years post LVS vaccination, only 25-50% 
were protected (Hornick and Eigelsbach, 1966).  Immunization of individuals with a high dose 
(106-108 bacteria) of aerosolized LVS improved its efficacy but commonly resulted in severe 
adverse side effects (Hornick and Eigelsbach, 1966).  This variable efficacy may be due to 
reversion of the blue variant to grey, since certain preparations of LVS contained as much as 
20% of the grey variant (Sandstrom, 1994).  For this reason, in addition to its undefined 
attenuation and mechanism of protection, LVS is not licensed for public use by the FDA (Wayne 
Conlan and Oyston, 2007). 
Researchers are currently working to obtain licensure of LVS by addressing the concerns 
of the FDA.   Two genetic loci were identified to be responsible for the attenuation of LVS 
(Salomonsson et al., 2009).  Expression of pilA and FTT0918 in LVS restored virulence in mice, 
resembling infection with a virulent type B strain (Salomonsson et al., 2009).  Production of LVS 
under current good manufacturing practices yielded a new lot comprised 100% of the blue 
variant (Pasetti et al., 2008).  This lot was recently tested in human phase I clinical trials and 
shown to be safe and immunogenic (El Sahly et al., 2009).  Alternatively, researchers have 
introduced mutations into LVS to improve its efficacy, typically targeting genes involved in 
metabolism or virulence (Barry et al., 2009).  Deletion of the purMCD purine biosynthesis 
operon in LVS protected mice against lethal LVS challenge (Pechous et al., 2006), but not Schu 
S4 (Pechous et al., 2008).  Similar results were observed with a guaAB mutant, lacking critical 
enzymes in the guanine nucleotide biosynthetic pathway (Santiago et al., 2009).  Mutation of 
virulence genes in LVS yielded more efficacious vaccine candidates. 84% of mice immunized 
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with an O-antigen polymerase mutant, Ft.LVS::∆wzy, and 40% of mice immunized with the 
superoxide dismutase mutant, sodBFt, survived Schu S4 challenge (Bakshi et al., 2008; Kim et 
al., 2012). 
LVS mutants may not afford complete protection against Schu S4 challenge due to 
differences in the protective antigens expressed by each strain (Pechous et al., 2009).  Therefore, 
several Schu S4 mutants have been generated and tested as vaccines.  A few of these mutants 
elicited better protection than LVS against Schu S4 challenge.  Approximately 75-80% of mice 
vaccinated with ∆FTT1103 survived Schu S4 challenge (Qin et al., 2009).  FTT1103 encodes a 
predicted hypothetical protein sharing homology with DsbA proteins that catalyze disulfide bond 
formation (Qin et al., 2009).  Immunization of mice with ∆FTT0918 doubled the median time to 
death following challenge with a type A Francisella strain compared to LVS (Twine et al.,  
2005).  A similar increase in median time to death was observed in Schu S4 ∆clpB-vaccinated 
mice following Schu S4 challenge (Conlan et al., 2010).  The clpB gene in Schu S4 encodes for a 
heat shock protein (Conlan et al., 2010), while FTT0918 encodes a hypothetical protein of 
unknown function (Twine et al., 2005). 
 
1.3.4 Anti-Francisella therapies 
Since the effectiveness of antibiotics wanes if treatment is delayed, researchers have been 
working to develop alternative tularemia therapies.   One approach that has been successful is 
non-specific stimulation of the innate immune response.  Treatment of mice with aerosolized 
nontypeable Haemophilus influenzae lysate prolonged survival following challenge with a broad 
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group of pa thogens inc luding F. tularensis Schu S4 (Evans et al., 2010).  Administration of 
bacterial CpG DNA or a synthetic TLR4 agonist, aminoalkyl glucosaminide phosphate (AGP), 
protected mice against challenge with lower virulence F. tularensis strains, however, their 
efficacy against Schu S4 is unknown (Elkins et al., 1999b; Lembo et al., 2008).  Intranasal 
administration of cationic liposome-DNA complexes (CDLC) extended the median time to death 
of mice challenged with Schu S4 by one to two days (Troyer et al., 2009).  Similar results were 
observed when mice were administered the TLR3 agonist, poly (I:C) (Pyles et al., 2010).  If poly 
(I:C) was combined with levofloxacin treatment at day 5, however, 100% of mice were protected 
against Schu S4 infection (Pyles et al., 2010).  Acai polysaccharides and anti-LPS monoc lonal 
antibodies have also been shown to prolong survival following Schu S4 infection (Lu et al.,  
2012; Skyberg et al., 2012). 
1.4 STATEMENT OF THE PROBLEM 
F. tularensis possesses multiple strategies to passively and actively avoid recognition and 
clearance by the host.  F. tularensis adapts to the host environment by altering its expression of 
surface carbohydrates, eluding recognition by TLR2 (Zarrella et al., 2011).   Moreover, the LPS 
structure of F. tularensis is distinct from other Gram-negative bacteria and poorly immunogenic 
(Gunn and Ernst, 2007). As a means of actively suppressing the host, F. tularensis inhibits NF-
κB signaling in macrophages and dendritic cells, resulting in the production of low levels of 
proinflammatory cytokines (Bosio et al., 2007; Bosio and Dow, 2005; Carlson et al., 2007; 
Loegering et al., 2006; Russo et al., 2011; Telepnev et al., 2003; Telepnev et al., 2005). F. 
tularensis also inhibits assembly of the NADPH oxidase complex, preventing the production of 
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reactive oxygen species (McCaffrey and Allen, 2006).  Thus, the success of F. tularensis as an 
intracellular pathogen is dependent on its ability to evade the host innate immune response. 
  Compared to other respiratory pathogens such as Klebsiella pneumoniae, the innate 
immune  response to F. tularensis is delayed. Typically, innate immune cell recruitment and 
proinflammatory cytokine production are observed within 24 hours of infection. In the case of F. 
tularensis, neutrophils and monocytes do not increase in number in the lungs until three days 
post infection.  Proinflammatory cytokines are not detected until four days post infection.  The 
role of this inflammatory response in tularemia pathogenesis is not well understood.   
We hypot hesize that inadequate innate host defenses contribute to mortality in acute F. 
tularensis infection and poor protection in a vaccination model of pneumonic tularemia.  First, 
we performed a comprehensive comparison of the early host response to the virulent type A F. 
tularensis strain Schu S4 and the attenuated type B strain LVS to define unique characteristics 
assoc iated with type  A pathogenesis.  Initial characterization identified NK cells as an immune  
cell pop ulation that may contribute to the pathological process in Schu S4-infected mice.  
Therefore, add itional work focused on elucidating the role of NK cells in type A F. tularensis 
infection.  We also investigated whether early activation of the innate immune response through 
stimulation of antigen-presenting cells would improve LVS-mediated protection against Schu S4 
challenge.  The results of this study expand our knowledge of the innate immune response to F. 
tularensis and its role in tularemia pathogenesis. 
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2.0  CHARACTERIZATION OF THE HOST RESPONSE TO A VIRULENT F. 
TULARENSIS STRAIN  
2.1 ABSTRACT 
Tularemia is caused by the intracellular bacterium, Francisella tularensis, and varies in clinical 
presentation and disease severity depending on the infecting strain.  Type B F. tularensis causes 
a mild pneumonia, while infection with Type A results in a severe, potentially fatal illness. In 
mouse models of pneumonic tularemia, infection with a low dose of the attenuated type B strain 
LVS is effectively controlled and cleared, while the virulent type A strain Schu S4 is letha l.  In 
this study, we sought to identify factors that contribute to the morbidity and mortality associated 
with type A F. tularensis infection. We found the kinetics of Schu S4 growth was more rapid 
during the earliest stages of infection.  One significant immunological difference between these 
strains was a reduction in the number of viable lung cells, particularly NK cells and T cells, in 
Schu S4- infected mice.  Cell numbers declined in Schu S4-infected mice despite high levels of 
chemok ines in the lung.  This decline correlated with lower proinflammatory cytokines and more 
TUNEL-positive cells.  While neutrophils were found within foci containing TUNEL-positive 
cells, they did not play a role in the induction of cell death.  In conclusion, the mortality of Schu 
S4 infection is associated with early dissemination, cell death, and loss of proinflammatory 
cytokines. 
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2.2 INTRODUCTION 
Tularemia is caused by the Gram-negative bacterium, Francisella tularensis.  Inhalation of less 
than 10 organisms can result in a lethal pneumonia if left untreated (Dennis et al., 2001; 
McLendon et al., 2006).  Due to the high infectivity and mortality associated with F. tularensis, 
the Centers for Disease Control and Prevention has classified this pathogen as a category A 
bioterrorism agent (Barry et al., 2009).  Within F. tularensis, there are two clinical relevant 
subspecies, tularensis (type  A) and holarctica (type  B) (Molins et al., 2010).  An attenuated type 
B strain, LVS (live vaccine strain), is commonly used as a model organism to investigate 
Francisella immunology (Metzger et al., 2007).  While LVS is avirulent in humans, mice are 
susceptible to LVS infection through various administration routes (Metzger et al., 2007).  
Furthermore, murine infection with this strain mimics the course of disease observed in humans 
(Metzger et al., 2007). To confirm that phenotypes within this model translate to a fully virulent 
strain, researchers make use of the type A F. tularensis strain Schu S4 (Metzger et al., 2007). 
Compa rison of these strains has yielded numerous similarities in pathogenesis. 
Although LVS and Schu S4 primarily infect macrophages, these bacteria can also infect 
dendritic cells, neutrophils, and alveolar epithelial cells (Bosio and Dow, 2005; Elkins et al., 
2007; Hall et al., 2007; Hall et al., 2008).  Additionally, LVS and Schu S4 possess similar 
immune evasion strategies including poor stimulation of macrophages and dendritic cells, 
suppression of TLR signaling, and inhibition of the respiratory burst (Bosio et al., 2007; Bosio 
and Dow, 2005; Carlson et al., 2007; Loegering et al., 2006; McCaffrey and Allen, 2006; 
McCaffrey et al., 2010; Russo et al., 2011; Telepnev et al., 2003; Telepnev et al., 2005).  In vivo, 
both strains replicate exponentially in the lung and disseminate to the spleen and liver during 
respiratory infection (Metzger et al., 2007). Furthermore, inflammatory cell infiltrates recruited 
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to the lung were comparable between LVS and Schu S4. (Hall et al., 2008)  Despite these 
similarities, LVS and Schu S4 exhibit different disease outcomes in mouse models of pneumonic 
tularemia.   
Following low dose respiratory challenge, mice effectively clear LVS two to three weeks 
post infection (Metzger et al., 2007).  Mice infected with the type A strain Schu S4, however, fail 
to control bacterial replication and succumb within six days (Metzger et al., 2007).  To identify 
mechanisms contributing to the severe mortality associated with Schu S4, a comparative analysis 
of LVS and Schu S4 infection in mice was performed.  Overall, the natural course of disease was 
similar, although the kinetics of bacterial growth and cytokine and chemokine production were 
delayed with LVS compared to Schu S4.  Moreover, widespread cell death was observed in the 
lungs of Schu S4-infected mice, correlating with declining levels of proinflammatory cytokines. 
Together, these results indicate that bacterial and host factors contribute to Schu S4 virulence in 
vivo. 
 
2.3 MATERIALS AND METHODS 
2.3.1 Francisella strains and growth conditions 
F. tularensis subspecies holarctica LVS was provided by Dr. Karen Elkins (U.S. Food and Drug 
Administration).  F. tularensis subspecies tularensis Schu S4 (strain FSC237, catalog number 
NR-643) was ob tained through t he National Institutes of Health (NIH) Biode fense and Emerging 
Infections Research Resources Repository, National Institute of Allergy and Infectious Diseases.  
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For cultivation of F. tularensis, frozen stock cultures were streaked onto chocolate II agar plates 
and incubated at 37°C, 5% CO2 for two to three days.  These bacteria were then used to inoculate 
cultures grown in MH broth [Mueller-Hinton broth (Difco) supp lemented with 0.1% glucose, 
0.025% ferric pyrophosphate (Sigma), and IsoVitaleX (Becton Dickinson)] at 37°C with shaking 
for 14-18 hours.  All work with F. tularensis Schu S4 was conducted under BSL-3 conditions at 
the University of Pittsburgh with approval from the Centers for Disease Control and Prevention 
Select Agent Program. 
2.3.2 Mice 
Six- to eight-week old female C57BL/6J and BALB/c mice were purchased from Jackson 
Laboratories (Bar Harbor, ME).  Mice were housed in microisolator cages under specific 
pathogen-free conditions in a biosafety level-3 animal facility.  All research involving animals 
was conducted in accordance with animal care and use guidelines, and animal protocols were 
approved by the University of Pittsburgh Animal Care and Use Committee. 
2.3.3 Infection of mice with F. tularensis 
LVS and Schu S4 were grown in MH broth as described above.  Mice were infected 
intratracheally (i.t.) by oropharyngeal instillation as described previously (Horzempa et al., 2010; 
Russo et al., 2011; Schmitt et al., 2012).  Briefly, mice were anesthetized with ketamine (8 
mg/kg) and xylazine (80 mg/kg) and suspended by their front incisors in an upright, vertical 
position. The tongue was extended and 50 µl of LVS or Schu S4 (100 CFU) was deposited at the 
base of the oropharynx and aspirated by the mouse. To confirm delivery of bacteria to the 
 56 
respiratory tract, a subset of mice was sacrificed at two hours pos t infection, and their lungs were 
homogenized and plated.  The actual dose was calculated by plating serial dilutions of the 
inoculum onto chocolate II agar plates.  Mice were monitored twice daily to assess morbidity and 
mortality following infection.   
2.3.4 Generation of tissue homoge nates and enumeration of bacteria 
Mice were sacrificed at indicated time points to measure CFU in lungs, spleens, and livers.  
Spleens and livers were homogenized in TSBc [trypticase soy broth (BD Biosciences) 
supplemented with 0.1% L-cysteine hydrochloride monohydrate (Fisher)]. Lungs were 
homogenized in RPMI containing 10% fetal bovine serum (FBS).  Blood was collected using a 
heparin-coated needle and syringe by cardiac puncture.  A portion of the organ homogenates and 
blood were serially diluted and plated onto chocolate II agar plates.  Plates were incubated at 
37°C at 5% CO2 and individual colonies were enumerated.  The remaining lung homogenate was 
centrifuged at 17,000 x g for three min. to remove cells and tissue debris.  The resulting 
supernatant from the lung homogenate was sterile- filtered through 0.2 µm syringe filters, treated 
with gentamicin (100 µg/ml), and saved for quantification of cytokines and chemokines.   
2.3.5 Isolation of lung cells  
Lungs were processed using two different enzymatic digestion techniques.  For the initial 
characterization of cellular infiltrates in the lungs of Schu S4-infected C57BL/6 mice, lungs were 
minced and incubated in RPMI (Gibco) supplemented with 1% heat-inactivated FBS, 1 mg/ml 
collagenase D (Roche), 10 µg/ml DNaseI (USB), and 3 mM CaCl2 for 30 min at 37°C with 
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shaking (170 rpm).  For all subsequent experiments, lungs were minced and incubated in RPMI 
(Gibco) supplemented with 2.4  mg/ml type I collagenase (Gibco), 20 µg/ml DNase I (USB), and 
3 mM CaCl2 for 30 min at 37°C with shaking (170 rpm). Similar changes in cellular infiltrates 
were observed over time in Schu S4- infected lungs with both methods, although the latter 
enzymatic digestion resulted in a two- to three-fold increase in the total number of cells isolated 
(Fig. 6).  The digested tissue was passed through a 40-µm cell strainer (BD Biosciences) to 
generate single cell suspensions.  Erythrocytes were lysed with ACK Lysis Buffer (Gibco) and 
remaining cells were washed with RPMI.  Total live cells were counted using trypan blue 
exclusion.  Lung cells were resuspended in FACS staining buffer [0.1% bovine serum albumin 
(BSA) and 0.1% sodium azide in PBS] prior to flow cytometric analysis.   
 
Figure 6.  Number of lung cells isolated using different enzymatic digestion techniques. 
Lungs were harvested from Schu S4-infected mice (n=2 mice/group) five dpi and processed using two different 
enzymatic digestion techniques.  For enzyme digestion 1, lungs were minced and incubated in RPMI (Gibco) 
supplemented with 1% heat-inactivated FBS, 1 mg/ml co llagenase D (Roche), 10 µg/ml DNaseI (USB), and 3 mM 
CaCl2 for 30 min at 37°C with shaking (170 rpm).  For enzyme digestion 2, lungs were minced and incubated in 
RPMI (Gibco) supplemented with 2.4 mg/ml type I co llagenase (Gibco), 20 µg/ml DNase I (USB), and 3 mM CaCl2 
for 30 min at 37°C with shaking (170 rpm).  Absolute cell numbers in the lung were enumerated by trypan blue 
exclusion.  Data are expressed as mean ± SD of one independent experiment 
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2.3.6 Flow cytometry and analysis of lung cells 
Individual immune cell populations from the lungs processed above were identified by flow 
cytometric analysis. Fc receptors were blocked with purified anti-mouse CD16/CD32 (clone 93, 
eBioscience) for 15 min on ice.  Cells were then stained with the following antibodies at 4°C for  
25 min:  FITC anti-CD49b (clone DX5, eBioscience), FITC anti-TCR-β  (clone H57-597, BD 
Biosciences), PE anti-Ly-6G (clone 1A8, BD Biosciences), APC anti-F4/80 (clone BM8, 
eBioscience), PerCP-Cy5.5 anti-CD11b (clone M1/70, eBioscience), Pacific Blue® anti-NK1.1 
(clone PK136, eBioscience), APC-Alexa Fluor750/eFluor™ 450 anti-CD11c (clone N418, 
eBioscience), APC-eFluor™ 780 anti-TCR-β  (clone H57-597), and PerCP-Cy5.5 anti-CD3 
(clone 145-2C11, eBioscience).  Isotype control antibodies were included in each experiment to 
confirm specificity.  Dead cells were stained using the LIVE/DEAD® Fixable Blue Dead Cell 
Stain Kit (Invitrogen).  Cells were then washed in PBS and fixed in 4% paraformaldehyde for 30 
min at 4°C.  After 25 min, cells were washed and fixed in 2% paraformaldehyde.  Samples were 
collected using a LSRII flow cytometer (BD Biosciences) and analysis gates were set on live 
cells (negative for LIVE/DEAD® Fixable Blue dye) excluding debris based on forward scatter 
and side scatter.  Approximately 100,000 events were collected for each sample.  Data was 
analyzed using FlowJo Software (Tree Star).  
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2.3.7 Cytokine and chemokine assays 
Cytokine and chemokine levels in lung s upernatants were determined by using the Milliplex 
23-plex Mouse Cytokine/Chemokine Panel (Millipore) on a Bio-Plex 200 system (Bio-Rad 
Laboratories).  Analyte concentrations were calculated against the standards using Bio-Plex 
Manager 5.0 software (Bio-Rad Laboratories, Inc.).   
2.3.8 Immunofluorescence staining of lung tissue sections 
Mice were sacrificed and lungs were fixed by inflating with 0.8 ml of 37% formalin for 5 min.  
Lungs were then harvested and submerged in 37% formalin for 24 hours.  Fixed tissues were 
placed into histology cassettes and transferred to 10% formalin.  Tissue sectioning was 
performed by the University of Pittsburgh, School of Medicine Histology Core in the 
Department of Pathology Development Laboratory. For immunofluorescence staining, paraffin-
embedded sections were deparaffinized in xylene and rehydrated through a series of ethanol 
washes.  The slides were subsequently rinsed with deionized water and incubated in PBS. 
Sections were blocked with 2.5% BSA in PBS for 30 min and then probed with either rabbit anti-
F. tularensis (1:500 dilution; BD Biosciences) or rat anti-Ly6G (1:350 dilution; BD Biosciences) 
overnight at 4°C.  As a control, a paired section was probed with normal rabbit IgG 
(Calbiochem) or rat IgG2a (BD Biosciences).  Sections were washed three times in PBS with 
0.2% Tween 20 and then probed with a secondary Alexa Fluor 568 goat anti-rabbit antibody 
(1:1000 dilution, Invitrogen) or Alexa Fluor 555 goat anti-rat antibody (1:1000 dilution, 
Invitrogen) for at least 1 hour at 25°C. TUNEL analysis was performed by first permeabilizing 
the tissue sections with permeabilization solution (0.1% Triton X-100, 0.1% sodium citrate) for 8 
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min on ice. Following permeabilization, the slides were washed three times in PBS and the 
TUNEL reaction was done using the Fluorescein In Situ Cell Death Detection Kit (Roc he) 
according to the manufacturer’s instructions.  Following another series of washes in PBS, 
sections were then stained with 0.5 μg/ml 4 ′,6-diamidino-2-phenylindole dihydrochloride (DAPI) 
(Invitrogen) and mounted in ProLong Gold antifade reagent (Invitrogen).  Sections were viewed 
under a Zeiss Axiovert 200 microscope and images were captured at 100x magnification with 
equal fluorescence exposure times.  AxioVision software was used to process the images and 
make uniform modifications in br ightness and contrast.  
2.3.9 In vivo depletion of neutrophils  
Mice were depleted of neutrophils using an anti-Ly6G antibody as described previously with 
minor modifications (Frazer et al., 2011).  Mice were administered 300 μg of rat anti-mouse 
Ly6G (clone 1A8, BioXCell, West Lebanon, NH) or rat IgG2a control (clone 2A3, BioXCell, 
West Lebanon, NH) intraperitoneally (i.p.) one day prior to infection with Schu S4 and every 
three days thereafter until sacrifice.  Administration of anti-Ly6G was effective at depleting 
>95% of neutrophils (Ly-6G+, CD11b+, F4/80-) in the blood (Frazer et al., 2011). 
2.3.10 Infection of human NK cells with F. tularensis Schu S4 
Lymphocytes were purified from human buffy coats from blood donations (Central 
Blood Bank, P ittsburgh, PA) using Ficoll gradients (Amersham Biosciences) to isolate peripheral 
blood mononuclear cells and Opt iprep gradients (Axis-Shield) to separate out monocytes.  NK 
cells were purified from lymphocytes using a Human NK Cell Isolation Kit (Miltenyi Biotec) per 
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the manufacturer’s instructions.  NK cells were washed and resuspended in RPMI supp lemented 
with 10% human serum, 25 mM HEPES, and 1% GlutaMAX.  Cells were seeded in 96-well 
round bottom culture dishes (BD Biosciences) at a density of 2.5 x 105 cells/well and infected 
with Schu S4 at an MOI of 250.  After three hours, cells were incubated with Hanks ba lanced 
salt solut ion (Gibco) containing gentamicin (50 µg/ml) for one hour to kill extracellular bacteria.  
Cultures were then washed three times with warm Hank’s balanced salt solution and incubated at 
37°C with 5% CO2 for another 21 hours with fresh culture medium.  Actual MOIs were 
measured by plating serial dilutions of inocula on chocolate II agar plates.  At the indicated time 
points post infection, cells were pelleted and lysed with 0.02% sodium dodecyl sulfate. Serial 
dilutions of the lysates were plated on chocolate II agar plates for enumeration of viable bacteria.   
2.4 RESULTS 
2.4.1 Schu S4 reduces the number of immune cells in the lung 
In order to directly compare differences in disease progression between LVS and SchuS4, 
C57BL/6 mice were infected with comparable doses of each Francisella strain (approximately 
100 CFU).  LVS and Schu S4 replicated exponentially in the lungs following pulmonary 
inoculation (Fig. 7).   Both strains grew similarly from one to three days post infection (dpi), but 
Schu S4 outgrew LVS in the first 24 hours and sustained a higher plateau (Fig. 7). Schu S4 
disseminated to the spleen and liver one day earlier than LVS and reached burdens that were 
three to four logs higher by four dpi (Fig. 7).  Similar growth kinetics of Schu S4 were observed 
in BALB/c mice (Fig. 8).  All mice succumbed to Schu S4 infection within five days.  In 
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contrast, LVS growth plateaued three dpi in the lung and five dpi in the spleen and liver, then 
declined beginning nine dpi (Fig. 9).  By 17 dpi, only half of the LVS-infected mice had 
detectable CFU in the lung (Fig. 9). 
 
 
Figure 7.  Schu S4 exhibits higher bacterial burdens and earlier dissemination than LVS in vivo. 
LVS or Schu S4 (~100 CFU) was admin istered to C57BL/6 mice i.t. (n=4 mice/group). At indicated time points, 
mice were sacrificed and lungs, spleens, and livers were harvested and homogenized as described in Materials and 
Methods.  Organ homogenates were diluted and plated for CFU enumeration.  Data are expressed as mean ± SEM 
and represent a combination of four independent experiments.  For most data points, the error bars are smaller than 
the symbols. The limit of detection (dashed line) for the spleen and liver was 100 CFU and 200 CFU, respectively.  
Statistical significance was determined by two-way ANOVA, followed by Bonferroni comparison of means (*, 
p<0.05). 
 
 
Figure 8.  Replication and dissemination of Schu S4 in BALB/c mice. 
 63 
Schu S4 (~100 CFU) was admin istered to BALB/c mice i.t. (n=4 mice/group). At indicated time points, mice were 
sacrificed and lungs, spleens, and livers were harvested and homogenized as described in Materials and Methods.  
Organ homogenates were diluted and plated for CFU enumeration.  Data are expressed as mean ± SEM and 
represent a combination of two independent experiments.  For most data points, the error bars are smaller than the 
symbols. The limit of detection (dashed line) fo r the spleen and liver was 100 CFU and 200 CFU, respectively.   
 
 
Figure 9. Clearance of LVS from the lung and peripheral organs following infection. 
LVS  (~100 CFU) was administered to C57BL/6 mice i.t. (n=2-4 mice/group). At indicated time points, mice were 
sacrificed and lungs, spleens, and livers were harvested and homogenized as described in Materials and Methods.  
Organ homogenates were diluted and plated for CFU enumeration.  Data are expressed as mean ± SD and represent 
two independent experiments.  For most data points, the error bars are smaller than the symbols. The limit of 
detection (dashed line) for the spleen and liver was 100 CFU and 200 CFU, respectively. 
 
Since the lung is the primary site of F. tularensis infection, we first analyzed changes in its 
cellular composition. As bacterial burden increased over time, the total number of live cells also 
significantly increased in the lungs of LVS-infected mice compared to PBS controls (Fig. 10).  In 
contrast, the number of viable cells decreased in mice infected with Schu S4, beginning two dpi 
(Fig. 10).  After four days, a significant 60-70% reduction in cell numbers was observed (Fig. 
10).  A similar decline in viable cells was observed in Schu S4-infected BALB/c mice (Fig. 10).  
To determine whether the loss in viable cells was attributable to differences in burden, a 100-fold 
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higher dose of LVS was administered to mice and lung cell numbers were evaluated over time.  
Similar to low dose LVS challenge, the number of live cells increased four dp i with a high dose 
of LVS compared to PBS (Fig. 11). 
 
Figure 10.  Reduction in viable lung cells in Schu S4-infected mice. 
PBS, LVS, or Schu S4 (~100 CFU) was administered to C57BL/6 or BALB/c mice i.t. (n=2-4 mice/group). At 
indicated time points, mice were sacrificed and lungs were harvested and homogenized as described in Materials and 
Methods.  Absolute cell numbers in the lung were enumerated by trypan blue exclusion.  For C57BL/6 mice, data 
are expressed as mean ± SEM and represent a combination of at least 4 independent experiments.  For BALB/c 
mice, data are expressed as mean ± SD and are representative of two independent experiments.  Statistical 
significance was determined by two-way ANOVA, followed by Bonferroni comparison of means (a p<0.05 
significant compared to PBS; bp<0.05 significant compared to day1). 
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Figure 11.  Administration of a higher dose of LVS does not result in reduced numbers of viable cells four 
dpi. 
PBS, LVS (~100 CFU for low or ~10,000 CFU for high), or Schu S4 (~100 CFU) was administered to C57BL/6 
mice i.t. (n=2-3 mice/group). At indicated time points, mice were sacrificed and lungs were harvested and 
homogenized as described in Materials and Methods.  Absolute cell numbers in the lung were enumerated by trypan 
blue exclusion.  Data are expressed as mean ± SD of one independent experiment. 
 
To identify which cell populations were being depleted, immune cells were then measured 
over time by flow cytometry.  Neutrophils were the predominant cell population recruited to the 
lungs after LVS infection (approximately 40% of total cells by day four, Fig. 12A), similar to 
published results (Hall et al., 2008).  The number of macrophages also increased in the lungs of 
LVS-infected mice (Fig. 12B).  No significant differences in the frequency or absolute number of 
DCs, T cells, or NK cells were observed in LVS-infected mice compared to PBS controls (Fig. 
12C-E).  Although neutrophil and macrophage numbers increased up to three dpi with Schu S4 
(Fig. 12A-B), similar to previous results (Hall et al., 2008), their numbers declined sharply from 
three to four dpi (Fig. 12A-B). In BALB/c mice, only a significant reduction in macrophages was 
observed four dpi, while neutrophils continued to increase (Fig 13B-C).  In C57BL/6 mice, 
approximately 90% of the NK cells and T cells were depleted in the lungs four days following 
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Schu S4 infection (Fig. 12D-E). A similar trend was observed in Schu S4- infected BALB/c mice, 
with approximately 65% of NK cells and T cells being depleted (Fig. 13D-E).  In summary, Schu 
S4 infection reduced cell viability in the lungs, particularly in the NK cell and T cell populations. 
 
 
Figure 12. Changes in immune cell populations in the lung over time following Schu S4 infection. 
PBS, LVS, or Schu S4 (~100 CFU) was administered to C57BL/6 mice i.t. (n=2-4 mice/group). At indicated time 
points, mice were sacrificed and lungs were harvested and homogenized as described in Materials and Methods. 
Different immune cell populations were identified using standard lineage markers by multi-parameter flow 
cytometry: neutrophils (Ly6G+, F4/80low), macrophages (F4/80+,Ly-6G-), dendritic cells (CD11chigh,F4/80-), NK 
cells (DX5+,TCR-β-), and T cells (DX5-,TCR-β+). Total cell numbers for each population were determined by 
multip lying the percentages derived for each cell population by the total number of lung cells from each individual 
mouse. Data are expressed as mean ± SEM and are representative of combination of 2-6 independent experiments.  
Statistical significance was determined by two-way ANOVA, fo llowed by Bonferroni comparison of means (a 
p<0.05 significant compared to PBS; bp<0.05 significant compared to day 1;  c p<0.05 significant compared to day 
3). 
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Figure 13.  Schu S4 depletion of lymphocytes in BALB/c mice. 
PBS or Schu S4 (~100 CFU) was admin istered to BALB/c mice i.t. (n=4 mice/group). At indicated time points, 
mice were sacrificed and lungs were harvested and homogenized as described in Materials and Methods. Different 
immune cell populations were quantified by multi-parameter flow cytometry as described in the legend of Fig. 12.  
Data are expressed as mean ± SD and are representative of two independent experiments.  Statistical significance 
was determined by two-way ANOVA, fo llowed by Bonferroni comparison of means (a p<0.05 significant compared 
to PBS; bp<0.05 significant compared to day1; c p<0.05 significant compared to day 3). 
 
2.4.2 Schu S4 infection modulates cytokine and chemokine production 
Since immune  cell numbers declined over time in Schu S4- infected mice, we next wanted to 
evaluate changes in the production of proinflammatory cytok ines and chemok ines.  Most 
cytokines and chemokines were detected in the lung three dpi with Schu S4, compared to four 
dpi with LVS (Fig. 14).  This delayed response in LVS-infected mice correlated with slower 
bacterial growth kinetics early following infection compared to Schu S4 (Fig. 7).  A number of 
monocyte, neutrophil, and T cell chemoattractants elicited by Schu S4, including KC, MCP-1, 
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M-CSF, MIP-2 and RANTES, reached levels 5 to 20-fold higher than LVS four dpi (Fig. 14). IL-
13, MIG, MIP-1α, and MIP-1β  production in LVS-infected mice was similar to Schu S4, albeit 
with a slight delay (Fig. 14). In LVS-infected mice, the production of several inflammatory 
mediators such as IFN-γ, IL-1β, IL-6, and IL-17 continually increased during the first four dpi 
(Fig. 14).  In contrast, these cytok ines decreased from three to four dpi with Schu S4 (Fig. 14).  
As cytokines like IFN-γ and IL-17 are known to play a critical role in control of LVS (Cowley 
and Elkins, 2011), this decline late during Schu S4 infection may contribute to death of the host.  
Therefore, we evaluated the effect recombinant adenoviruses expressing IFN-γ (AdIFN-γ) and/or 
IL-17 (AdIL-17) had on the natural course of disease following infection with Schu S4.  In 
contrast to AdIL-17 (Fig. 15), AdIFN-γ reduced bacterial burdens in the lung and peripheral 
organs following Schu S4 infection (Fig. 15-16). However, this treatment did not significantly 
alter the progression of disease in Schu S4-infected mice based on clinical signs and weight loss 
[14% weight loss in AdIFN-γ treated mice compared to 17% weight loss in mice treated with an 
empty adenovirus vector (AdY5)].  Therefore, reduced IFN-γ and IL-17 production in Schu S4-
infected mice four dpi is not associated with mortality. 
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Figure 14. Cytokine and chemokine levels in the lungs of Schu S4-infected mice. 
PBS, LVS, or Schu S4 (~100 CFU) was admin istered to C57BL/6 mice i.t. (n=2-4 mice/group). Supernatants from 
lung homogenates were assayed for multip le cytokines and chemokines using the Millip lex 23-plex Mouse 
Cytokine/Chemokine Panel (Millipore) on a Bio-Plex system (Bio-Rad Laboratories, Inc.).   Only those cytokines 
and chemokines reaching detectable levels following infection with Schu S4 or LVS are displayed here. Data are 
expressed as mean ± SEM (n=2-4 samples/group/timepoint) and are representative of combination of 3 independent 
experiments. Statistically significant differences in cytokine/chemokine production were determined by a two-way 
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ANOVA, followed by Bonferroni comparison of means (*, p<0.05 compared to PBS).  BD = below limits of 
detection. 
 
 
Figure 15.  Recombinant adenovirus expressing IFN-γ reduces bacterial burden in Schu S4-infected mice. 
BALB/c mice (n=3-4 mice per group) were admin istered i.t. a recombinant adenovirus expressing IFN-γ (AdIFN-γ, 
2x108 PFU)  and/or IL-17 (AdIL-17, 2x108 PFU) one day prior to i.t. infection with Schu S4 (100 CFU).  An empty 
adenovirus vector (AdY5) served as a control. Two dpi, mice were sacrificed and lungs, spleens, and livers were 
harvested and processed as described in the Materials and Methods.  Organ homogenates were diluted and plated for 
CFU enumeration. The limit of detection was 100 CFU per organ, except the liver, which was 200 CFU. Each data 
point represents an individual mouse with the bar indicating the mean. Statistical significance was determined by 
two-way ANOVA, fo llowed by Bonferroni comparison of means (*, p<0.05 significant compared to AdY5).   
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Figure 16.  Administration of recombinant adenovirus expressing IFN-γ reduces Schu S4 growth and 
dissemination in mice. 
BALB/c mice (n=4 mice per g roup) were admin istered i.t. recombinant adenovirus expressing IFN-γ (AdIFN-γ, 
2x108 PFU) either (A) one day prior or (B) one day prior and two days following i.t. infect ion with Schu S4 (100 
CFU).  An empty adenovirus vector (AdY5) served as a control.  At each timepoint, mice were sacrificed and the 
designated organs and blood were processed, diluted, and plated for CFU enumeration. The limit of detection was 
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100 CFU per organ, except the liver, which was 200 CFU.  Data are expressed as mean ± SD of one experiment. 
Statistical significance was determined by two-way ANOVA, followed by Bonferroni comparison of means (*, 
p<0.05 significant compared to AdY5). 
2.4.3 Widespread cell death in the lungs of Schu S4-infected mice 
To determine if the reduction in immune cells was due to cell death in the lungs of Schu S4-
infected mice, TUNEL staining was performed on lung sections from uninfected and infected 
mice.  There was a high frequency of TUNEL-positive cells within Schu S4-infected lungs 
compared to LVS-infected lungs and uninfected controls at four dpi (Fig. 17).  Although 
TUNEL-positive cells were found near regions where there was a concentration of Francisella  
ant igen, no costaining was detected (Fig. 17). We next sought to identify the specific cell 
populations contained within these infected foci.  Only Ly6G+ cells, presumably neutrophils, 
localized in regions with dense TUNEL staining, although these cells were not TUNEL-positive 
(Fig. 18). 
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Figure 17.  Extensive cell death in the lungs of Schu S4-infected mice. 
IT instillat ion was used to administer PBS, LVS, or Schu S4 (100 CFU) to C57BL/6 mice (n=2-4 mice/group).  Four 
dpi, lungs were harvested, fixed in formalin, and subsequently embedded in paraffin.  Deparaffinized lung sections 
were probed with rabbit anti-F. tularensis followed by an Alexa Fluor 568 goat anti-rabbit secondary. A Fluorescein 
In Situ Cell Death Detection Kit (Roche) was used for the TUNEL assay. DNA was stained with DAPI. Images 
were captured at 100x magnification with an equal fluorescence exposure time within each channel.  
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Figure 18.  Neutrophils are found within inflammatory foci near TUNEL-positive cells. 
Four dpi with Schu S4, lungs were harvested from C57BL/6 mice, fixed in formalin, and subsequently embedded in 
paraffin.  Deparaffin ized lung sections were probed with rat anti-mouse Ly6G fo llowed by an Alexa Fluor 555 goat 
anti-rat secondary. A Fluorescein In Situ Cell Death Detection Kit (Roche) was used for the TUNEL assay. DNA 
was stained with DAPI. The color merged image (red, Ly-6G; green, TUNEL; blue, DAPI) were captured at 100x 
magnificat ion with an equal fluorescence exposure time within each channel.  
 
Due to the proximity of TUNEL-positive cells and neutrophils, we hypothesized the recruitment 
of neutrophils was contributing to the widespread cell death observed in Schu S4-infected mice.  
Neutrophils were depleted prior to Schu S4 infection using an anti-Ly6G (1A8) antibod y and cell 
death and bacterial burden were evaluated.  No significant differences in bacterial burden were 
observed in neutrophil-depleted mice infected with Schu S4 compared to isotype-treated infected 
controls (Fig. 19A).  In addition, neutrophil depletion did not significantly alter the progression 
of disease in Schu S4- infected mice based on clinical signs and weight loss (18% for isotype 
controls and 17% for anti-Ly6G-treated four dpi).  Equivalent amounts of TUNEL staining were 
observed in lung sections from both neutrophil-depleted and isotype-treated Schu S4-infected 
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mice (Fig. 19B).  Therefore, we concluded the cell death observed in the lungs of Schu S4-
infected mice was independent of the recruitment of neutrophils.   
 
Figure 19.  Bacterial burden and TUNEL staining in neutrophil-depleted Schu S4-infected mice. 
C57BL/6 mice (n=4 per group) were admin istered anti-Ly6G or rat IgG2a one day prior to i.t. infection with Schu 
S4 (100 CFU) and every three days thereafter.  (A) Bacterial burdens of neutrophil-depleted Schu S4-infected mice.  
Four dpi, mice were sacrificed and lungs, spleens, and livers were harvested and processed as described in the 
Materials and Methods.  Organ homogenates were diluted and plated for CFU enumerat ion. The limit of detection 
was 100 CFU per o rgan, except the liver, which was 200 CFU.  Data are expressed as mean ± SD and are 
representative of one independent experiment. (B)  Immunofluorescence microscopy of lung sections from Schu S4-
infected mice depleted of neutrophils.  Four dpi, lungs were harvested, fixed in formalin, and embedded in paraffin.  
Deparaffinized lung sections were probed with rat anti-mouse Ly6G fo llowed by a secondary Alexa Fluor 555 goat 
anti-rat antibody. An In Situ Cell Death Detection Kit  (Roche) was used for the TUNEL assay. DNA was stained 
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with DAPI. The color merged images (red, Ly-6G; green, TUNEL; b lue, DAPI) were captured at 100x 
magnificat ion with an equal fluorescence exposure time within each channel.   
2.5 DISCUSSION 
Pulmonary infection of mice with the type A F. tularensis strain Schu S4 is frequently used 
as a model to investigate tularemia pa thogenesis (Metzger et al., 2007).  While these studies have 
elucidated novel pathologic and immunologic features of the infection, it is still not known, 
however, what contributes to the rapid death of the host.  In this study, we compared the course 
of disease with an attenuated and virulent F. tularensis strain to identify factors associated with 
mortality.  Major differences between the two strains included growth rate, cell death, and 
proinflammatory cytokine production. Thus, we concluded that both bacterial and host factors 
contribute to type A F. tularensis virulence in vivo. 
In the lung, LVS and Schu S4 exhibit similar growth rates, except during the first 24 hours 
of infection where Schu S4 demonstrates two logs of growth compared to one log of growth 
observed with LVS.  The enhanced growth of Schu S4 may be attributed to its broader resistance 
to host defenses compared to LVS.  For example, LVS is more susceptible to killing by ROS and 
RNS compared to Schu S4 (Lindgren et al., 2007).  Alternatively, the lower bacterial burdens of 
LVS may be due to the absence of critical virulence factors, such as pilA and FTT0918, in this 
strain (Salomonsson et al., 2009).  Reintroduction of these two genes restored full LVS virulence 
to wild-type levels of type B strains in vivo (Salomonsson et al., 2009). The higher growth 
plateau reached by Schu S4 may overwhelm the host, resulting in death of the mouse. 
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Recently, Schu S4 infection has been described to exhibit many hallmarks of sepsis 
including widespread cell death and hypercytokinemia (Sharma et al., 2011).  In this study, we 
observed a significant reduction in cell viability, particularly in the NK cell and T cell 
populations, in the lungs of Schu S4- infected mice.  Cell numbers declined despite enhanced 
production of numerous monocyte, neutrophil, and T cell chemoattractants.  In other models of 
seps is, the loss in lymphocytes is due to the induction of caspase 3-dependent apoptosis 
(Hotchkiss et al., 2005).  It is unlikely, however, that this pathway contributes to NK and T cell 
death in Schu S4- infected mice because few caspase 3-positive cells are detected in the lung 
following challenge (Bosio et al., 2007; Parmely et al., 2009).  Preliminary in vitro studies 
suggest Schu S4 can invade but not replicate in NK cells (Fig. 20).  Therefore, direct cell 
invasion may contribute to NK cell loss in vivo.  
 
Figure 20.  Invasion of human NK cells by F. tularensis Schu S4. 
NK cells were infected in gentamicin protection assays (MOI = 250) with Schu S4 and lysed at the indicated times 
post infection as described in Materials and Methods.  For both data points, the error bars are s maller than the 
symbols.  Data shown are mean ± SEM from two indiv idual experiments with different donors.  The dotted line 
represents the limits of detection for this assay. 
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There were also some differences in the influx of various immune cell populations into the 
lung following Schu S4 infection between C57BL/6 and BALB/c mice.  Compared to the 
gradual decrease in NK cells observed in C57BL/6 mice (Fig. 12D), NK cells numbers remained 
unchanged during the first three days following Schu S4 infection in BALB/c mice with a 
dramatic reduction in this population only occuring four dpi (Fig. 13D).  In addition, no 
significant decline in neutrophils was observed in BALB/c mice (Fig. 13A).  These differences 
could not be attributed to differences in bacterial burden since similar growth and dissemination 
kinetics of Schu S4 were observed in both mouse strains (Fig. 7-8).  One possible explanation for  
these contrasting phenotypes may be differences in the cytok ine and chemokine response elicited 
by Schu S4 in each mouse strain.  The distinct cytokine profiles of C57BL/6 and BALB/c mice 
have been well documented (Gueders et al., 2009; Kuroda et al., 2002; Kuroda and Yamashita, 
2003; Mills et al., 2000; Watanabe et al., 2004).  These differences in immune cell recruitment, 
however, did not affect their susceptibility to Schu S4 infection since the median time to death 
for both mouse strains is 5 d ays (Conlan et al., 2003). 
In addition to the reduced cell numbers in the lung, there was a decrease in cytokines like 
IFN-γ and IL-17 in Schu S4- infected mice four dpi.  In LVS-infected mice, these cytokines 
continually increase and are essential for control of bacterial replication and clearance (Cowley 
and Elkins, 2011). While administration of AdIFN-γ reduced bacterial burdens in Schu S4-
infected mice (Fig. 15-16), neither this treatment nor AdIL-17 significantly altered morbidity or 
mortality. These data suggest IFN-γ and IL-17 do not play a beneficial role in tularemia caused 
by type A strains. 
In a recent study involving MMP-9-/- mice, excessive neutrophil recruitment was 
associated with death following Schu S4 infection (Malik et al., 2007).  Depletion of neutrophils, 
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however, had no significant effect on bacterial burden or disease progression in Schu S4-infected 
mice. Similar results were observed by KuoLee and colleagues using a different depletion 
strategy (KuoLee et al., 2011).  These data suggest the recruitment of neutrophils does not 
directly contribute to morbidity or mortality following Schu S4 infection.  
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3.0  ROLE OF NK CELLS IN HOST DEFENSE AGAINST PULMONARY TYPE A 
FRANCISELLA TULARENSIS INFECTION 
An adapted version of this chapter has been submitted: 
Schmitt, D.M., D.M. O’Dee, M.J. Brown, J. Horzempa, B.C. Russo, P.A. Morel, and G.J. Nau. 
2012.  Role of NK cells in host defense against pulmonary type A Francisella tularensis 
infection.  Microbes and Infection.  Submitted.  
3.1 ABSTRACT 
Pneumonic tularemia is a potentially fatal disease caused by the Category A bioterrorism agent 
Francisella tularensis.  Understanding the pulmonary immune response to this bacterium is 
necessary for developing effective vaccines and therapeutics.  In Chapter 2, characterization of 
immune cell populations in the lungs of mice infected with the type A strain Schu S4 revealed a 
significant loss in NK cells over time.   Since this decline in NK cells correlated with morbidity 
and mortality, we hypothesized these cells contribute to host defense against Schu S4 infection.  
Depletion of NK cells prior to Schu S4 challenge significantly reduced IFN-γ and granzyme B in 
the lung but had no effect on bacterial burden or disease progression.   Conversely, increasing 
NK cell numbers with the anti-apoptotic cytokine IL-15 and soluble receptor IL-15Rα had no 
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significant impact on Schu S4 growth in vivo.   A modest decrease in median time to death, 
however, was observed in LVS-vaccinated mice depleted of NK1.1+ cells and challenged with 
Schu S4.  Therefore, NK cells do not contribute to host defense against acute respiratory 
infection with type A F. tularensis in vivo, but they play a minor role in protection elicited by 
LVS vaccination. 
3.2 INTRODUCTION 
The intracellular bacterium Francisella tularensis causes the disease tularemia (Oyston, 2008), 
which can be lethal in 30-60% of untreated individuals after inhalation (Dennis et al., 2001).  
Among the four different subspecies, only tularensis (type A) and holarctica (type B) are 
clinically important (Molins et al., 2010).  Type A strains are the most virulent and cause 
approximately 90% of the tularemia cases detected in North America (Choi, 2002).  
Furthermore, F. tularensis is a potential bioterrorism agent due to its low infectious dose, ease of 
aerosolization, and high mortality rate (McLendon et al., 2006). The development of effective 
therapeutics and vaccines against F. tularensis depends on a thorough understanding of the 
pulmonary immune response to this pathogen. 
Several studies have characterized the innate immune  response elicited following 
respiratory challenge with the type A F. tularensis strain Schu S4 in mice.  After inhalation, this 
bacterium infects and replicates in multiple cell types in the lung, including alveolar 
macrophages, airway dendritic cells (DCs), and type II alveolar epithelial cells (Bosio and Dow, 
2005; Hall et al., 2007; Hall et al., 2008).  Although macrophages and DCs typically facilitate 
clearance of bacterial infections (Lambrecht et al., 2001), F. tularensis poorly activates these 
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cells (Bosio et al., 2007; Carlson et al., 2009; Russo et al., 2011).  F. tularensis- infected 
macrophages and DCs secrete low levels of proinflammatory cytokines, do not upregulate 
costimulatory molecules, and are unresponsive to stimulation with TLR ligands (Bos io et al.,  
2007; Carlson et al., 2009; Russo et al., 2011).  Consequently, F. tularensis replicates 
exponentially in the lung and disseminates to the spleen and liver two to three days following 
infection (Metzger et al., 2007).  Inflammatory cell infiltrates comprised predominantly of 
monocytes and neutrophils are observed in the lung three days pos t infection (Conlan et al.,  
2003; Hall et al., 2008; Metzger et al., 2007).  F. tularensis infects neutrophils and inhibits the 
NADPH oxidase complex, blocking the production of reactive oxygen species (Hall et al., 2008; 
McCaffrey et al., 2010).  Depleting or enhancing the recruitment of neutrophils has no impact on 
Schu S4 infection suggesting these cells are not major contributors to host defense (KuoLee et 
al., 2011).  The role of other innate immune cells in type A Francisella infection in vivo has not  
been investigated.   
NK cells serve two primary functions in combating bacterial infections: perforin-
mediated cytolys is and secretion of IFN-γ.  While perforin contributes to control of LVS growth 
in vitro, prf-/- mice remain equally susceptible to F. tularensis (Sanapala et al., 2012).   Early 
during infection, NK cells are recruited to the lung and are the primary source of IFN-γ (Bokhari 
et al., 2008; Lopez et al., 2004).  Depletion of NK cells results in lower IFN-γ production and 
shortened mouse survival from lethal pulmonary challenge with LVS (Bokhari et al., 2008; 
Lopez et al., 2004; Metzger et al., 2007).  In addition, a number of therapies that reduce mortality 
associated with pneumonic tularemia are dependent on NK cells.  For example, protection 
mediated by acai polysaccharides and CpG DNA was attributed to inhibition of F. tularensis 
intramacrophage replication by NK cells (Elkins et al., 2009; Elkins et al., 1999b; Skyberg et al., 
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2012).  NK cells are also required to prolong survival after treatment with recombinant IL-12 and 
cationic liposome DNA-complexes (Duckett et al., 2005; Troyer et al., 2009).   While these 
studies suggest NK cells play a beneficial role in Francisella immun ity, the contribution of NK 
cells during type A pneumonic tularemia has not been directly investigated.  
Previously, we demonstrated NK cell numbers significantly declined over time in the 
lungs of type A F.tularensis-infected mice (Fig. 12D and 13D), correlating with morbidity and 
mortality.  To assess the role of NK cells in type A Francisella infection, we used two different 
strategies to modulate NK cell numbers: antibody-mediated depletion and treatment with IL-15 
and its receptor (IL-15Rα).  Our results indicate that NK cells do not play a major role in host 
defense against acute respiratory infection with type A F. tularensis, but make a limited 
contribution in a vaccinated animal. 
3.3 MATERIALS AND METHODS 
3.3.1 Francisella strains and growth conditions 
F. tularensis subspecies holarctica LVS was provided by Dr. Karen Elkins (U.S. Food and Drug 
Administration).  F. tularensis subspecies tularensis Schu S4 (strain FSC237, catalog number 
NR-643) was obtained through the National Institutes of Health (NIH) Biodefense and Emerging 
Infections Research Resources Repository, National Institute of Allergy and Infectious Diseases.  
Frozen stock cultures were streaked onto chocolate II agar plates and incubated at 37°C with 5% 
CO2 for two to three days.  These bacteria were then used to inoculate cultures grown in MH 
broth [Mueller-Hinton broth (Difco) supplemented with 0.1% glucose, 0.025% ferric 
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pyrophosphate (Sigma), and IsoVitaleX (Becton Dickinson)] at 37°C with shaking.  All work 
with Schu S4 was conducted under BSL-3 conditions at the University of Pittsburgh with 
approval from the CDC Select Agent Program. 
3.3.2 Infection and immunization of mice 
Six- to eight-week old female C57BL/6J mice purchased from Jackson Laboratories (Bar 
Harbor, ME) were housed in microisolator cages under specific pathogen-free conditions in a 
biosafety level-3 animal facility.  Mice were infected intratracheally [~100 colony forming units 
(CFU)] by oropharyngeal instillation as described previously (Horzempa et al., 2010; Russo et 
al., 2011; Schmitt et al., 2012).  For LVS vaccinations, mice were administered ~1000 CFU 
intranasally (Schmitt et al., 2012).  Mice were challenged with Schu S4 five weeks following 
LVS vaccination.  All research involving animals was conducted in accordance with animal care 
and use guidelines, and animal protocols were approved by the Institutional Animal Care and 
Use Committee. 
3.3.3 Generation of tissue homoge nates and enumeration of bacteria 
Mice were sacrificed at indicated time points to measure CFU in lungs, spleens, and livers 
(Horzempa et al., 2010; Russo et al., 2011; Schmitt et al., 2012).  Spleens and livers were 
homogenized in TSBc [trypticase soy broth (BD Biosciences) supplemented with 0.1% L-
cysteine hydrochloride monohydrate (Fisher)]. Lungs were homogenized in RPMI containing 
10% fetal bovine serum (FBS).  Blood was collected using a heparin-coated needle and syringe 
by cardiac puncture.  A portion of the organ homogenates and blood were serially diluted and 
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plated onto chocolate II agar plates.  Plates were incubated at 37°C at 5% CO2 and individual 
colonies were enumerated.  The limit of detection was 100 CFU per organ (or per ml blood), 
except the liver, which was 200 CFU.  The remaining lung homogenate and blood was 
centrifuged at 17,000 x g for three min. to remove cells and tissue debris.  The resulting 
supernatant from the lung homogenate was sterile- filtered through 0.2 µm syringe filters, treated 
with gentamicin (100 µg/ml), and saved for quantification of cytok ines and chemok ines.  Plasma 
was treated with gentamicin (300 µg/ml) and ciprofloxacin (25 µg/ml) and also saved for 
quantification of cytokines and chemokines.   
3.3.4 Isolation of lung cells  
Lungs were minced and incubated in RPMI (Gibco) supplemented with 2.4 mg/ml type I 
collagenase (Gibco), 20 µg/ml DNase I (USB), and 3 mM CaCl2 for 30 min. at 37°C with 
shaking (170 rpm).  The digested tissue was passed through a 40-µm cell strainer (BD 
Biosciences) to generate single cell suspensions.  Erythrocytes were lysed with ACK Lysis 
Buffer (Gibco) and remaining cells were washed with RPMI.  Total live cells were counted using 
trypan blue exclus ion.  Lung cells were resuspended in FACS staining buffer [0.1% bovine 
serum albumin (BSA) and 0.1% sodium azide in PBS] prior to flow cytometric analysis.   
3.3.5 Flow cytometry and analysis of lung cells 
Individual immune cell populations from the lungs processed above were identified by flow 
cytometric analysis. Fc receptors were blocked with purified anti-mouse CD16/CD32 (clone 93, 
eBioscience) for 15 min. on ice.  Cells were then stained with the following antibodies at 4°C for  
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25 min.:  FITC anti-CD49b (clone DX5, eBioscience), FITC anti-TCR-β  (clone H57-597, BD 
Biosciences), PE anti-Ly-6G (clone 1A8, BD Biosciences), APC anti-F4/80 (clone BM8, 
eBioscience), PerCP-Cy5.5 anti-CD11b (clone M1/70, eBioscience), Pacific Blue® anti-NK1.1 
(clone PK136, eBioscience), APC-Alexa Fluor750 /eFluor™ 450 anti-CD11c (clone N418, 
eBioscience), APC-eFluor™ 780 anti-TCR-β  (clone H57-597), eFluor™ 450 anti-CD4 (clone 
RM4-5, eBioscience),  APC-eFluor™ 780 anti-CD8 (clone 53-6.7, eBioscience) and PerCP-
Cy5.5 anti-CD3 (clone 145-2C11, eBioscience).  Isotype control antibod ies were included in 
each experiment to confirm specificity.  Dead cells were stained using the LIVE/DEAD® 
Fixable Blue Dead Cell Stain Kit (Invitrogen).  Cells were then washed in PBS and fixed in 4% 
paraformaldehyde for 30 min. at 4°C.  For intracellular staining of granzyme B, fixed cells were 
washed, permeabilized with 0.1% saponin in FACS buffer, and stained with PE-conjugated anti-
granzyme B (clone GB11, Invitrogen).  After 25 min., cells were washed and fixed in 2% 
paraformaldehyde.  Samples were collected using a LSRII flow cytometer (BD Biosciences) and 
analysis gates were set on live cells (negative for LIVE/DEAD® Fixable Blue dye) excluding 
debris based on forward scatter and side scatter.  Approximately 100,000 events were collected 
for each sample.  Data was analyzed using FlowJo Software (Tree Star).  
3.3.6 Cytokine and chemokine assays 
Cytokine and chemokine levels in lung supernatants and plasma were determined by ELISA 
(mouse IFN-γ, R&D Systems) or using the Milliplex 23-plex or 32-plex Mouse 
Cytokine/Chemokine Panel (Millipore) on a Bio-Plex 200 system (Bio-Rad Laboratories).  
Analyte concentrations were calculated against the standards using Bio-Plex Manager 5.0  
software (Bio-Rad Laboratories, Inc.).  Granzyme B levels were measured in lung supernatants 
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by ELISA (eBioscience).  The limits of detection were 31 pg/ml for IFN-γ and 39 pg/ml for 
granzyme B. 
3.3.7 In vivo depletion of NK cells  
Mice were depleted of NK cells using either an anti-asialo GM1 (Lopez et al., 2004) or anti-
NK1.1 (Thatte et al., 2011) antibody as described previously with minor modifications.  Mice 
were administered 20 µl of anti-asialo GM1 (Cedarlane) or normal rabbit IgG control (Alpha 
Diagnostic International Inc.) intranasally (i.n.) and intraperitoneally (i.p.) three days prior to 
infection with Schu S4 and every three days thereafter until sacrifice.  For depletion with anti-
NK1.1, mice were administered 200 µg of antibody (Bio X Cell) or mouse IgG2a control (Bio X 
Cell) i.n. and i.p. three days prior to infection with Schu S4 and every seven days thereafter until 
sacrifice.  Administration of either anti-asialo GM1 or anti-NK1.1 was effective at depleting 
>90% of the NK cells (DX5/NK1.1+ CD3/TCR-β-) (Lopez et al., 2004; Thatte et al., 2011).   
3.3.8 Administration of IL-15 and IL-15Rα  to mice  
Mice were treated with a combination of recombinant mouse IL-15 (eBioscience) and mouse IL-
15Rα subunit Fc chimera (R&D Systems) as described previously with some modifications 
(Inoue et al., 2010).  Briefly, IL-15+IL-15Rα complexes were formed by incubating 300 µg of 
IL-15 and 1.4 mg of IL-15Rα-Fc together in PBS (total volume of 1 ml) at 37°C for 20 min.  
Samples were then diluted 10-fold in PBS.  Each mouse was then administered 50 µl of the IL-
15+IL-15Rα (1.5 µg IL-15 and 7 µg IL-15Rα) solution intratracheally (i.t.) one day prior, on the 
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same day, and two days following Schu S4 infection.  For experiments where IL-15+IL-
15Rα was administered intratracheally with recombinant IFN-γ (eBioscience), mice were treated 
with IL-15+IL-15Rα two days prior, on the same day, and one day following Schu S4 infection. 
IFN-γ (10 μg) was given on the same day as Schu S4 infection and one day later. 
3.3.9 Immunofluorescence staining o f lung t issue sections 
Lungs were inflated, harvested, and processed as described previously (Horzempa et al., 2010).  
Deparaffinized tissue sections were blocked with 2.5% BSA in PBS for 30 min. and then probed 
with rabbit anti-F. tularensis (1:500 dilution; BD Biosciences) overnight at 4°C.  As a control, a 
paired section was probed with normal rabb it IgG (Calbiochem).  Sections were washed three 
times in PBS with 0.2% Tween 20 and then probed with a secondary Alexa Fluor 568 goat anti-
rabb it antibody (1:1000 dilution, Invitrogen) for at least 1 hour at 25°C. TUNEL analysis was 
performed by first permeabilizing the tissue sections with permeabilization solution (0.1% Triton 
X-100, 0.1% sodium citrate) for 8 min. on ice.  Following permeabilization, the slides were 
washed three times in PBS and the TUNEL reaction was done using the Fluorescein In Situ Cell 
Death Detection Kit (Roche).  After three PBS washes, sections were then mounted in ProLong 
Gold antifade reagent containing 4′,6 -diamidino-2-phenylindole dihydrochloride (DAPI) 
(Invitrogen).  Sections were viewed under a Zeiss Axiovert 200 microscope and images were 
captured at 100x magnification with an equal exposure times within each channel.  AxioVision 
software was used to adjust brightness and contrast uniformly across all images.  
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3.4 RESULTS 
3.4.1 Schu S4 infection modulates secretion of NK cell effectors IFN-γ  and granzyme B 
The loss of NK cells during Schu S4 infection (Fig. 12D and 13D) suggested there would 
be immunological consequences.  In LVS infection, NK cells are the major producers of IFN-γ 
(Lopez et al., 2004).  Mice depleted of NK cells are more susceptible to pulmonary challenge 
with a sublethal dos e of LVS (Lopez et al., 2004).  To evaluate the function of NK cells in Schu 
S4 infection, both cytokines and extracellular granzyme B levels were measured in the lungs of 
infected mice.  In LVS-infected mice, IFN-γ was detected at three dpi in the lung and continued 
to increase until seven dpi (Fig. 21A-B).  In contrast, IFN-γ levels peaked three dpi with Schu S4 
and declined four dpi (Fig. 21A).  No IFN-γ was detected in PBS controls at any of the time 
points (Fig. 21A).  
 
Figure 21.  Increase in IFN-γ in the lungs of LVS- and Schu S4-infected mice.   
At the indicated time points, IFN-γ was measured in lung supernatants from mice treated i.t. with either PBS, LVS, 
or Schu S4 (100 CFU) using the Milliplex 23-plex Mouse Cytokine/Chemokine Panel (Millipore) on a Bio -Plex 
system (Bio-Rad Laboratories, Inc.) (n=2-4 mice/group). (A) Data are expressed as mean ± SEM of at least 2 
independent experiments. Statistical significance was determined by two-way ANOVA, followed by Bonferroni 
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comparison of means (*** p<0.001 significant compared to PBS). (B) For the LVS t imecourse, data are expressed as 
mean ± SD of one experiment. BD = below limits of detection. 
 
The lytic activity of NK cells was measured by the release of extracellular granzyme B in 
the lung.  Granzyme B was only modestly elevated in the lungs of LVS-infected mice at four dpi 
compared to PBS controls (Fig. 22A).  In contrast, granzyme B levels in Schu S4-infected mice 
were higher than PBS controls beginning three dpi; and by four dpi (Fig. 22A), approximately 
three- to four- fold more granzyme B was detected compared to LVS-infected mice (Fig. 22A). 
Since the accumulation of granzyme B in the lung of Schu S4- infected mice correlated with a 
decline in NK cells, we were interested in identifying the granzyme B-positive cell populations 
present in the lung.  Lung cells were isolated three dpi from Schu S4- infected mice and stained 
for intracellular granzyme B.  Approximately 78% of the granzyme B-positive cells in the lung 
were NK cells (Fig. 22C).  The remaining granzyme B-positive populations were primarily T 
cells and DX5- TCR-β- cells (Fig. 22C).  Therefore, reduced NK cell numbers in Schu S4-
infected mice inversely correlated with the release and accumulation of granzyme B in the lung.  
IFN-γ levels, however, did not have a clear correlation with loss of NK cells since IFN-γ peaked 
three dpi when NK cell numbers were beginning to decline.   
 
Figure 22.  Increase in extracellular granzyme B levels in the lung of Schu S4-infected mice.   
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(A) At the indicated time points, granzyme B was measured in lung supernatants from mice treated i.t. with either 
PBS, LVS, or Schu S4 (100 CFU) using an ELISA kit (n=2-4 mice/group).  Data are expressed as mean ± SEM of at 
least 2 independent experiments. Statistical significance was determined by two-way ANOVA, fo llowed by 
Bonferron i comparison of means (*** p<0.001 significant compared to PBS). BD = below limits of detection.   (B) 
Representative dot plot illustrating the percentage of granzyme B-positive cells in the lung of Schu-S4 infected mice 
that are expressing surface markers specific for NK cells (CD49b/DX5) and T cells (TCR-β) three dpi.  (C)  
Cumulat ive data from two independent experiments representing the mean percentage (± SEM) of each cell 
population that is granzyme B-positive.  Cells that were negative for both DX5 and TCR-β were defined as “other”.   
3.4.2 Depletion of NK cells in Schu S4-infected mice reduces IFN-γ and granzyme B levels 
in the lung but does not change  bacterial burden 
Widespread tissue damage and cell death is observed in the lungs of Schu S4-infected mice four 
dpi (Sharma et al., 2011).  Concomitantly, there was a significant decline in lung NK cells (Fig. 
12D and 13D) corresponding with reduced IFN-γ and high levels of granzyme B (Fig. 21A and 
22A).  To determine whether NK cells have a beneficial or pathologic role in acute Schu S4 
infection, NK cells were depleted with an anti-asialo GM1 antibody prior to and during infection.  
Approximately 10-fold less IFN-γ and granzyme B was detected in the lungs of Schu S4-infected 
mice receiving anti-asialo GM1 compared to an isotype control four dpi (Fig. 23A-B), whereas 
the treatments had no appreciable effect in mice given PBS (Fig. 23A-B).  Based on these data, 
NK cells were the primary source of IFN-γ and granzyme B in the lung following Schu S4 
infection. 
We next investigated the effect of NK cell depletion on the course of Schu S4 infection.  
Despite substantial effects on IFN-γ and granzyme B (Fig. 23A-B), no differences in bacterial 
burdens were seen in Schu S4- infected mice treated with the anti-asialo GM1 antibody compared 
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to isotype controls four dpi (Fig. 23C).  In addition, Schu S4-infected mice depleted of NK cells 
exhibited similar clinical signs of illness and weight loss (14% for isotype and 16% for anti-
asialo GM1 four dpi) compared to infected controls.  Furthermore, perforin-deficient mice, 
which lack NK cell lytic function, were equally susceptible to Schu S4 infection as wild-type  
mice (median time to death of 5 days). Therefore, NK cells did not have a demonstrable impact 
on hos t de fense against acute Schu S4 infection. 
 
Figure 23.  Depletion of NK cells in Schu S4-infected mice reduces IFN-γ and granzyme B in the lung but does 
not change bacterial burdens.   
Mice (n=4 per group) were administered anti-asialo GM1 or normal rabbit IgG i.n. and i.p three days prior to i.t. 
infection with Schu S4 (100 CFU) and every three days thereafter.  PBS-treated mice (n=4 per group) administered 
either anti-asialo GM1 or rabbit IgG served as controls.  Four dpi, mice were sacrificed and lungs, spleens, livers, 
and blood were harvested and processed as described in the Materials and Methods.  (A-B) IFN-γ and granzyme B 
were measured in lung supernatants by ELISA.   (C) Organ homogenates and blood were diluted and plated for CFU 
enumeration.  Data are expressed as mean ± SEM of 3 independent experiments. Statistical significance was 
determined by two-way ANOVA, fo llowed by Bonferroni comparison of means (** p<0.01 , *** p<0.001 significant 
compared to rabbit IgG). BD = below limits of detection. 
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3.4.3 Contribution of NK cells in host resistance to Schu S4 challenge  in LVS-vaccinated 
mice 
In addition to their role in innate immunity, NK cells also influence adaptive immune responses 
(Hall et al., 2010).  Though NK cell depletion had little effect on acute infection, we considered 
the possibility that NK cells might contribute to host resistance to Schu S4 infection in LVS-
vaccinated mice. To assess the role of NK cells in protection elicited by LVS, NK cells were 
depleted from vaccinated mice with antibodies prior to Schu S4 infection. Four dpi, a 0.5-1.5 log 
increase in Schu S4 burden was measured in all organs of vaccinated mice that received anti-
asialo GM1 compared to vaccinated mice treated with control rabbit IgG (Fig. 24A).   We 
hypothesized that greater Schu S4 burdens would translate to reduced survival after NK cell 
depletion.  Anti-asialo GM1 treatment caused a significant reduction in survival of LVS-
vaccinated mice compared to controls, where the median time to death (MTD) shifted from 10 to 
6 days (Fig. 24B).  These data demonstrate that anti-asialo GM1 treatment increased infection 
severity and reduces surviva l of LVS-vaccinated mice following Schu S4 challenge. 
Although asialo-GM1 is predominantly expressed on NK cells, this marker is also 
expressed on a subset of other immune cell populations such as CD8+ T cells and basophils (Lee 
et al., 1996; Nishikado et al., 2011).   To test the specificity of the results obtained with anti-
asialo GM1, we used an alternative depletion strategy with a different antibody, anti-NK1.1, 
prior to challenge with Schu S4.  Compared to the four day difference in survival observed with 
anti-asialo GM-treated vaccinated mice and isotype controls, vaccinated mice treated with anti-
NK1.1 succumbed to Schu S4 challenge only one to two days earlier than mouse IgG controls 
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(Fig. 24C).  This difference in survival between the two depletion strategies suggested NK cells 
had a minor role in LVS-mediated protective immunity to Schu S4 challenge. 
 
Figure 24.  Contribution of NK cells in LVS-mediated immunity to Schu S4 challenge.   
Mice were vaccinated intranasally with LVS (1000 CFU).  Five weeks later, mice were challenged i.t with Schu S4 
(100 CFU). (A)  Treatment of vaccinated mice with anti-asialo GM1 increases bacterial burdens in the organs and 
blood following Schu S4 in fection.  LVS-vaccinated mice (n=4-5 mice per group) were admin istered anti-asialo 
GM1 or normal rabbit IgG prior to infection with Schu S4 as described in the Materials and Methods.  Four days 
post Schu S4 infection, mice were sacrificed and the designated organs and blood were processed, diluted, and 
plated for CFU enumeration.  Data are expressed as mean ± SEM of two independent experiments. Statistical 
significance was determined by two-way ANOVA, followed by Bonferroni comparison of means (* p<0.05 
significant compared to rabbit IgG).  BD = below limits of detection.  (B) Reduced survival of LVS-vaccinated mice 
treated with anti-asialo GM1and infected with Schu S4.  The data are combined from two independent experiments 
(n=5 mice per group). p<0.001, log-rank test. (C)  NK cells play a minor ro le in immunity to Schu S4 infection in 
LVS vaccinated mice.  LVS-vaccinated mice (n=5-6 mice per g roup) were administered anti-NK1.1 or mouse IgG 
prior to infection with Schu S4 as described in the Materials and Methods. Survival was monitored over time.  The 
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data are combined from two independent experiments.  Statistical significance was reached in only one experiment 
(p<0.05, log-rank test). 
 
 
3.4.4 Enhanced surviva l of lymphocytes and reduced systemic cytokine production 
induced by IL-15+IL-15Rα  does not improve host resistance to acute Schu S4 infection 
Depletion of NK cells failed to exacerbate or ameliorate acute Schu S4 infection. 
Augmenting NK cell numbers and activation, however, may improve host defenses since these 
cells are major producers of IFN-γ (Lopez et al., 2004).  The anti-apoptotic cytokine IL-15 plays 
a critical role in the deve lopment, homeos tasis, and function of NK cells and enhances the 
proliferation of NK cells in vivo when given with a soluble form of its receptor (IL-15Rα) 
(Bulfone-Paus et al., 1997; Oh et al., 2008; Rubinstein et al., 2006; Stonier and Schluns, 2010). 
IL-15+IL-15Rα treatment reduces NK cell apoptosis, increases expression of IFN-γ, and 
improves survival in two murine models of sepsis (Inoue et al., 2010).   Since Schu S4 infection 
also has features of sepsis, we tested the effects of IL-15+IL-15Rα in this model. 
Four dpi, intratracheal IL-15+IL-15Rα treatment increased viable lung cells of Schu S4-
infected mice by two-fold compared to Schu S4-infected controls treated with PBS (Fig. 25A).  
A similar increase in lung cells was observed in uninfected mice receiving IL-15+IL-15Rα (Fig. 
25A). Among the lung immune cells evaluated, no significant differences in the frequency or 
absolute number of macrophages and neutrophils were observed in Schu S4- infected mice after 
IL-15+IL-15Rα treatment (Fig 25B-C).  Although IL-15+IL-15Rα significantly increased the 
frequency of DCs in the lung of uninfected controls, there was no effect on DCs in Schu S4-
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infected mice (Fig. 25D).  More importantly, IL-15+IL-15Rα treatment significantly increased 
the frequency of NK cells and T cells in the lungs of bot h uninfected and Schu S4- infected mice 
by 70-80% (Fig. 25E-F).  Therefore, IL-15+IL-15Rα treatment enhanced the number of viable 
cells during Schu S4 infection. 
We next tested whether IL-15+IL-15Rα treatment altered systemic cytokines and 
chemokines after Schu S4 infection.  In other models of sepsis, IL-15+IL-15Rα modulated the 
levels of circulating IFN-γ, IL-6, and TNF-α.  Analyzing plasma by Luminex, there was a 
statistically significant reduction in IFN-γ and IL-6 in Schu S4- infected mice treated with IL-
15+IL-15Rα compared to PBS-treated controls (Fig. 25G).  TNF-α levels in Schu S4-infected 
mice remained unchanged in response to IL-15+IL-15Rα treatment (Fig. 25G).  In addition to 
IFN-γ and IL-6, ten other cytokines and chemokines were significantly downregulated in Schu 
S4-infected mice treated with IL-15+IL-15Rα compared to PBS (Table 3).  No statistically 
significant differences in chemokine and cytokine concentrations were detected in uninfected 
mice treated with IL-15+IL-15Rα and PBS (Table 3).  Therefore, IL-15+IL-15Rα reduced 
inflammatory mediators in the bloodstream of Schu S4-infected mice. 
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Figure 25.  Changes in lung immune cell populations and systemic cytokine and chemokine production 
following IL-15+IL-15Rα treatment of Schu S4-infected mice.   
Mice (n=4 per group) were administered PBS or IL-15+IL-15Rα i.t. one day prior, on the same day, and two days 
following i.t. Schu S4 infection (100 CFU).  Uninfected (Uninf.) mice (PBS-treated, n=4 per group) administered 
PBS or IL-15+IL-15Rα served as controls.  Mice were sacrificed four dpi and lungs were processed as described in 
Materials and Methods.  (A) Absolute cell numbers in the lungs were enumerated by trypan blue exclusion.  (B-F) 
Changes in individual immune cell populations were evaluated by flow cytometric analysis: neutrophils (Ly6G+, 
F4/80low), macrophages (F4/80+, Ly-6G-), dendritic cells (CD11chigh, F4/80-), NK cells (DX5+, TCR-β-), and T cells 
(DX5-, TCR-β+).  (G) Lung supernatants were assessed for multip le cytokines and chemokines using the Millip lex 
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32-plex Mouse Cytokine/Chemokine Panel (Millipore) on a Bio-Plex system (Bio-Rad Laboratories, Inc.).  The 
cytokines shown here were prev iously demonstrated to be modulated by IL-15+IL-15Rα in other models of sepsis 
(Inoue et al., 2010).  All other cytokine and chemokine values can be found in Table 3.  Data are expressed as mean 
± SEM of two independent experiments.  Statistical significance was determined by two-way ANOVA for each cell 
type and analyte comparing the effects of infection and treatment, followed by Bonferroni comparison of means 
(*p<0.05, **p<0.01, significant compared to PBS treatment). BD = below limits of detection.   
 
Table 3.  Plasma cytokine and chemokine levels following IL-15+IL-15Rα treatment of Schu S4-infected mice. 
Infection Uninfected Schu S4 
Treatment PBS IL-15+IL-15Rα PBS IL-15+IL-15Rα 
Analytes 
(pg/ml) 
    
Eotaxin 295.12 (± 25.31) 268.20 (± 9.31) 1528.34 (± 223.28) 1465.66 (± 171.11) 
G-CSF 89.20 (± 18.13) 269.21 (± 17.76) 46192.76 (± 135.93)b 46680.28 (± 1089.98)b  
GM-CSF 6.31 (± 1.04) 12.99 (± 3.18) 85.10 (± 3.28) 70.61 (± 2.03)c 
IFN-γ 3.55 (± 0.40) 5.08 (± 2.29) 9282.53 (± 406.68)b  5926.99 (± 1014.94)b, c 
IL-1α 14.51 (± 5.06) 18.65 (± 4.03) 371.64 (± 11.49) 358.42 (± 8.03) 
IL-1β BD BD 44.54 (± 4.35) 58.70 (± 3.26)c 
IL-2 BD BD 3.66 (± 0.27) 4.05 (± 0.60) 
IL-3 BD BD BD BD 
IL-4 BD BD BD BD 
IL-5 5.16 (± 1.31) 9.18 (± 1.86) 20.75 (± 1.12) 14.24 (± 2.86) 
IL-6 3.35 (± 0.17) 8.34 (± 2.74) 13024.09 (± 684.81)b 8362.11 (± 383.54)b, c 
IL-7 BD BD 4.27 (± 0.84) 4.47 (± 1.27) 
IL-9 63.47 (± 21.59) 82.35 (± 38.69) 41.66 (± 3.17) 27.14 (± 2.81) 
IL-10 BD BD 145.97 (± 10.16) 138.54 (± 8.12) 
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IL-12 (p40) 4.05 (± 0.37) 5.99 (± 1.23) 20.03 (± 1.30) 14.50 (± 2.48) 
IL-12 (p70) 4.72 (± 0.04) 5.19 (± 1.99) 69.98 (± 4.85) 51.29 (± 0.50)c 
IL-13 35.60 (± 8.79) 45.60 (± 10.24) 938.27 (± 80.52) 808.23 (± 67.79) 
IL-15 15.45 (± 4.37) 372.53 (± 360.23) 83.00 (± 16.27) 46.50 (± 2.49) 
IL-17 BD BD 12.16 (± 0.08) 7.49 (± 1.15)c 
IP-10 55.54 (± 6.81) 159.24 (± 30.09) 3331.32 (± 260.90) 3376.18 (± 451.18) 
KC 23.31 (± 6.43) 65.60 (± 15.99) 9457.03 (± 1158.09)b 5992.04 (± 894.92)b  
LIF BD 3.62 (± 0.42) 44.50 (± 16.71) 12.07 (± 3.88) 
MCP-1 3.44 (± 0.24) 9.31 (± 3.85) 7245.75 (± 129.83)b  3255.51 (± 1195.59)b, c 
M-CSF BD 3.47 (± 0.27) 72.37 (± 4.46) 32.26 (± 11.16)c 
MIG 19.35 (± 0.07) 60.91 (± 17.05) 12814.46 (± 592.76)b 12348.07 (± 425.51)b 
MIP-1α 8.71 (± 0.36) 13.24 (± 4.18) 192.20 (± 17.89) 122.22 (± 19.49)c 
MIP-1β 14.18 (± 7.05) 16.33 (± 4.32) 727.24 (± 36.14) 326.06 (± 59.94)c 
MIP-2  BD 10.87 (± 1.31) 1671.68 (± 107.40) 598.28 (± 127.01)c 
RANTES  5.61 (± 0.40) 7.73 (± 1.48) 169.30 (± 8.98) 99.54 (± 6.73)c 
TNF-α  BD BD 65.08 (± 8.67) 53.24 (± 1.51) 
VEGF  BD BD 3.42 (± 0.10) BD 
LIX 620.82 (±426.10) 469.70 (± 145.79) 913.93 (± 46.49) 616.62 (± 192.55) 
aBD = below limits of detection. 
bValues were ext rapolated from the standard curve for a subset of samples. 
cp<0.05  by two-way ANOVA comparing the effects of treatment and infection and Bonferroni comparison of 
means, significant compared to PBS treatment 
 
 
The effect of IL-15+IL-15Rα on bacterial burdens in Schu S4- infected mice was then 
measured.  Despite changes in immune cells and modulation of cytokines, IL-15+IL-15Rα had 
no impact on bacterial numbers measured four dpi (Fig. 26).  In addition, IL-15+IL-15Rα did not 
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significantly alter the progression of disease in Schu S4- infected mice based on clinical signs and 
weight loss (17% for PBS-treated and 16% for IL-15+IL-15Rα-treated four dpi).  Administration 
of IL-15+IL-15Rα by different routes, either intraperitoneally or both intraperitoneally and 
intratracheally, did not affect bacterial burdens following Schu S4 infection (Fig. 27).  Therefore, 
IL-15+IL-15Rα treatment did not improve host resistance to pulmonary Schu S4 infection. 
 
Figure 26.  Bacterial burden following IL-15+IL-15Rα treatment of Schu S4-infected mice.   
Mice were admin istered PBS or IL-15+IL-15Rα and infected with Schu S4 as described in the legend to Fig. 26. 
Bacterial burdens in the organs and blood of Schu S4-infected mice treated with IL-15+IL-15Rα four dpi (n=4 mice 
per group).  Data are expressed as mean ± SEM and are representative of two independent experiments.  
 
Figure 27.  Bacterial burden following pulmonary and/or systemic administration of IL-15+IL-15Rα to Schu 
S4-infected mice. 
Mice (n=4 per group) were admin istered PBS i.t. or IL-15+IL-15Rα i.t ., i.p., or i.t. and i.p. one day prior, on the 
same day, and two days following i.t . Schu S4 infection (100 CFU).  Four dpi, mice were sacrificed and the 
designated organs and blood were processed, diluted, and plated for CFU enumerat ion.  Data are expressed as mean 
± SD of one independent experiment. 
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Although IL-15+IL-15Rα improved the absolute number of viable cells present in the 
lungs of Schu S4- infected mice, there was still a 60-70% loss in viable lung cells after Schu S4 
infection irrespective of treatment group (Fig. 25A).  This suggested IL-15+IL-15Rα was not  
limiting the widespread cell death that occurred in the lungs of Schu S4-infected mice.  To 
investigate this further, lung sections from treated and untreated Schu S4-infected mice were 
probed for apoptotic cells.  As observed previously (Sharma et al., 2011), robust TUNEL 
staining was localized around regions of infection in the lung of Schu S4- infected mice four dpi 
(Fig. 28).  A similar pattern of TUNEL staining was observed in Schu S4- infected mice that were 
treated with IL-15+IL-15Rα  (Fig. 28).  In regions with no bacterial antigen staining, a low 
frequency of TUNEL+ cells was detected (Fig. 28).    Limited TUNEL staining was also seen in 
uninfected mice (Fig. 28).  These results corroborated the loss in lung cells observed by flow 
cytometric analysis and suggest that the inability of IL-15+IL-15Rα to limit cell death in the 
lung may contribute to its poor effectiveness as a treatment for type A F. tularensis. 
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Figure 28.  TUNEL staining following IL-15+IL-15Rα treatment of Schu S4-infected mice.  
Immunofluorescence microscopy of lung sections from uninfected and Schu S4-infected mice treated with IL-
15+IL-15Rα.  Four dpi, lungs were harvested, fixed in formalin, and embedded in paraffin.  Deparaffinized lung 
sections were probed with rabbit anti-F. tularensis followed by a secondary Alexa Fluor 568 goat anti-rabbit 
antibody. An In Situ Cell Death Detection Kit (Roche) was used for the TUNEL assay. DNA was stained with 
DAPI. The color merged images (red, F. tularensis; green, TUNEL; blue, DAPI) were captured with an equal 
fluorescence exposure time within each channel and are representative of two independent experiments with a total 
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of 3-4 mice per g roup. The scale bars in the upper left hand corners of the images represent a length of 100 µm.  The 
top panel of images from Schu S4-infected mice represents areas with dense F. tularensis antigen staining while the 
bottom panel of images represents areas with little to no F. tularensis antigen staining. 
3.5 DISCUSSION 
NK cells can promote or antagonize host resistance to bacterial pathogens (Badgwell et al.,  
2002; Feng et al., 2006; Le-Barillec et al., 2005; Sherwood et al., 2004).  In studies with LVS, 
NK cells are important for the early control of infection through the secretion of IFN-γ (Bokhari 
et al., 2008; Lopez et al., 2004; Metzger et al., 2007).  We began investigating NK cells in Schu 
S4 infection because of their role in LVS immunity and because of the marked changes observed 
after pulmonary challenge (Fig. 12D and 13D).  Similar to neutrophils (Fig. 17) (KuoLee et al., 
2011), modulation of NK cells did not have a demonstrable effect on Schu S4 infection in vivo.  
Neither depletion with antibodies nor enhanced NK cell numbers via treatment with IL-15+IL-
15Rα had an impact on bacterial burden or the progression of disease following Schu S4 
challenge.  Our results suggest NK cells are dispensable for host resistance to acute type A 
Francisella infection.   
Different results were observed when NK cells were depleted with anti-asialo GM1 or anti-
NK1.1 in the vaccination/challenge model (Fig. 24B-C).  Anti-asialo GM1 treatment reduced 
survival of LVS-vaccinated mice challenged with Schu S4.  An explanation for this effect is a 
partial loss in CD8+ T cells in anti-asialo GM1-treated mice.  Although asialo GM1 is expressed 
predominantly on NK cells, it is also detected on a subpopulation of NK T cells, activated CD8+ 
T cells, gamma-delta T cells, and basophils (Nishikado et al., 2011; Trambley et al., 1999).  
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While no off-target effects of anti-asialo GM1 were observed in naive mice, there was a 60% 
reduction in the number of CD8+ T cells in vaccinated mice treated with anti-asialo GM1 
compared to isotype controls four days post Schu S4 infection (Fig. 29).   Previous work by 
Conlan et al. demonstrated that depletion of CD8+ T cells significantly reduces survival from 
secondary challenge with type A Francisella (Wayne Conlan et al., 2005).  Anti-asialo GM1, 
therefore, may have depleted Francisella-immune  CD8+ T cells making mice more susceptible 
to challenge with Schu S4.  Additionally,  the biological impact of anti-NK1.1 treatment, which 
does not affect CD8+ T cells, was small (Fig. 24C).  Together, these results suggest NK cells 
minimally contribute to LVS-mediated protective immunity.  
 
Figure 29.  Reduction in CD8+ T cells following anti-asialo GM1 treatment of LVS-vaccinated mice 
challenged with Schu S4. 
Four days post Schu S4 in fection, single cell suspensions from the lungs of LVS-vaccinated mice (n=4-5 mice per 
group) administered either anti-asialo GM1 or normal rabbit IgG were stained with fluorescently conjugated 
antibodies against CD3, CD4, CD8, and CD49b (DX5). The frequency of CD8+ T cells was measured by gating on 
those cells that were CD3+DX5-CD8+CD4-.  Data are expressed as mean ± SD of one independent experiment. 
 
While NK cell depletion failed to alter acute Schu S4 infection, we also tested the effect of 
increasing NK cell numbers.  IL-15+IL-15Rα  treatment had a significant effect on survival in a 
mouse model of cecal ligation and puncture (CLP) and Pseudomonas aeruginosa pneumonia 
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(Inoue et al., 2010).  However, no difference in bacterial burden or disease severity was observed 
between IL-15+IL-15Rα-treated and PBS-treated mice infected with Schu S4 (Fig. 26-27).  
There are several possible explanations for the effects of IL-15+IL-15Rα in these different sepsis 
models.  Although serum IFN-γ levels increased with IL-15+IL-15Rα in CLP mice (Inoue et al.,  
2010), IFN-γ decreased following IL-15+IL-15Rα treatment in Schu S4-infected mice (Fig. 
25G).  This decrease in IFN-γ inversely correlated with an increase in total cells, specifically NK 
cells and T cells, following IL-15+IL-15Rα treatment.  The presence of more cells in the lung 
may have resulted in the enhanced consumption of IFN-γ and the detection of lower levels by 
Luminex. To compensate for the reduced availability of IFN-γ, we treated Schu S4- infected mice 
with recombina nt IFN-γ along with IL-15+IL-15Rα.  However, no significant difference in 
bacterial burden or disease progression was observed in Schu S4- infected mice treated with IFN-
γ+IL-15+IL-15Rα compared to PBS controls (Fig. 30).   
 
Figure 30.  Bacterial burden following IL-15+IL-15Rα+IFN-γ treatment of Schu S4-infected mice.   
Mice (n=4 per group) were admin istered IL-15+IL-15Rα and/or IFN-γ to Schu S4-infected mice (100 CFU) as 
described in Materials and Methods.  Two dpi, mice were sacrificed and the designated organs and blood were 
processed, diluted, and plated for CFU enumeration.  Data are expressed as mean ± SD of one experiment. 
 
Other cytokines may also contribute to the limited effect of IL-15+IL-15Rα in pneumonic 
tularemia.  Systemic levels of TNF-α and IL-6 were significantly lower in CLP mice treated with 
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IL-15+IL-15Rα, but only IL-6 was significantly reduced in IL-15+IL-15Rα-treated Schu S4-
infected mice (Fig. 25G and Table 3).  The differential regulation of TNF-α and IL-6 has been 
observed in other treatment models and was hypothesized to be due to different cellular origins 
of these two cytokines (Di Santo et al., 1997).  The persistently elevated TNF-α levels in Schu 
S4-infected mice may worsen disease despite IL-15+IL-15Rα therapy, since high circulating 
levels of TNF-α are associated with mortality in some models of sepsis (Hotchkiss and Karl, 
2003). 
IL-15+IL-15Rα also prevents the apop totic depletion of lymphocytes and DCs in CLP mice 
(Inoue et al., 2010).  However, a 60-70% loss in viable lung cells was still observed in IL-15+IL-
15Rα-treated mice infected with Schu S4 compared to uninfected controls (Fig. 25A).  The 
absolute number of DCs, T cells, and NK cells also declined at a similar rate (Fig. 25D-F). 
TUNEL staining of lung tissue sections from both PBS and IL-15+IL-15Rα-treated mice 
infected with Schu S4 confirmed that cell death was not limited by cytokine treatment (Fig. 28).  
These results suggest the mechanism of cell death in Schu S4-infected mice may differ from the 
Bim and PUMA-dependent apop tosis in CLP mice (Inoue et al., 2010).  In summary, IL-15+IL-
15Rα has different effects on systemic cytokine production and cell death in two independent 
sepsis models: CLP and pneumonic tularemia.  This suggests IL-15+IL-15Rα may not be 
generally applicable to treat sepsis of different etiologies. 
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4.0  A FRANCISELLA TULARENSIS STRAIN THAT IMPROVES STIMULATION 
OF ANTIGEN-PRESENTING CELLS DOES NOT ENHANCE VACCINE EFFICACY 
This chapter is adapted from the original publication: 
Schmitt, D.M., D.M. O’Dee, J. Horzempa, P.E. Carlson, Jr., B.C. Russo, J.M. Bales, M.J. 
Brown, and G.J. Nau. 2012.  A Francisella tularensis Live Vaccine Strain That Improves 
Stimulation of Antigen-Presenting Cells Does Not Enhance Vaccine Efficacy. PLoS One. 7: 
e31172. 
 
This is an open-access article distributed under the terms of the Creative Commons Attribution 
License, which permits unrestricted use, distribution, and reproduction in any medium, provided 
the original author and source are credited. 
4.1 ABSTRACT 
Vaccination is a proven strategy to mitigate morbidity and mortality of infectious 
diseases.  The methodology of identifying and testing new vaccine candidates could be improved 
with rational design and in vitro testing prior to animal experimentation.  The tularemia vaccine, 
Francisella tularensis live vaccine strain (LVS), does not elicit complete protection against 
lethal challenge with a virulent type A Francisella strain.  One factor that may contribute to this 
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poor performance is limited stimulation of antigen-presenting cells.  In this study, we examined 
whether the interaction of genetically modified LVS strains with human antigen-presenting cells 
correlated with effectiveness as tularemia vaccine candidates.  Human dendritic cells infected 
with wild-type LVS secrete low levels of proinflammatory cytokines, fail to upregulate 
costimulatory molecules, and activate human T cells poor ly in vitro.  One LVS mutant, strain 
13B47, stimulated higher levels of proinflammatory cytokines from dendritic cells and 
macrophages and increased costimulatory molecule expression on dendritic cells compared to 
wild-type.  Additionally, 13B47- infected dendritic cells activated T cells more efficiently than 
LVS-infected cells.  A deletion allele of the same gene in LVS displayed similar in vitro 
characteristics, but vaccination with this strain did not improve survival after challenge with a 
virulent Francisella strain.  In vivo, this mutant was attenuated for growth and did not stimulate 
T cell responses in the lung comparable to wild-type.  Therefore, stimulation of antigen-
presenting cells in vitro was improved by genetic modification of LVS, but did not correlate with 
efficacy against challenge in vivo within this model system.   
4.2 INTRODUCTION 
The development of vaccines is essential to combat harmful infectious diseases (Hinman, 
1998). Obtaining licensure after discovery of a vaccine, however, can take up to 20 years due to 
the stringent testing required to confirm the safety and efficacy of the vaccine (Barrett and 
Beasley, 2009).  To expedite this process, in vitro tests could be developed to define correlates of 
protection and identify more promising vaccine candidates.  These assays would be particularly 
beneficial with vaccine candidates for highly pathogenic organisms, such as the bacterium 
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Francisella tularensis, when challenge studies cannot be performed in humans because of 
contemporary regulations that govern clinical trials (Quill and Giovanni, 2004). 
F. tularensis is the causative agent of tularemia (Oyston, 2008).  This zoonotic disease is 
endemic in North America and parts of Europe and Asia, and outbreaks in these regions are 
frequently associated with the handling of infected animals or transmission by arthropod vectors 
(Oyston, 2008; Sjostedt, 2007).  F. tularensis is also classified by the Centers for Disease 
Control and Prevention as a Category A bioterrorism agent (McLendon et al., 2006).  When 
inhaled, less than 10 organisms can cause an acute pneumonia that is lethal in up to 60% of 
infected individuals if left untreated (Dennis et al., 2001).  The World Health Organization 
predicted that if virulent F. tularensis was aerosolized over a metropolitan area of five million 
people, more than 19,000 people would die and 250,000 individuals would be incapacitated 
(McLendon et al., 2006).  An effective vaccine would be useful to reduce the number of 
naturally occurring tularemia cases and to protect against a possible intentional release. 
To date, two different types of tularemia vaccines have been studied in humans.  The 
Foshay vaccine consisted of chemically killed F. tularensis and was effective at reducing the 
incidence of laboratory-acquired tularemia cases from approximately 100% to 30% in the 1950s 
(Foshay, 1950; Kadull et al., 1950).  However, killed F. tularensis provided only minimal 
protection from aerosol type A Francisella challenge in a vaccine trial (Saslaw et al., 1961).  
Researchers in the former Soviet Union took a different approach and developed a range of live 
attenuated Francisella strains to immunize people against tularemia (Titball and Oyston, 2003).  
One of these strains, a live attenuated strain of F. tularensis subsp. holarctica, live vaccine strain 
(LVS), was superior to the Foshay-type vaccines at providing protection (Burke, 1977; 
McCrumb, 1961; Saslaw et al., 1961).  While two clinical studies involving small numbers of 
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human vaccinees demonstrated effectiveness of LVS against aerosol challenge by virulent type 
A Francisella (McCrumb, 1961; Saslaw et al., 1961), a later study showed variable efficacy that 
diminished over time (Hornick and Eigelsbach, 1966).  Vaccination of individuals by aerosol 
improved the efficacy of LVS but this required a high dose of 106 to 108 organisms which 
frequently resulted in severe adverse side effects (Hornick and Eigelsbach, 1966).   
Currently, LVS is not approved by the Food and Drug Administration (FDA) due to 
concerns about its undefined attenuation, mechanism of protection, and reversion frequency 
(Wayne Conlan and Oyston, 2007).  In order to obtain FDA approval, several groups are 
working to address these issues.  Recent work by Salomonsson et al. identified two regions of 
difference, RD18 and RD19, which are deleted in LVS and account for its attenuation 
(Salomonsson et al., 2009).  Additional studies improved the manufacturing process of LVS in 
compliance with good manufacturing practice guidelines (Pasetti et al., 2008).   This new lot of 
LVS was further characterized in human phase I clinical trials (El Sahly et al., 2009).  
Researchers are also introducing mutations into LVS in order to improve its efficacy and bolster 
attenuation. One example is an LVS mutant deficient in iron superoxide dismutase (sodBFt).  
Compared to LVS, sodBFt increases median time to death and percent survival of C57BL/6 mice 
from pulmonary type A Francisella challenge (Bakshi et al., 2008).  As work toward the 
licensing o f LVS continues, attempts have been made to replace LVS with a genetically defined, 
attenuated type A Francisella strain.  For example, Schu S4 ΔFTT_1103 and Schu S4 ΔclpB, 
provide 75% and 60% protection, respectively, from virulent type A Francisella challenge in 
BALB/c mice (Conlan et al., 2009; Qin et al., 2009).  Nevertheless, LVS remains the only 
tularemia vaccine to date that has been shown to be effective in humans (McCrumb, 1961; 
Saslaw et al., 1961).  
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A potential limitation of LVS as a vaccine is its relative stimulation of antigen-presenting 
cells (APCs).  Published work has shown LVS stimulates murine and human DCs (Ben Nasr et 
al., 2006; Katz et al., 2006), though it is now known that culture conditions influence stimulation 
of innate immunity (Carlson et al., 2007; Carlson et al., 2009; Hazlett et al., 2008; Loegering et 
al., 2006; Zarrella et al., 2011).  In contrast, other studies have shown that LVS supp resses the 
activation of murine macrophages (Bosio and Dow, 2005; Loegering et al., 2006; Parsa et al., 
2008; Telepnev et al., 2003; Telepnev et al., 2005) and dendritic cells (DCs) (Bosio and Dow, 
2005).  Murine macrophages and DCs cultured with LVS produce little to no proinflammatory 
cytokines in vitro compared to DCs cultured with other bacteria or TLR ligands (Bosio and Dow, 
2005; Loegering et al., 2006; Telepnev et al., 2003; Telepnev et al., 2005).  Stimulation with 
TLR ligands such as Escherichia coli LPS fails to restore cytokine secretion by these cells 
suggesting that LVS is actively suppressing TLR signaling (Bosio and Dow, 2005; Carlson et al., 
2007; Loegering et al., 2006; Telepnev et al., 2003).  Another study showed that this suppression 
is due to downregulation of critical inflammatory signaling pathways involved in MAPK and 
NF-κB activation (Telepnev et al., 2005).   
In this study, we tested whether in vitro screening of potential tularemia vaccine 
candidates for enhanced stimulation of APCs would improve a candidate’s immunogenicity, and 
ultimately protection after challenge.  After initial testing of several LVS strains, we evaluated 
one genetic locus in detail with mutant strains that showed desirable vaccine characteristics in 
vitro, including attenuation in macrophages and enhanced DC stimulation.  Despite these traits, 
they did not predict better protection against virulent type A Francisella challenge.   
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4.3 MATERIALS AND METHODS 
4.3.1 Francisella strains and growth conditions 
For cultivation of F. tularensis LVS strains and Schu S4, frozen stock cultures were 
streaked onto chocolate II agar plates and incubated at 37°C, 5% CO2 for 2-3 days.  LVS strains 
were grown in Chamberlain’s chemically defined broth medium (CDM) (Chamberlain, 1965) or 
MH broth [Mueller-Hinton broth (Difco) supplemented with 0.1% glucose, 0.025% ferric 
pyrophosphate (Sigma), and IsoVitaleX (Becton Dickinson)] for in vitro infections. For mouse 
vaccinations, MH broth or TSBc [trypticase soy broth (BD Biosciences) supplemented with 
0.1% L-cysteine hydrochloride monohydrate (Fisher)] was used for culturing of LVS strains.  
Schu S4 was grown in MH broth for infections of vaccinated mice.  Broth cultures were grown at 
37°C with shaking for 14-18 hours.  When required, antibiotics were added to the media at the 
following concentrations: kanamycin at 10 μg/ml, chloramphenicol at 5 μg/ml, and hygromycin 
at 200 μg/ml. 
4.3.2 Generation of formalin-fixed F. tularensis Schu S4 (ffSchu S4) 
Schu S4 was grown in MH broth as described above.  Following overnight culture, 
bacteria were washed, resuspended in PBS (Gibco), and adjusted to an OD600 of 0.3. Bacteria 
were then resuspended in 10% buffered formalin (Fisher) and incubated at 25°C for 10 min with 
shaking (200 rpm).  Bacteria were washed five times and resuspended in PBS for an approximate 
concentration of 1 – 3 x 108 CFU/ml.  Bacterial killing was confirmed by plating of formalin-
fixed Schu S4 on chocolate II agar plates in which no colonies were observed following 
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extensive incubation (data not shown).  Prior to formalin fixation, an aliquot of the bacterial 
suspension was removed and tested for  viable CFU by plating serial dilutions on chocolate II 
agar. 
4.3.3 Construction of LVS mutants 
Construction of LVS strain 1664d was described previously (Horzempa et al., 2008a).  The 
F. tularensis LVS ΔcapC mutant was generated using homologous recombination with a suicide 
plasmid.  This plasmid contained two segments homologous to regions flanking FTL_1415 and 
one third of the 5’ and 3’ ends of this ORF, surrounding a chloramphenicol acetyltransferase 
gene (cat) under the control of the F. tularensis groE promoter (Table 4).  Linearized plasmid 
was electroporated into LVS (Baron et al., 1995) and double cross-over events were selected on 
cysteine heart agar with 5% defibrillated rabbit blood containing 2.5 µg/ml chloramphenicol.  
Recombination was confirmed by PCR. 
 
Table 4.  Bacterial strains, plasmids, and primers used in this study. 
Strain, plasmid, or primer Description Source or Reference 
F. tularensis Strains   
LVS F. tularensis subsp. holarctica live vaccine strain Karen Elkins 
13B47 LVS with the Tn from pSD26 disrupting FTL_0883 in 
base pair 115 of 842 from the 5′ end  This study 
1664d LVS deoB (FTL_1664) disruption mutant (Horzempa et al., 2008a) 
ΔcapC LVS containing cat replacing the central one third of 
capC (FTL_1415) This study 
ΔFTL_0883 LVS FTL_0883 in-frame deletion mutant (Russo et al., 
2011) 
ΔFTL_0883::pJH1-FTL-0883 LVS ΔFTL_0883 cis-complement (Russo et al., 
2011) 
E. coli Strains   
sd-4 Streptomycin-dependent E. coli mutant (ATCC 11143) ATCC 11143 
Plasmids   
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pSD26  E. coli shuttle plasmid (colE1, ApR) encoding the C9 
transposase and himar transposon (KmR) 
Simon Dillon and 
Eric Rubin 
Primers   
capC-1 5’–CCGCGGAAGCGACACATGGACTTTTGA–3’ This study 
capC-2 5’–GAATTCAATATGATAATAGTTACTATAACT–3’ This study 
capC-3 5’–ATGCATTTATATTATCCCTGGACTTAT–3’ This study 
capC-4 5’–ACTAGTTTAGATTTTTTATTATCGTTA–3’ This study 
 
 
 
To generate strain 13B47, p lasmid pSD26 (a gift from Eric Rubin and Simon Dillon) was 
electroporated into LVS as previously described (Horzempa et al., 2008b).  pSD26 is an E. coli 
plasmid de livery vector (colE1, ApR) that encodes a Himar1 transposase (Rubin et al., 1999) and 
a transposon containing a kanamycin resistance cassette under the control of the F. tularensis 
groE promoter (Table 4).  Following recovery in trypticase soy broth supplemented with 0.1% 
cysteine, bacteria were plated on cysteine heart broth with 5% defibrinated rabbit blood  
containing kanamycin (5 µg/ml).  Colonies that emerged in the presence of kanamycin were 
isolated and screened for lack of response to extracellular spermine (Russo et al., 2011). The 
selection phenotype was lack of growth in CDM plus an inhibitor of endogenous po lyamine  
biosynthesis, dicyclohexylamine (Russo et al., 2011).  Transposon mutants that failed to grow 
were then tested for their ability to stimulate cytokines (Russo et al., 2011).  Strain 13B47 
elicited high concentrations of TNF-α from human macrophages and had a transposon insertion 
in FTL_0883 (Russo et al., 2011).  DNA sequencing showed that the precise location of this 
transposon was in base pair 115 of 842 from the 5′ end of FTL_0883 . Construction of an in-
frame deletion mutant, ΔFTL_0883, and a cis-complement strain was described previously 
(Russo et al., 2011).   
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4.3.4 Infection of macrophage s and DCs with F. tularensis LVS strains 
Human monocytes were differentiated into macrophages and DCs by in vitro culture as 
described previously (Horzempa et al., 2008a).  Briefly, monocytes were purified from human 
buffy coats from blood donations (Central Blood Bank, Pittsburgh, PA) using Ficoll gradients 
(Amersham Biosciences) to isolate peripheral blood mononuclear cells, Optiprep gradients 
(Axis-Shield) to enrich for monocytes, and panning on plastic to further purify monocytes (final 
purity, >95% based on microscopy). For macrophages, cells were cultured in 60-mm-diameter 
culture dishes for 7 days at 37°C with 5% CO2 in 5 ml of Dulbecco's modified Eagle's medium 
(Invitrogen) supplemented with 20% fetal bovine serum (Invitrogen), 10% human serum 
(Gemini Biosciences), 25 mM HEPES (Gibco), and 1% GlutaMAX (Invitrogen). Beginning on 
day 4 of culture, 0.5 ml of fresh media was added daily.  On day 7, macrophages were removed 
from the culture dish by using a lidocaine-EDTA solution (5 mM EDTA and 4 mg of 
lidocaine/ml in PBS, pH 7.2). For DCs, human monocytes were seeded at a density of 1 × 106 
cells/ml in 24 well plates (Costar) in complete RPMI [10% FCS, 25 mM HEPES, 1% non-
essential amino acids, 1% sodium pyruvate, 1% Glutamax and 0.1% 2-mercaptoethanol (all from 
Gibco)] supplemented with 1000 U/ml GM-CSF and 1000 U/ml IL-4 (both from eBioscience) 
and incubated at 37°C with 5% CO2. On day 3 of culture, 10% of the media was replaced with 
fresh complete RPMI supplemented with GM-CSF and IL-4 and non-adherent cells were 
harvested at day 5. 
For generation of murine DCs, bone marrow was flushed from femurs and tibias of 
C57BL/6J mice with complete DC medium [DMEM supplemented with 10% heat- inactivated 
FBS, 25 mM HEPES, 1% non-essential amino acids, 1% sodium pyruvate, 1% GlutaMAX and 
0.1% 2-mercaptoethanol (all from Gibco)].  Freshly isolated cells were washed and red blood 
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cells were lysed with ACK Lysis Buffer (Gibco).  After washing and counting, cells were 
resuspended in complete DC media supplemented with 500 U/ml GM-CSF (eBioscience) and 
seeded into T75 flasks or 24-well plates at a concentration of 20-30 million cells per flask or 1 x 
106 cells/well, respectively.  Cells were incubated at 37°C, 5% CO2 for 5-6 days and fresh 
complete DC media with 500 U/ml GM-CSF was added every 2 days.  Bone marrow DCs 
(BMDCs) were purified using CD11c magnetic beads (Miltenyi Biotec) per the manufacturer’s 
instructions.  The resulting cells were greater than 90% CD11c+ as assessed by flow cytometry. 
For cytokine and flow cytometry experiments, human cells were washed and resuspended 
in DMEM supplemented with 1% human serum, 25 mM HEPES, and 1% GlutaMAX.  Murine 
BMDCs were washed and resuspended in DMEM supplemented with 10% FBS, 25 mM HEPES, 
1% non-essential amino acids, 1% sodium pyruvate, 1% GlutaMAX and 0.1% 2-
mercaptoethanol (all from Gibco).  DCs and macrophages were seeded into 24-well plates 
(Costar) at 5 x 105 cells/well and 1.5 x 105 cells/well, respectively.  Infections were conducted 
using two different methods with the goal of maintaining eukaryotic cell viability.  A multiplicity 
of infection (MOI) of 10 was used for 24-hour co-cultures at 37°C with 5% CO2, allowing 
cultures to proceed without washing.  In other experiments, DCs were cultured with bacteria at 
an MOI of 500 for two hours as described below, which results in a high infection rate but with 
minimal effects on cell viability (Carlson et al., 2007; Horzempa et al., 2008a).  As a positive 
control, macrophages and DCs were stimulated with E. coli strain sd-4 (ATCC 11143) (Nau et 
al., 1997).  Supernatants were collected at various times post infection (6, 12, 24, and 48 hours) 
and DCs were prepared for flow cytometric analysis. 
Gentamicin protection assays were used to assess intracellular growth (Small et al.,  
1987).  Here, macrophages and DCs were seeded in Primaria 96-well culture dishes (BD 
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Biosciences) at a density of 5 x 104 cells/well and infected with bacteria at an MOI of 500.  After 
two hours, cells were incubated with Hanks balanced salt solution (Gibco) containing gentamicin 
(20 µg/ml) for 20 min to kill extracellular bacteria.  Cultures were then washed three times with 
warm Hank’s balanced salt solution and incubated at 37°C with 5% CO2 for another 22 hours 
with fresh culture medium.  Actual MOIs were measured by plating serial dilutions of inocula on 
chocolate II agar plates.  At the indicated time points post infection, viable CFU were measured 
as described previously (Horzempa et al., 2008a; Horzempa et al., 2010).  Bacterial growth was 
compared using Student’s t-test.   
 For DC-T cell co-culture assays, DCs were resuspended in complete T cell 
medium [DMEM supplemented with 10% heat- inactivated FBS, 25 mM HEPES, 1% non-
essential amino acids, 1% sodium pyruvate, 1% GlutaMAX and 0.1% 2-mercaptoethanol (all 
from Gibco)] and seeded in 96-well round bo ttom plates (BD Biosciences) at a density of 2 x 104 
cells/well.  DCs were cultured with different F. tularensis LVS strains at an MOI of 10 for 24 
hours pr ior to co-culture with T cells (see “Human DC-CD4+ T cell co-culture”).   
4.3.5 Flow cytometry and analysis of human monocyte-derived DCs 
Surface markers on F. tularensis- infected human monocyte-derived DCs were evaluated 
by flow cytometric analysis.  Following infection, DCs were removed from 24-well plates using 
a 2 mM EDTA solution.  Cells were washed once and resuspended in FACS staining buffer 
[0.1% bovine serum albumin and 0.1% sodium azide in PBS].  Nonspecific antibody binding 
was blocked with human FcR Blocking Reagent (Miltenyi Biotec).  Cells were stained with 
fluorescein isothiocyanate (FITC)-conjugated anti-CD1b (clone MT-101, AbD Serotec), 
phycoerythrin (PE)-conjugated anti-CD86 (clone IT2.2, eBioscience), PE-Cy5-conjugated anti-
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CD80 (clone 2D10.4, eBioscience), and PE-Cy7-conjugated anti-HLA-DR (clone LN3, 
eBioscience) at 4°C for 30 min.  Isotype control antibodies were included in each experiment to 
confirm specificity of staining.  After washing and fixing in 2% paraformaldehyde for 30 min at 
4°C, cells were analyzed using a LSRII flow cytometer (BD Biosciences) and FlowJo Software 
(Tree Star).  Statistically significant differences in CD80, CD86, and HLA-DR expression by 
infected DCs were determined by one-way ANOVA, followed by Bonferroni comparison of 
means. 
4.3.6 Human DC-CD4+ T cell co-culture 
DC-T cell co-cultures were performed similarly to previous studies (Le Nouen et al.,  
2010; Munir et al., 2011; Torres et al., 2007).  CD4+ T cells were purified from human peripheral 
blood mononuclear cells that passed through the Optiprep gradient by positive selection using 
the Dynal CD4 Positive Isolation Kit (Invitrogen) per the manufacturer’s instructions.  These 
cells were > 95% CD3+CD4+ T cells as assessed by flow cytometry.  Purified CD4+ T cells were 
then stained with 2.5 μM CFSE for 10 min at 37°C, washed, and resuspended in complete T cell 
medium.  CFSE-labeled T cells from a single donor were then added to DCs from a different 
donor that had been exposed to bacteria.  DC-T cell co-cultures were performed in a 96-well 
round bottom plate at a ratio of 10:1 (2 x 105 T cells/2 x 104 DCs/well) for a period of 5 days at 
37°C with 5% CO2.  After harvesting supernatants, cells were washed once and resuspended in 
FACS staining buffer, treated with human FcR Blocking Reagent (Miltenyi Biotec), and stained 
with APC-conjugated anti-CD4 (clone OKT4, eBioscience) at 4°C for 30 min.  After washing 
and fixing in 2% paraformaldehyde for 30 min at 4°C, fluorescence was measured using a 
FACSCalibur flow cytometer (BD Biosciences) and analyzed with FlowJo Software (Tree Star).  
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For T cell proliferation, CFSElow cells were measured in the CD4+ gate.  Statistically significant 
differences in the percentage of proliferating T cells following co-culture with infected DCs were 
determined by one-way ANOVA, followed by Bonferroni comparison of means. 
4.3.7 Mice 
Six- to eight-week old female C57BL/6J mice were purchased from Jackson Laboratories (Bar 
Harbor, ME).  Mice were housed in microisolator cages under specific pathogen-free conditions 
in a biosafety level-3 animal facility.  All research involving animals was conducted in 
accordance with animal care and use guidelines, and animal protocols were approved by the 
University of Pittsburgh Animal Care and Use Committee. 
4.3.8 Immunization of mice 
LVS and ΔFTL_0883 were cultured in MH broth or TSBc as described above.  Mice 
were immunized subcutaneously (s.c.) or intratracheally (i.t.).  Vaccinations were performed i.t. 
by oropharyngeal instillation as described previously (Horzempa et al., 2010).  A subset of mice 
was sacrificed at 2 hours post infection, and their lungs were homogenized and plated to confirm 
delivery of bacteria to the respiratory tract.  Actual administered doses were determined by 
plating serial dilutions of the inocula onto chocolate II agar plates. 
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4.3.9 Infection of mice with F. tularensis Schu S4 
Schu S4 was grown in MH broth as described above.  Mice were infected i.t. with 100 
CFU of Schu S4 six weeks following LVS or ΔFTL_0883 vaccination.  The actual dose was 
calculated by plating serial dilutions of the inoculum onto chocolate II agar plates.  Following 
infection, mice were monitored daily for survival. 
4.3.10 Measurements of bacterial burden in vivo 
Bacterial burdens in the organs of mice vaccinated with LVS strains were measured as 
previously described (Horzempa et al., 2010; Russo et al., 2011).  Mice were sacrificed at the 
indicated time points and lungs, spleens, and livers were removed and homogenized in 1 ml 
(lungs, spleens) or 2 ml (livers) of TSBc.  A portion of the organ homogenates were serially 
diluted and plated onto chocolate II agar plates.  Plates were incubated at 37°C at 5% CO2 and 
individual colonies were enumerated. 
4.3.11 In vitro stimulation of lung cells from vaccinated mice 
Six weeks following vaccination with LVS or ΔFTL_0883, lungs were excised, minced, 
and incubated in RPMI (Gibco) supplemented with 12 mg type I collagenase (Gibco), 100 μg 
DNase I (USB), and 3 mM CaCl2 for 30 min at 37°C with shaking (170 rpm).  The digested 
tissue was passed through a 40 μm cell strainer (BD Biosciences) to generate single cell 
suspensions.  Erythrocytes were lysed with ACK Lysis Buffer (Gibco) and remaining cells were 
washed with RPMI.  Viable cells were counted using trypan blue exclusion.  Cells were 
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resuspended in complete RPMI [RPMI supplemented with 10% heat- inactivated FBS, 25 mM 
HEPES, 1% non-essential amino acids, 1% sodium pyruvate, 1% GlutaMAX and 0.1% 2-
mercaptoethanol (all from Gibco)] and seeded into 96-well round bottom plates at 1.5 x 106 
cells/well.  Lung cells from naïve mice served as controls.  BMDCs were generated as described 
above without CD11c magnetic bead purification.  BMDCs were resuspended in complete RPMI 
and added at a 1:10 ratio (1.5 x 105 BMDCs/1.5 x 106 lung cells) to lung cells.  Cells were 
incubated at 37 °C with either media alone or ffSchu S4 at dose of 10 CFU per cell.  After 48 
hour co-culture, supernatants were collected for analysis of cytokines and chemokines. 
4.3.12 Cytokine and chemokine assays 
DCs and macrophage supernatants were tested by ELISA using commercially available kits 
to measure TNF-α (R&D Systems), IL-12p40 (human, R&D Systems; mouse, eBioscience), and 
IL-6 (human, R&D Systems) according to the manufacturer’s instructions.  IFN-γ in supernatants 
from human DC-CD4+ T cell co-cultures was also measured by ELISA (human, R&D Systems).  
The limits of detection for the ELISAs were: human TNF-α – 15.6 pg/ml, human and mouse IL-
12p40 – 31.2 pg/ml, human IL-6 – 9.7 pg/ml, and human IFN-γ – 15.6 pg/ml.  Cytok ine and 
chemokine levels in lung supernatants from in vitro re-stimulation assays were determined by 
ELISA (mouse IFN-γ, R&D Systems; mouse IL-17A, Biolegend) or by using the Milliplex 32-
plex Mouse Cytokine/Chemokine Panel (Millipore) on a Bio-Plex 200 system (Bio-Rad 
Laboratories).  Analyte concentrations were calculated against the standards using Milliplex 
Analyst software (version 3.5; Millipore).  The limits of detection for the ELISAs were 31.2  
pg/ml for  mouse IFN-γ and 15.6 pg/ml for mouse IL-17A.  Statistically significant differences in 
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cytokine production were identified by one- or two-way ANOVA followed by Bonferroni 
comparison of means.   
4.4 RESULTS 
4.4.1 Limited inflammatory response of human DCs to LVS 
We have shown previously that human macrophages have a limited capacity to produce 
proinflammatory cytokines following infection with LVS (Carlson et al., 2007).  We 
hypothesized that human DCs would also be hyporesponsive to LVS stimulation.  To test this, 
human macrophages and DCs were co-cultured with LVS, and then supernatants were harvested 
and analyzed for the proinflammatory cytokines TNF-α, IL-6, and IL-12p40.  Similar to our 
find ings with macrophages (Fig. 31A), LVS elicited little to no proinflammatory cytokines from 
human DCs (Fig. 31B).  As a positive control, human DCs were stimulated with E. coli (Nau et 
al., 1997).  E. coli-stimulated DCs produced significantly higher levels of all cytokines measured 
compared to untreated DCs or DCs cultured with LVS (Fig. 31B). 
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Figure 31.  F. tularensis LVS strain 13B47 stimulates human monocyte-derived DCs and macrophages to 
produce proinflammatory cytokines.   
LVS and LVS mutants, 13B47, ΔcapC, and 1664d, were cu ltured overnight in a chemically defined media (CDM) 
or Mueller-Hinton (MH) broth.  The four bacterial cultures were used to inoculate macrophages (A, 1.5 x 105 
cells/well) and DCs (B and C, 5 x 105 cells/well) at an MOI of 10.  As a positive control, DCs and macrophages 
were cultured with E. coli strain sd-4 (MOI=10).  Supernatants were harvested after 24 hours (A-B) or at indicated 
times (C), and TNF-α, IL-6, and IL-12p40 were measured by ELISA.  Data are expressed as the mean ± SEM of 
three individual experiments with different donors.  The level of cytokine production from each group was 
compared by a one (A-B) or two-way ANOVA (C), fo llowed by the Bonferroni comparison of means.  ($$$, 
p<0.001 for E. coli vs. all other groups).  When comparing only the DCs infected with the F. tularensis strains, 
13B47 elicited higher cytokine production than the uninfected group (A-B) or LVS cultured in the same media (C). 
*, p<0.05; **, p<0.01;  ***, p<0.001.  BD = below limits of detection of the ELISA.   
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4.4.2 Identification of an immunostimulatory F. tularensis LVS strain  
We hypothesized that a LVS mutant inducing a stronger proinflammatory response from 
APCs in vitro would be a more effective tularemia vaccine candidate.  Surveying pre-existing 
LVS mutants generated in our laboratory, we tested several for their ability to stimulate cytokine 
production from human DCs and macrophages (Table 4).  Human DCs and macrophages were 
co-cultured with each of the mutants in parallel with wild-type LVS, and supernatants were 
analyzed for cytokines.  Cytokine production by DCs and macrophages infected with either 
ΔcapC or 1664d was similar to LVS- infected cells at 24 hours post infection (Fig. 31A-B).  In 
contrast, DCs and macrophages infected with the 13B47 strain produced elevated levels of all 
cytokines measured (Fig. 31A-B).  Although the cytokine levels elicited by 13B47 were lower 
than those produced by cells stimulated with E. coli (Fig. 31A-B), each was readily detected.  
Among the LVS strains tested, therefore, 13B47 stimulated the most proinflammatory cytokines 
from human APCs. 
We next assessed whether the medium used to grow the bacteria would influence 
stimulation of DCs.  LVS grown in media containing high levels of polyamines such as CDM 
stimulates low levels of proinflammatory cytokines from macrophages (Carlson et al., 2007; 
Carlson et al., 2009; Russo et al., 2011).  To address the effect culture conditions may have on 
the DC phenotypes observed here, LVS and 13B47 were cultured in CDM or MH broth prior to 
co-culture with human DCs.  At various time points post infection, supernatants were harvested 
and analyzed for detection of IL-12p40.  At 24 and 48 hours post infection, greater than 10- fold 
higher levels of IL-12p40 were produced by human DCs cultured with 13B47 compared to wild-
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type LVS (Fig. 31C).  IL-12p40 production by DCs was higher regardless of whether 13B47 was 
cultured in CDM or MH broth (Fig. 31C).  This result indicated that induction of cytokine 
production by 13B47 was not dependent on the growth medium used to culture this strain. 
4.4.3 Maturation of DCs infected with F. tularensis strain 13B47 
In addition to the secretion of cytokines, DCs must undergo a process called maturation 
in order to efficiently prime T cells and initiate the adaptive immune response .  Among these 
alterations, the expression of MHC and costimulatory molecules increases.  Since 13B47 
stimulated cytokine production from human DCs, we next evaluated whether these cells also 
changed their surface phenotype in response to this mutant. The expression of CD80, CD86, and 
HLA-DR was measured on DCs following culture with either wild-type F. tularensis LVS, 
13B47, ΔcapC, 1664d, or E. coli as a positive control for maturation.  LVS elicited little to no 
change in expression of maturation markers on the surface of human DCs (Fig. 32A-C).  Similar 
results were observed with the LVS mutants ΔcapC and 1664d (Fig. 32B-C).  In contrast, the 
percentage of high-expressing cells and/or geometric mean fluorescence intensity increased after 
culture with 13B47 for CD80 and CD86 (Fig. 32).  A similar trend of heightened expression of 
HLA-DR was also observed with 13B47- infected DCs (Fig. 32).  Likewise, E. coli-stimulated 
DCs increased expression of costimulatory molecules and MHC (Fig. 32).  These data suggest 
that DCs undergo maturation after expos ure to F. tularensis strain 13B47 and, therefore, may be 
better suited to initiate an adaptive immune response. 
 126 
 
Figure 32.  Human monocyte-derived DCs mature following exposure to LVS strain 13B47.   
DCs were stimulated with either LVS, 13B47, ΔcapC, 1664d, or E. coli for 24 hours (MOI=10).  Cells were 
harvested and analyzed for changes in surface expression of CD86, CD80, and HLA-DR.  Cells were gated on 
CD1b-positive population.  (A)  Representative histograms for CD86, CD80, and HLA-DR expression on LVS-, 
13B47-, and E. coli-treated DCs from one experiment.  Histograms for ΔcapC- and 1664d-in fected DCs were 
similar to LVS (data not shown).  (B) Mean percentages of DCs with high CD86, CD80, and HLA -DR expression 
(± SEM) from three indiv idual experiments with different donors. (C)  Geometric mean fluorescence intensities 
(GMFI) of CD86, CD80, and HLA-DR (± SEM) on DCs from three indiv idual experiments with different donors.  
Statistically significant differences in CD86, CD80, and HLA -DR expression by infected DCs were determined by 
one-way ANOVA, followed by Bonferroni comparison of means (*, p<0.05; **, p<0.01; ***, p<0.001). 
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4.4.4 Growth of 13B47 in human macrophages and DCs  
Intracellular growth is a hallmark of pathogenic Francisella strains.  Although 13B47 
stimulated APCs to secrete cytokines and upregulate costimulatory molecules, it was unclear if 
its intracellular growth was altered.  To test this, human DCs and macrophages were infected 
with either wild-type LVS or strain 13B47, and lysed at various times post infection to 
enumerate intracellular bacteria.  13B47 was attenuated for growth at 24 hours post infection in 
human macrophages (Fig. 33).  Surprisingly, 13B47 was still capable of replicating in human 
DCs (Fig. 33), albeit with a slightly slower rate compared to wild-type LVS (estimated 
generation time of 783 minutes versus 275 minutes for wild-type).  These data suggest that, 
while the cytokine response to 13B47 is similar between macrophages and DCs, these cells differ 
in their ability to control growth of this mutant. 
 
Figure 33.  LVS strain 13B47 is attenuated for growth in human macrophages and replicates slowly in DCs. 
DCs or macrophages were infected in gentamicin protection assays (MOI = 500) with LVS or 13B47 and lysed at 
the indicated times post infection.  Data shown are mean ± SEM from three individual experiments with different 
donors.  Statistically significant differences in growth at 24 hours post infection were determined by Student’s t-test 
(*, p<0.05). 
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4.4.5 Enhanced activation of CD4+ T cells by F. tularensis strain 13B47-infected DCs 
Enhanced maturation of human DCs by 13B47 led us to hypothesize the resulting DCs 
would stimulate T cells more effectively.  This was tested by measuring human CD4+ T cell 
proliferation and cytok ine production following co-culture with allogeneic DCs pre-treated with 
LVS, 13B47, or E. coli.  T cell proliferation was measured by CFSE dilution after co-culture 
with infected DCs for 5 days as described previously (Le Nouen et al., 2010; Munir et al., 2011; 
Torres et al., 2007).  An increase in the percentage of proliferating CD4+ T cells was observed 
following co-culture with 13B47- infected DCs compared to unstimulated CD4+ T cells (Fig. 34A 
and B).  This increased percentage of proliferating CD4+ T cells was comparable to the level of 
proliferating T cells observed following co-culture with E. coli-infected DCs (Fig. 34A and B).   
In contrast, the percentage of proliferating CD4+ T cells following co-culture with LVS-treated 
DCs was not significantly different from the baseline level of proliferation observed with 
unstimulated DCs (Fig. 34B).  Culturing T cells with bacteria alone in the absence of DCs also 
did not induce high levels of proliferation (7.52% proliferating CD4+ T cells for LVS, 8.22% 
proliferating CD4+ T cells for 13B47). 
T cell activation following co-culture with infected DCs was also assessed by cytokine 
production.  IFN-γ concentrations in the supernatants of the DC-T cell co-cultures described 
above showed a similar trend to the proliferation data.  CD4+ T cells cultured with 13B47-
infected DCs produced higher levels of IFN-γ compared to those stimulated with LVS-infected 
DCs (Fig. 34C).  T cells stimulated with bacteria alone in the absence of DCs did not produce 
measurable levels of IFN-γ (< 15.6 pg/ml).  The proliferation and cytokine production data 
together suggest DC maturation induced by 13B47 had measurable consequences on T cells in 
vitro. 
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Figure 34.  Enhanced proliferation and IFN-γ production by CD4+ T cells stimulated with LVS strain 13B47-
infected DCs.   
Purified CFSE-labeled CD4+ T cells from a single donor were co-cultured with either E. coli-infected, F. tularensis 
LVS-infected, or 13B47-infected DCs from a different donor at a ratio of 10:1 (2 x 105 T cells/2 x 104 DCs/well) for 
5 days.  (A) Representative dot plots showing loss of CFSE fluorescence versus CD4 staining on day 5 for each 
group from one experiment.  (B) The mean percentages of proliferating CD4+ T cells were calculated (± SEM) from 
five individual experiments with different donors.  (C) IFN-γ levels were measured in day 5 supernatants by ELISA.  
Data are presented as the mean ± SEM from four individual experiments with different donors that were represented 
in Figure 4B.  BLD = below limits of detection of the ELISA.  Statistically significant differences in mean 
percentages and GMFI for all groups were determined by one-way ANOVA, followed by Bonferroni comparison of 
means (*, p<0.05; **, p<0.01; ***, p<0.001). 
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4.4.6 Evaluation of the LVS FTL_0883 mutant as a tularemia vaccine 
Protection from virulent type A Francisella infection is largely dependent on the 
development of robust T cell-mediated immunity (Elkins et al., 2007).  Based on the data 
obtained with human cells in vitro, we hypothesized that vaccination with 13B47 would prolong 
survival and improve T cell responses compared to LVS in mice challenged with virulent 
Francisella.  However, 13B47 is not optimal since it contains a transposon that could be 
unstable.  To generate a more suitable vaccine candidate, an in-frame deletion mutant was 
created in LVS, ΔFTL_0883, that does not incorporate an antibiotic resistance marker (Russo et 
al., 2011).  Similar to human macrophages (Russo et al., 2011), more IL-12p40 and TNF-α was 
produced by human DCs cultured with ΔFTL_0883 than wild-type LVS (Fig. 35A-B).  These 
cytokine levels were similar to, o r greater than, that produced by DCs cultured with 13B47 (Fig. 
35A-B).  Moreover, IL-12p40 and TNF-α levels continued to rise from 24-48 hours when DCs 
were cultured with ΔFTL_0883 (Fig. 35B).  To confirm the heightened stimulation of 
macrophages and DCs was due to deletion of FTL_0883, an in cis-complementing construct 
(pJH1-FTL_0883) was generated and introduced into ΔFTL_0883 (Russo et al., 2011).  
Complementation of ΔFTL_0883 with the wild-type copy of the gene significantly reduced IL-
12p40 and TNF-α production by human macrophages (Russo et al., 2011) and DCs (Fig. 35B).  
Differential induction of IL-12p40 from human DCs by FTL_0883 mutants and wild-type LVS 
was also observed at a higher MOI of 500 (Fig. 35C). 
 131 
 
Figure 35.  FTL_0883 deletion mutant, ΔFTL_0883, elicits maturation of DCs and is attenuated for growth 
similar to 13B47.    
Human (A-E) and murine DCs (F-G) were cultured with either LVS, 13B47, ΔFTL_0883, or ΔFTL_0883::pJH1- 
FTL_0883 at an MOI of 10 (A-B, D, and F) or 500 fo llowed by gentamicin treatment (C-E, and G).  For cytokines, 
supernatants were harvested at 24 hours (A, C, and F) or the indicated time points (B), and IL-12p40 and TNF-α 
were measured by ELISA.  For flow cytometry experiments (D), DCs were harvested 24 hours post infection and 
GMFIs for CD80 and CD86 were measured.  For gentamicin protection assays (E, G), DCs were infected with LVS 
strains at an MOI of 500 and then lysed at indicated time points to enumerate intracellular bacteria.  Data are 
presented as the mean ± SEM from at least two independent experiments.  Statistically significant differences 
between groups were determined by one (A, C, D, and F) or two-way ANOVA (B, E, and G), followed by 
Bonferron i comparison of means (*, p<0.05; **, p<0.01; ***, p<0.001).  BLD = below limits of detection of the 
ELISA.   
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 Changes in CD80 and CD86 expression were also evaluated in human DCs cultured with 
either wild-type LVS or FTL_0883 mutants.  As demonstrated previously in Fig. 32, expression 
of CD80 and CD86 was not altered on human DCs cultured with wild-type LVS at a low MOI 
(Fig. 35D).  Culturing of human DCs with 13B47 or ΔFTL_0883, however, caused a statistically 
significant increase in expression of both costimulatory molecules on the surface (Fig. 35D). 
CD80 and CD86 expression were also higher on DCs cultured with 13B47 or ΔFTL_0883 than 
on LVS-infected DCs using a higher MOI (Fig. 35D).  Lower levels of CD80 and CD86 were 
also measured on human DCs cultured with the ΔFTL_0883 strain complemented with a wild-
type copy of the gene compared to DCs cultured with ΔFTL_0883 (Fig. 35D).  
Deletion of FTL_0883 in LVS reduces its ability to replicate in human and murine 
macrophages (Russo et al., 2011).  Additionally, the LVS mutant containing a transposon 
insertion in the FTL_0883 gene, 13B47, was attenuated for growth in human macrophages and 
replicated slowly in human DCs (Fig. 33).  To measure ΔFTL_0883 replication in human DCs, 
DCs were infected with either wild-type LVS, 13B47, ΔFTL_0883, or the complemented strain, 
and lysed at various times post infection to enumerate intracellular bacteria.  ΔFTL_0883 
replicated more slowly in human DCs than wild-type LVS, exhibiting at least 5- fold less growth 
24 hours post infection (Fig. 35E).  Similar results were observed 48 and 72 hours post infection 
with up to a 20- fold difference in growth between ΔFTL_0883 and LVS measured 72 hours post 
infection (Fig. 35E).  The growth kinetics for ΔFTL_0883 and 13B47 in human DCs over the 72 
hour pe riod were indistinguishable (Fig. 35E).  Complementation of ΔFTL_0883 with a wild-
type copy of the gene restored growth of the mutant to near wild-type levels (Fig. 35E).  In 
summary, 13B47 and ΔFTL_0883 were similar with 1) reduced growth in human DCs, 2) 
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increased expression of CD80 and CD86, and 3) stimulation of IL-12p40 and TNF-α production 
by human DCs. 
To test whether the phenotypes observed in human DCs were species-specific, murine DCs 
were also tested with these LVS strains.  IL-12p40 levels were higher in supernatants from 
murine DCs cultured with either 13B47 or ΔFTL_0883 compared to LVS (Fig. 35F).  Growth of 
strains with mutations in FTL_0883 was also less than wild-type in murine DCs (Fig. 35G).  
Similar to published work (Bosio and Dow, 2005), LVS replicated approximately 100-fold over 
24 hours in murine DCs (Fig. 35G).  Both 13B47 and ΔFTL_0883 grew less robustly in murine 
DCs, which was less than wild-type at 24, 48, and 72 hours post infection (Fig. 35G).  Growth of 
the ΔFTL_0883 was nearly restored to wild-type levels by the complementing construct 
containing a wild-type copy of the gene (Fig. 35G).  These results showed that human and 
murine DCs responded similarly to 13B47 and ΔFTL_0883. 
Having established the in vitro phenotypes of the ΔFTL_0883 strain, we next assessed its 
ability to stimulate adaptive immune responses in vivo.  C57BL/6J mice were vaccinated by 
either subcutaneous (s.c.) or respiratory (i.t.) routes with LVS or ΔFTL_0883.  Mice were 
challenged six weeks later i.t. with the type A F. tularensis strain Schu S4.  V accination of 
C57BL/6J mice with LVS prolongs survival but does not completely protect against a secondary 
challenge with a type A Francisella strain (Chen et al., 2003; Wu et al., 2005).  This 
experimental design allowed us to determine whether ΔFTL_0883 vaccination conferred better 
protection than LVS.  All mice that received a sham vaccination with PBS succumbed to the 
Schu S4 infection within 5 days following challenge (Table 5).  Although mice vaccinated s.c. 
with LVS and ΔFTL_0883 survived longer than sham-vaccinated controls, they still required 
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euthanasia within 7 days of Schu S4 infection (Table 5).  No survival differences were observed 
between animals vaccinated s.c. with LVS and ΔFTL_0883 (Table 5). 
Vaccination by a respiratory route, however, showed statistically significant differences in 
protective efficacy.  The median time to death of mice vaccinated i.t. with LVS was 
approximately 10-12 days following Schu S4 challenge (Table 5).  This median time to death 
was double the median time to death for sham-vaccinated controls (5 days, Table 5) and was 
similar to previous work (Wu et al., 2005).  In contrast, mice vaccinated with ΔFTL_0883 
survived for a median of 6 days (Table 5).  Therefore, vaccination with ΔFTL_0883 by a 
respiratory route provided less protection than that elicited by wild-type LVS.  
  
Table 5.  Survival of immunized mice following intratracheal Schu S4 challenge 
Route Vaccine Vaccination 
Dose 
Time to Death of 
Individual Mice (days) 
Median Time to 
Death (days) 
Control PBS N/A 5, 5, 5, 5, 5 5 
Subcutaneous LVS 1 x 104 6, 7, 7, 7, 7 7 
 ΔFTL_0883 1 x 104 6, 6, 7, 7, 7 7 
Intratracheal Experiment 1    
 LVS 1 x 103 10,12,12, >33, >33 12b 
 ΔFTL_0883 1 x 103 5, 6, 6, 7, 7 6 
 Experiment 2    
 LVS 2 x 103 9, 9, 10, 11, 12 10b 
 ΔFTL_0883 2 x 103 6, 6, 6, 7, 7 6 
 
aMice were immunized with either LVS or ΔFTL_0883 at the indicated dose and then challenged with 
100 CFU of Schu S4 i.t. 
bSignificant difference  p < 0.005 by log rank test. 
 
 
To investigate the differences in the protection elicited by the two strains, we evaluated 
bacterial burdens in the lung and pe ripheral organs following respiratory vaccination. LVS 
replicated exponentially in the lung for the first three days following i.t. immunization (Fig. 36).  
The lung bacterial burden remained steady until day 6 post immunization and then slowly began 
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to decline up to day 10 (Fig. 36).  Dissemination to the spleen and liver occurred at day 3 with 
LVS burden peaking at day 6 and being cleared by day 10 (Fig. 36).  Despite comparable doses 
of bacteria used in the vaccinations, lower levels of ΔFTL_0883 were detected at all time points 
in the lung and beginning at day 3 in peripheral organs post immunization (Fig. 36).  While 
clearance of LVS from the lung does not occur until 22 days post infection (Jia et al., 2010), 
ΔFTL_0883 was cleared more rapidly at approximately 10 days post infection (Fig. 36).  Viable 
ΔFTL_0883 were measured in the spleens and livers of seven of eight mice by day 6, but none 
were detected in these organs at day 10 (Fig. 36).   Therefore, LVS achieved higher numbers for 
a longer period of time in the lung and periphery following vaccination. 
 
 
Figure 36.  ΔFTL_0883-vaccinated mice have reduced bacterial burdens. 
Mice were vaccinated i.t. (1.5 x 103 CFU) with either LVS or ΔFTL_0883 (n=4 mice/group/time point).  At 
indicated time points (days 1, 3, and 6 for experiment 1; days 3, 6, and 10 for experiment 2), mice were sacrificed 
and the CFU/organ was determined as described in Materials and Methods.  The limits of detection for the lung, 
spleen, and liver are depicted by the black dashed lines and were 100, 100, and 200 CFU, respectively.  Data are 
presented as mean ± SD for each individual experiment.  Statistically significant differences between groups in each 
experiment were determined by two-way ANOVA, followed by Bonferroni comparison of means (*, p<0.05; ***, 
p<0.001).   
 
We next sought an immunological explanation for the performance of ΔFTL_0883 
vaccination.  We hypothesized wild-type LVS induced superior T cell responses than 
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ΔFTL_0883, and measured cytokine and chemokine responses by lung cells after i.t. vaccination.  
Cells were harvested from the lungs of LVS- and ΔFTL_0883-vaccinated mice and were re-
stimulated in vitro with ffSchu S4.  Cells from mice vaccinated with LVS produced higher 
amounts of IFN-γ with re-stimulation than cells from naïve mice or those that received 
ΔFTL_0883 (Fig. 37A).  IFN-γ production by lung cells from mice vaccinated with ΔFTL_0883, 
however, was not statistically significantly different than naïve controls (Fig. 37).  Increasing the 
vaccination dose of ΔFTL_0883 by three- fold failed to improve IFN-γ responses by the lung 
cells (Fig. 37).  Consistent with the IFN-γ results, the IFN-γ inducible chemokine MIG was also 
higher in cultures from mice vaccinated with LVS (Table 6).  In contrast to IFN-γ, cells from 
both vaccination groups produced comparable amounts of IL-17 after re-stimulation.  A 2-3 fold 
increase in IL-17 production was observed in lung cells from mice vaccinated with ΔFTL_0883 
and LVS compared to naïve controls (Fig. 37).  No other statistically significant differences were 
consistently detected in the other cytokines and chemokines that were tested (Table 6). 
Therefore, the protection elicited by LVS against Schu S4 challenge correlated with IFN-γ 
production by lung cells after re-stimulation with antigen. 
 
Figure 37.  Cells from mice vaccinated with LVS produce more IFN-γ after re-stimulation.    
Mice were vaccinated i.t. with either LVS or ΔFTL_0883 (n=3-4 mice/group). Age-matched naïve mice (n=3) 
served as negative controls.  Lung cells were isolated from vaccinated and unvaccinated mice 30 days post 
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vaccination and incubated with formalin-fixed SchuS4 (ffSchu S4) and BMDCs for 48 hours. (A)  Culture 
supernatants were collected and assessed for mult iple cytokines and chemokines using the Milliplex 32-p lex Mouse 
Cytokine/Chemokine Panel (Millipore) on a Bio-Plex system (Bio-Rad Laboratories, Inc.).  Baseline levels of 
cytokine/chemokine production were established by the culturing of lung cells in media alone (no antigen).  Data are 
presented as the mean ± SD of trip licate wells from one ind ividual experiment.  Another experiment of similar 
design was performed with a vaccination dose of 500 CFU i.t., and IL-17 and IFN-γ levels were measured by 
ELISA.  Similar results were observed in both experiments. (B) IFN-γ production by lung cells isolated from mice 
vaccinated with two different doses of ΔFTL_0883 as measured by ELISA.  Statistically significant differences in 
cytokine/chemokine production were determined by one-way ANOVA, followed by Bonferroni comparison of 
means. (**, p<0.01 for LVS v . ΔFTL_0883 fo llowing ffSchu S4 re-stimulation). BD = below levels of detection. 
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Table 6.   Cytokine and chemokine levels following re-stimulation of lung cells from LVS- and ΔFTL_0883-
vaccinated mice. 
Cytokines media ffSchu S4 
 unvaccinated LVS ΔFTL_0883 unvaccinated LVS ΔFTL_0883 
Eotaxin  36.22 
(± 36.64) 
6.54 
(± 5.79) 
17.56 
(± 20.90) 
21.49 
(± 17.00) 
BD 8.52 
(± 6.32) 
G-CS F  747.33 
(± 762.62) 
574.67 
(±140.20) 
499.33 
(± 252.75) 
729.33 
(± 436.38) 
1172.33 
(± 246.67) 
847.67 
(± 352.55) 
GM-CS F  17.67 
(± 17.37) 
10.15 
(± 5.41) 
15.70 
(± 8.72) 
19.10 
(± 13.67) 
37.10 
(± 10.66) 
39.03  
(± 3.21) 
IFN-γ  3.58 
(± 0.65) 
136.98 
(± 102.23) 
5.67 
(± 2.96) 
3.13 
(± 0.13) 
3393.33a 
(± 1326.94) 
437.00 
(± 177.60) 
IL-1α  54.11  
(± 36.80) 
48.71 
(± 9.74) 
43.33 
(± 14.64) 
50.19 
(± 23.69) 
86.74 
(± 14.39) 
61.49 
(± 11.33) 
IL-1β  5.64 
(± 4.22) 
4.21 
(± 1.01) 
4.21 
(± 1.02) 
7.02 
(± 4.23) 
10.50 
(± 3.81) 
7.16 
(± 2.50) 
IL-2 15.29 
(± 1.50) 
5.73 
(± 2.37) 
14.77 
(± 2.14) 
10.67 
(± 3.05) 
10.19 
(± 2.91) 
30.35 
(± 16.48) 
IL-3 5.91 
(± 1.48) 
3.14 
(± 0.10) 
8.55 
(± 3.61) 
3.79 
(± 1.38) 
BD 5.71 
(± 4.34) 
IL-4 BD 
 
BD BD BD BD BD 
IL-5 2490.33 
(± 1492.86) 
846.00 
(± 602.44) 
2929.00 
(± 313.23) 
2053.00 
(± 1079.36) 
1394.67 
(± 986.09) 
2786.33 
(± 178.77) 
IL-6 7068.67 
(± 5028.98) 
6212.67 
(± 3448.59) 
7974.33 
(± 2762.77) 
7267.33 
(± 4588.33) 
7729.33 
(± 1940.69) 
8717.00 
(± 1750.64) 
IL-7 BD 
 
BD BD BD BD BD 
IL-9 4.66 
(± 2.53) 
BD 14.20 
(± 19.05) 
BD BD BD 
IL-10 13.96 
(± 9.98) 
14.93 
(± 8.76) 
14.35 
(± 4.05) 
12.30 
(± 4.39) 
16.98 
(± 7.53) 
16.36 
(± 4.06) 
IL-12p40  BD 
 
BD BD BD BD BD 
IL-12p70  6.27 
(± 2.87) 
3.92 
(± 1.59) 
4.88 
(± 1.67) 
5.55 
(± 3.17) 
5.85 
(± 0.95) 
5.78 
(± 0.12) 
IL-13 31.02 
(± 20.80) 
18.97 
(± 11.75) 
24.41 
(± 10.22) 
25.57 
(± 17.67) 
36.73 
(± 7.69) 
28.62 
(± 7.96) 
IL-15  3.79 
(± 0.51) 
BD BD 3.30 
(± 0.18) 
BD BD 
IL-17 BD 3.67 
(± 0.81) 
3.33 
(± 0.22) 
BD 12.21 
(± 5.08) 
19.00 
(± 10.26) 
IP-10  1189.00  
(± 862.87) 
800.67 
(± 334.83) 
828.67 
(± 202.02) 
1055.33 
(± 490.12) 
704.00 
(± 52.26) 
1459.33 
(± 511.86) 
KC  2202.00 
(± 2584.55) 
1089.00 
(± 415.29) 
1037.33 
(± 661.61) 
2144.67 
(± 2085.64) 
2183.33 
(± 706.93) 
1809.00 
(± 671.22) 
LIF  79.60 
(± 65.33) 
32.50 
(± 19.64) 
54.34 
(± 22.58) 
60.52 
(± 46.15) 
32.90 
(± 11.02) 
53.54 
(± 13.34) 
MCP-1  3227.33 
(± 2018.19) 
1303.67 
(± 786.34) 
1685.00 
(± 909.16) 
2808.67 
(± 1153.49) 
872.67 
(± 180.59) 
1772.00 
(± 218.63) 
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M-CSF  BD 
 
BD BD BD BD BD 
MIG  124.30 
(± 78.80) 
1982.00 
(± 484.81) 
297.00 
(± 45.92) 
99.85 
(± 39.88) 
7559.00b  
(± 1019.65) 
1732.67 
(± 980.18) 
MIP-1α  34.19 
(± 9.90) 
18.20  
(± 11.15) 
24.37 
(± 8.64) 
34.85 
(± 7.74) 
16.07 
(± 3.41) 
29.39 
(± 4.31) 
MIP-1β  94.45 
(± 26.82) 
32.42  
(± 15.69) 
53.45 
(± 25.14) 
90.73 
(± 11.05) 
29.66 
(± 16.52) 
69.52 
(± 11.99) 
MIP-2  278.67 
(± 155.00) 
422.00  
(± 134.97) 
180.72 
(± 87.05) 
427.67 
(± 206.73) 
1462.67 
(± 582.14) 
686.00 
(± 476.43) 
RANTES  82.34 
(± 52.90) 
73.95  
(± 24.44) 
84.49 
(± 23.50) 
93.70 
(± 50.31) 
111.68 
(± 26.61) 
146.33 
(± 18.34) 
TNF-α  17.36 
(± 4.21) 
26.54  
(± 1.71) 
18.09 
(± 3.31) 
20.99 
(± 5.56) 
41.39b 
(± 4.48) 
27.05 
(± 1.92) 
VEGF  294.67 
(± 280.23) 
258.00  
(± 83.21) 
260.00 
(± 93.82) 
253.33 
(± 188.23) 
516.00 
(± 122.26) 
340.67 
(± 163.93) 
LIX  579.72 
(± 692.87) 
195.88  
(± 153.91) 
291.00 
(±193.12) 
504.70 
(± 514.62) 
222.00 
(± 48.54) 
315.00 
(± 86.56) 
ap<0.05 by one-way ANOVA followed by Bonferroni comparison of means, significant compared to ΔFTL_0883 
following ffSchu S4 re-stimulation by both Luminex and ELISA 
bp<0.05 by one-way ANOVA followed by Bonferroni comparison of means, significant compared to ΔFTL_0883 
following ffSchu S4 re-stimulation by Luminex only  
cBD = below levels of detection 
4.5 DISCUSSION 
Several studies, including this one, indicate LVS poor ly stimulates innate immune cells 
(Bosio and Dow, 2005; Carlson et al., 2007; Carlson et al., 2009; Loegering et al., 2006; 
Telepnev et al., 2003; Telepnev et al., 2005).  This suggests insufficient activation of DCs could 
contribute to incomplete protection engendered by LVS.  In this study, we sought to improve 
vaccine efficacy with a LVS strain that stimulated APCs better than wild-type LVS.  The LVS 
mutants used in this study (Table 4) were selected based on specific characteristics.  All three of 
these genes (FTL_1415, FTL_1664, and FTL_0883) have been identified in negative selection 
screens in F. novicida and/or LVS to be necessary for growth and/or survival in mice (Su et al.,  
2007; Weiss et al., 2007).  The ΔcapC mutant was of interest because another LVS mutant in the 
capBCA operon, ΔcapB, afforded protection in BALB/c mice against challenge with the virulent 
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Francisella strain Schu S4 (Jia et al., 2010).  Mutation of FTL_1664 in LVS resulted in 
diminished uptake by human DCs (Horzempa et al., 2008a), which may affect DC activation.  
Recently, our laboratory has shown that LVS FTL_0883 mutants like 13B47 stimulate innate 
immune cells and are attenuated in vitro and in vivo, making this mutant a possible vaccine 
candidate (Russo et al., 2011).   
Strains with mutations in the FTL_0883 locus of LVS showed promise based on in vitro 
results.  The 13B47 and ΔFTL_0883 derivatives of LVS stimulated human DCs and 
macrophages (Fig. 31, 32, and 35), which was associated with better stimulation of T cells in 
vitro (Fig. 34).  Contrary to our hypothesis, however, improving APC stimulation in vitro with 
the ΔFTL_0883 strain did not enhance protection in vivo.  The median time to death doubled in 
mice vaccinated in the respiratory tract with LVS compared to naïve animals.  In contrast, the 
median time to death of mice vaccinated with ΔFTL_0883 was similar to naïve animals (Table 
5).  Enhancing DC stimulation with ΔFTL_0883, therefore, failed to establish a protective 
immune response. 
The poor performance of ΔFTL_0883 as a vaccine may be due directly to its attenuation.  
Mutation of the FTL_0883 locus in LVS attenuates growth in macrophages and DCs (Russo et 
al., 2011).  In addition, bacterial burdens in the lung and periphery of ΔFTL_0883-vaccinated 
mice are less than animals that received wild-type (Fig. 36).  Based on these findings , the 
attenuation and accelerated clearance of ΔFTL_0883 in vivo may prevent a sufficient adaptive 
immune response from being established.  Consistent with this model, restimulation of lung cells 
isolated from ΔFTL_0883-vaccinated mice produced less IFN-γ than mice receiving wild-type 
(Fig. 37A).  Since IFN-γ is a critical mediator of protective immunity against tularemia (Chen et 
al., 2003; Elkins et al., 2010; Wayne Conlan et al., 2005), the diminished IFN-γ response we 
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observed following restimulation likely contributed to the lack of protection after vaccination 
with ΔFTL_0883. 
Additional factors may also contribute to the vaccination results seen in this study.  Though 
the molecular function of the protein encoded by FTL_0883 is unknown, it is possible that 
protective antigens may not be expressed since spermine responsiveness and transcription are 
altered after mutation of FTL_0883 (Russo et al., 2011).  Alternatively, different cytokine 
profiles stimulated in the host by the ΔFTL_0883 mutant may influence the vaccine 
performance.  Inflammatory signals such as IL-12 can modulate T cell differentiation, promoting 
the generation of more short- lived effector cells compared to memory precursors (Joshi et al., 
2007).  The higher levels of IL-12 stimulated by ΔFTL_0883 (Fig. 35) may have shifted T cell 
development, impairing the development of memory cells.  Each of these possibilities is 
consistent with the reduced IFN-γ observed during re-stimulation of lung cells with antigen in 
vitro.  The mechanism(s) accounting for the poor recall responses observed with ΔFTL_0883 is 
currently being investigated.  
The results presented here with the FTL_0883 mutants share common outcomes with studies 
of other genetically altered Francisella.  Mutation of iglC or mglA, genes important for 
intracellular growth of Francisella, or deletion of the purMCD purine biosynthesis operon 
resulted in highly attenuated strains that did not provide better protection than LVS against 
virulent Francisella challenge (Pechous et al., 2008; Twine et al., 2005; West et al., 2008).  In 
contrast, vaccination with a ΔclpB mutant in the Schu S4 background is superior to wild-type  
LVS (Conlan et al., 2009).  A greater IFN-γ response was measured four days after challenge of 
mice vaccinated with the more successful ΔclpB mutant than those vaccinated with LVS (Shen et 
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al., 2010).  Coupled with our results, IFN-γ responses measured during restimulation could be a 
useful predictor of vaccine efficacy.  
Several recent studies have shown that IL-17 is also required for control of F. tularensis 
growth and the generation of an effective Th1 response following pulmonary challenge (Cowley 
et al., 2010; Lin et al., 2009; Markel et al., 2010).   Although the role of IL-17 in the immune 
response to acute F. tularensis infection has been characterized (Cowley et al., 2010; Lin et al., 
2009; Markel et al., 2010), its role in vaccination against tularemia remains to be elucidated.  
Paranavitana et al. demonstrated that PBMCs from LVS-vaccinated individuals produce high 
levels of IL-17 following in vitro re-stimulation (Paranavitana et al., 2010).  Similarly, we have 
shown that pulmonary vaccination of mice with LVS results in an increase in IL-17 compared to 
naïve controls (Fig. 37A).  Production of IL-17, however, did not correlate with vaccine efficacy 
since comparable levels of IL-17 were produced by cells from mice receiving wild-type or 
ΔFTL_0883 vaccinations (Fig. 37A).  Additionally, neutralization of IL-17 in mice successfully 
protected by a Schu S4 ΔclpB vaccine did not  reduce surviva l after a pulmonary type  A 
challenge despite increasing bacterial burden (Shen et al., 2010).  Therefore, IL-17 alone is not 
sufficient to predict vaccine efficacy. 
Defining an optimal strategy for vaccine development remains a significant challenge for 
many pathogens.  Improving APC stimulation using genetic modifications of LVS in this project 
failed to improve protection against a virulent F. tularensis strain.  In addition, modeling 
vaccination and challenge in vitro with human cells did not predict in vivo responses in mice.  
Comparison of different vaccine strains and the protection conferred, however, confirmed IFN-γ 
production as a potential correlate of protection.  A similar experimental approach by Shen et al. 
successfully characterized the immune response to Francisella strains that varied in vaccine 
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efficacy (Shen et al., 2010).  Nevertheless, our current study and that of Shen et al. are limited by 
the conditions tested (the number of vaccine and mouse strains used), the limited number of 
output variables measured (relying pr imarily on multiplex cytokine measurements), and the 
timing o f sampling (responses tested after challenge in vitro or in vivo).  This leaves open the 
possibility that more comprehensive investigations could yield additional insights.  Recently, a 
systems-wide analysis of vaccine responses against yellow fever has met with significant success 
(Pulendran et al., 2010; Querec et al., 2009).  In this app roach, genome-wide transcriptional 
studies using microarrays provided a broader assessment of in vivo host responses to vaccination 
(Querec et al., 2009).  A seminal application of these concepts to Francisella was also recently 
published by De Pascalis et al. (De Pascalis et al., 2012).  Here, an in vitro lymphocyte-
macrophage co-culture was used to model the immune responses elicited by LVS vaccines of 
varying efficacies (De Pascalis et al., 2012). Analysis of 84 immunologically-relevant genes by 
real time PCR identified a list of immune  mediators whose expression pattern correlated with 
protection from F. tularensis infection, including IFN-γ (De Pascalis et al., 2012).  These higher 
order analyses, which integrate multi-parameter data sets of a variety of measurements, 
combined with traditional testing of specific hypotheses could yield insight into additional 
correlates of protection and biological response modifiers that may be exploited during acute 
infection and vaccination. 
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5.0  SUMMARY AND DISCUSSION 
The innate immune system acts as a first line of defense to limit the replication and 
dissemination of invading pathogens (Finlay and McFadden, 2006).  By delaying the activation 
of the innate immune response and possessing multiple strategies to avoid host recognition, F. 
tularensis establishes a productive systemic infection resulting in significant morbidity and 
mortality (Cowley, 2009). Increased understanding of how F. tularensis circumvents innate 
immunity will facilitate the development of novel vaccines and therapeutics.  In this thesis, we 
assessed the contribution of inna te host de fenses against F. tularensis in the context of acute 
infection and vaccina tion.  Novel findings from this work include determining immunologic 
parameters of type A F. tularensis infection associated with mortality, the first characterization 
of NK cells in type A F.tularensis infection, and evaluation of an LVS strain that better 
stimulates antigen-presenting cells. 
In Chapter 2, a side-by-side comparison of the early host response to an attenuated (LVS) 
and virulent (Schu S4) F. tularensis strain was conducted.   A similar analysis was performed 
previously by Hall and colleagues (Hall et al., 2008), although only a limited number of 
immunological parameters and timepoints were investigated.   By expanding our study to look at 
additional immune cell populations (NK and T cells), timepoints (two and four dpi), and soluble 
mediators of the host response (cytokines and chemokines), we identified several unique features 
of type A F. tularensis infection.  In the lung, the growth rate of Schu S4 is faster than LVS 
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during the first 24 hours of infection (Fig. 7).  This suggests the enhanced fitness of Schu S4 may 
be due to e ither an inherent resistance to innate host defenses or a failure to activate them.  Since 
neither Schu S4 nor LVS elicits proinflammatory cytokine production (Fig. 14) or immune cell 
recruitment (Fig. 12) during the first two dpi, the latter explanation is unlikely.  In suppo rt of the 
resistance hypothesis, Schu S4 is less susceptible to killing by ROS, RNS, and antimicrobial 
peptides than LVS (Lindgren et al., 2007) (Brian Russo, personal communication).  Our 
laboratory is currently utilizing a Schu S4 mutant that is susceptible to antimicrobial peptides to 
investigate the role of these molecules in host defense in vivo. 
Schu S4 also elicits a distinct cytokine and chemokine profile from LVS.  
Proinflammatory cytokines including IFN-γ and IL-17 are only transiently produced in Schu S4-
infected mice, reaching peak levels three dp i then decreasing four dpi, while these cytokines 
continually increase over time in LVS-infected mice (Fig. 14 and 21).  The reduction in 
cytokines in Schu S4- infected mice did not directly correlate with the decline in cell number 
since peak production was observed (Fig. 14) when viable cells were already decreasing (Fig. 
10).  A possible explanation for this loss in cytokines is direct suppression of their production by 
Schu S4.  For example, Bauler et al. recently identified a novel Schu S4-specific immune 
evasion strategy involving the induction of IFN-β, which inhibits IL-12p40 production by human 
dendritic cells in vitro (Bauler et al., 2011).  The effects of IFN-β on other cytokines and its role 
in vivo have yet to be determined.   In addition to cytokines, Schu S4 and LVS also differ in the 
chemokine response elicited.  High levels of numerous chemokines are produced following Schu 
S4, but not LVS, infection (Fig. 14).  The upregulation of these analytes mimics the classic 
“cytokine storm” described in different models of sepsis (Sharma et al., 2011).  Since the 
“cytokine storm” is a major contributor of disease pathogenesis in these models (Hotchkiss and 
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Nicholson, 2006), various therapeutics such as IL-15+IL-15Rα have been tested to limit this 
response (Inoue et al., 2010). In Schu S4-infected mice, IL-15+IL-15Rα treatment effectively 
reduces the systemic production of 12 different cytokines and chemokines (Fig. 25G and Table 
3), many of which are associated with disease severity and mortality in other models of sepsis 
(Bozza et al., 2007; Ebong et al., 1999; Walley et al., 1997).  Despite these effects of IL-15+IL-
15Rα, the progression of disease remains unchanged in Schu S4- infected mice (Fig. 26 and 27).  
These data suggest that the cytokines and chemokines downregulated by IL-15+IL-15Rα may 
not contribute to morbidity from type A F. tularensis infection. The possibility that other 
inflammatory mediators not affected by this treatment, e.g. TNF-α, contribute to tularemia 
pathogenesis remains to be investigated.  The ineffectiveness of IL-15+IL-15Rα in this model 
highlights the need for careful consideration when applying this treatment to sepsis of different 
etiologies. 
Another notable feature of Schu S4 infection is the significant decline in viable lung cells 
four dpi (Fig. 10).  Although cell death correlated with mortality in Schu S4- infected mice, we 
were unable to demonstrate its direct involvement with death of the hos t. While treatment with 
IL-15+IL-15Rα increased total cell numbers in the lung (Fig. 25A), it did not have the desired 
effect of preventing cell death during Schu S4 infection (Fig. 28).  This suggests cell death in 
Schu S4- infected mice occurs through a novel mechanism, independent of the PUMA and Bim-
mediated apoptosis observed in other models of sepsis (Inoue et al., 2010). Even though there is 
a high frequency of TUNEL-positive cells in Schu S4- infected mice, few caspase-3 positive cells 
are detected providing further support that cells are not dying through apoptosis (Bosio et al., 
2007; Parmely et al., 2009).  Direct infection also does not explain death of the cells since there 
was no detectable costaining of Francisella antigen and TUNEL (Fig. 15).  Other possible 
 147 
explanations include the release of bacterial effectors by F. tularensis or the induction of 
bystander cell death by hos t-produced factors.   Understanding the mechanism of cell death will 
allow evaluation of its contribution to morbidity and mortality during type A F. tularensis 
infection. 
 In Chapter 2, we observed marked changes in the NK cell population following Schu S4 
challenge (Fig. 12D and 13D). Previously, NK cells were shown to contribute to host defense 
against F. tularensis based on studies using t he attenuated strain, LVS (Lopez et al., 2004).  In 
add ition, NK cells are required for the protective effect of CpG DNA, cationic- liposome DNA 
complexes, and acai polysaccharides on the type A strain Schu S4 (Elkins et al., 2009 ; Elkins et 
al., 1999b; Skyberg et al., 2012; Troyer et al., 2009).  Based on these findings, we hypothesized 
NK cells would play a beneficial role in type A F. tularensis infection.  Modulation of this cell 
population, however, did not have a demonstrable effect on disease progression following Schu 
S4 challenge (Chapter 3).  This suggests NK cells are dispensable for host resistance to type A F. 
tularensis infection.  A potential explanation for the divergent role of NK cells in naïve animals 
compared to those treated with immunostimulants is poor activation of these cells by Schu S4.  
Our results indicate this is unlikely since NK cells produce high levels of IFN-γ and granzyme B 
in na ïve animals infected with Schu S4 (Fig. 21-23).  Alternatively, stimulation of NK cells pr ior 
to three dpi may be essential for host resistance.  These immunotherapies may also prevent NK 
cells from declining during Schu S4 challenge, allowing this cell population to persist in the lung 
and control the infection.  The effects of CpG DNA, cationic- liposome DNA complexes, and 
acai polysaccharides on NK cell survival remains to be elucidated.  The work in Chapter 3 also 
highlights the constraints of using LVS as a model to study Francisella immunology. While LVS 
does mimic many features of Schu S4 infection as detailed in Chapter 2, there are also distinct 
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differences between infections with these two strains, such as the contribution of NK cells 
discussed in Chapter 3. Therefore, it is important to confirm any findings in the LVS mouse 
mod el with the virulent strain.   
There are also limitations to studying type A F. tularensis infection in mice.  Mice are 
highly susceptible to type A F. tularensis, succumbing to infection within six days (Metzger et 
al., 2007). In contrast, pneumonic tularemia in humans can persist for several weeks or months 
and is not always lethal (Dennis et al., 2001).  The rapid time to death in mice makes it difficult 
to fully characterize the innate and adaptive immune response to type A F. tularensis. While 
Schu S4 infection of other animal species like non-human primates and Fischer 344 r ats better 
reflects human susceptibility to F. tularensis, there are limited too ls available to study the hos t 
response of these animals (Dennis et al., 2001; Ray et al., 2010; Rick Lyons and Wu, 2007).  An 
alternative approach is to improve upon the wide ly used mouse model of tularemia so it more 
closely mimics the course of disease in humans.  By treating Schu S4- infected mice with a low 
dose of levofloxacin three dpi, Crane and colleagues prolonged the time to death from five days 
to three weeks and lowered the mortality rate from 100% to 40% in Schu S4- infected mice 
(Crane et al., 2012). In this new model, NK cells still declined during the first seven days of 
infection, as described in Chapter 2 of this thesis, but an increase in this population was observed 
at subsequent timepoints (Crane et al., 2012).  Assessing NK cells at later stages within this 
mod el may improve our understand ing of their role during infections by type A F. tularensis. 
In Chapter 4, we further investigated the innate immune response by examining a 
vaccination/challenge model.  We utilized a LVS mutant ∆FTL_0883 that stimulates robust 
proinflammatory cytokine production and costimulatory molecule expression by DCs (Fig. 35) 
and macrophages (Russo et al., 2011)  to evaluate whether enhanced stimulation of APCs would 
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improve vaccine efficacy.  While ∆FTL_0883 failed to elicit protection against Schu S4 
challenge (Table 5), characterization of this mutant provided important knowledge about desired 
features of an optimal tularemia vaccine.  First, protection from type A F. tularensis infection 
requires a robust IFN-γ response.  LVS and ∆FTL_0883 significantly differed in their ability to 
induce the secretion of IFN-γ in an ex vivo restimulation assay (Fig. 37). The heightened IFN-γ 
production measured with LVS (Fig. 37) correlated with a longer median time to death following 
Schu S4 challenge (Table 5).  Studies by Shen et al. and De Pascalis et al. further support the 
classification of IFN-γ as a predictor of tularemia vaccine efficacy (De Pascalis et al., 2012; Shen 
et al., 2010).  The superior protection elicited by immunization with a Schu S4 ΔclpB mutant 
compared to LVS was associated with higher levels of IFN-γ four days after Schu S4 challenge 
(Shen et al., 2010).  Similarly, the degree of protection provided by different LVS variants was 
directly proportional to the expression level of IFN-γ pos t vaccination (De Pascalis et al., 2012).  
Second, protective immunity against type A F. tularensis is influenced by the duration of ant igen 
exposure.  LVS and ΔFTL_0883 exhibit significant differences in bacterial growth in vivo.  
Lower levels of ΔFTL_0883 were detected at all time points in the lung and peripheral organs 
(Fig. 37).  Additionally, ΔFTL_0883 was cleared more rapidly (~10 days) from the lung than 
LVS (~22 days).  The sustained presence of bacteria in LVS-vaccinated mice was associated 
with a robust recall response and enhanced protection against Schu S4 challenge. Studies with 
other attenuated LVS mutants both support and contradict this finding.  Similar to ΔFTL_0883, 
LVS ∆purMCD was severely attenuated for growth in vivo and elicited poo r protection from S-
chu S4 challenge (Pechous et al., 2006; Pechous et al., 2008).  In contrast, mice immunized with 
LVS ∆capB, which is cleared within 10 days like ΔFTL_0883, were completely resistant to Schu 
S4 (Jia et al., 2010).  A possible explanation for this conflicting data is the use of different mouse 
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mod els and routes of administration.  Utilizing a prime-boost vaccination strategy with 
ΔFTL_0883 will allow evaluation of the role of additional ant igen exposure in the development 
of adaptive immunity to F. tularensis. 
Determining the contribution of innate host defenses in immunity to F. tularensis is a 
large problem that can only be answered with multiple experimental approaches.  In this thesis, 
we focused on two specific aspects of the innate immune response:  the role of NK cells in type 
A F. tularensis infection and the influence of APC stimulation on tularemia vaccine efficacy.  
Modulation of NK cells through antibody depletion or IL-15+IL-15α treatment did not alter 
disease progression.  Similarly, activation of APCs with an immunostimulatory LVS mutant did 
not enhance protection from Schu S4 challenge.  Overall, this body of work demonstrated that 
control of F. tularensis is not dependent on one individual aspect of the innate immune response.  
Thus, virulent strains of F. tularensis must possess a large repertoire of strategies to avoid 
recognition and clearance by the host.  Therefore, tularemia pathogenesis would best be 
investigated using a combined app roach of studying the specific bacterial factors involved in 
immune  evasion and the host defenses necessary for control of F. tularensis. 
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APPENDIX A 
HISTOPATHOLOGICAL CHANGES IN THE LUNG FOLLOWING TYPE A F. 
TULARENSIS INFECTION 
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Figure 38.  Histopathology of lung tissue from mice infected with the type A F. tularensis strain Schu S4.  
C57BL/6 mice were infected intratracheally with Schu S4 (100 CFU). Three and four dpi, mice were sacrificed and 
lungs were fixed by inflat ing with 0.8 ml of 37% formalin for 5 min.  Lungs were then harvested and submerged in 
37% formalin for 24 hours.  Fixed tissues were placed into histology cassettes and transferred to 10% formalin.  
Tissue sectioning and hematoxylin and eosin staining was performed by the University of Pittsburgh, School of 
Medicine Histology Core in the Department of Pathology Development Laboratory. Lung sections from Schu S4-
infected mice three (A-B) and four dpi (C-D) showing foci of neutrophilic  infiltrates within  the alveolar spaces 
known as pyogranulomas. Scale bars represent 60 μm (A and C), 6 μm (B), and 30 μm (D). 
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